var title_f24_4_24640="Sunburn back";
var content_f24_4_24640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sunburn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema in sun-exposed areas is present in this patient with a sunburn on the back. Areas covered by clothing are not affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24640=[""].join("\n");
var outline_f24_4_24640=null;
var title_f24_4_24641="Treatment of severe alcohol withdrawal without diazepam*";
var content_f24_4_24641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Treatment of severe alcohol withdrawal when IV diazepam is not available*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 595px; background-image: url(data:image/gif;base64,R0lGODlhRQJTAsQAAP///wAAAIiIiERERLu7uyIiIt3d3WZmZpmZmTMzMxEREe7u7szMzFVVVXd3d6qqqj8/P5+fn8/Pz9/f3+/v7w8PD39/f19fX7+/vx8fH29vb09PT6+vrwAAAAAAAAAAACH5BAAAAAAALAAAAABFAlMCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjSMBkJGSk5SVlpeYmZqbnJ2djqChogGiNKSlqKmEp6ourK2wsXavsii0tbi5aLe6IrxcBgoPIg0Nvcewv7rKWwIFCw8KBsjUqMy411oDBwUCAAKQBQwLA5AK1eiF2S3k5t5MA94BBCcEp/ZH61gGAQMADAoYAHDQwN6CdAgH6VvhIIEIBP6ezKu3kEdFK/EAIJBUYGAABe8SitxzEUXDaSMM/ySAdABANwALhBEoAAkBgHgDCqhkWYJmAHHfIvmLdyASP0gJFvgsgG9nAAffCtBMqqMklYwABZZgEADlyK+zciw4oCBAApsNWgZj4CwqAAU2o91MMC0tgLUnCjjgOkzAUHn0UgZ4gA8AvmL/FBBwZiCmzRxWp2QMytIeT7CY6UROsVGpJAQxCZw9anSyz5ojxkY6gKDjt78AJjIoV7MwvgKPByDwKwJ31czAg9/YTKLBOwQKFtglwS3528ciJi8v0RlAggNcBTaAPRjAAYcLAiAwaJgUYq6LI/qGLLy9e1c5nIWj57Tr3QDvZoa7+a6+V6cFtFTUT7ANiNxP4i2wEv9TpDgFFW8uQTfcexRWWAJxU0x3BYYWdpgLh07QRpcWIHpoYislLpLiiSyGsmIinsQo44w01mjjjTi+2KIct1yXigAOmaCjhUPu+AYtCARJWQANkKaSN+FBGYBA4bnmwgOvDBjSC5b9FJhHj7XzkTcMrGSWhCjEhBRKk5FQJIVvGskGLQUMMxBQBgxAz0QEARCNMXJ9k4BiJQRzwEEk0DYCN1rJYM80DYkQ0wARRaqRPwlA9U1LKSlwKAqZivCAlY/IWUOcpqbxCj+ICiMkPXI5IMA5fbokwAGckjBWAbqRUFh4X5YAjlkCiRfgCI8CgJhG0th3EgkJRHTCrr3qul7/eI36kuoMqG5rxiszPeLVI4EFlECZZXpjEAHOnQCOlbZ9BMmW2XnnD5MldDkAm1BlNFZZZ/0z4ADZkvDuov2QwNSF3sbQbcNjgGslXK8SM+tA4Bw0IGq6clOtCIVxJap9D7kW7kS+doXcNKT9RF0AiIrwXQnUoqlsrgu7CfELD+8Mxqowi+DAwnnuGdisgCoAnquCkmBozMiyQjGWMde7XWzBlgdpUkBKKoxxDyUXsL1Oewo1AsZYlza2DPvMQs9ud0Gnnd6t5uQ/+MH0FLOCNdqyyzdFYpN+FBuMVLFZJ3tTTiEdYNxS9DgQyYiCcfSPmZSPKmTcK8DNOYnUKYlK/5ulfm6L6X/0mKsoXW+Ouuuvk4SQ55jRHvsUtst+e+m745G7Hr+LFHzvTAx/h/HpIE88EsprtnzzyxeR4/TUV2/989GfCH328HHf4fbedx4+kePLXT6c528Bfvp8rM8+7+9ndos9z5AdfxLu3x9Wvj8JKK3+0gNg7Uxgj40Q4AD+YNdHbCbA3zRwJPPrSk4Q+BZvIAdqD2RPBqshgQ1gIDYAwMAGJACyrnClH/xACck2qEEWIiMDAYChDKM2jaL4AyTfaJcLJ7TDY0RgEhGg4X0SWJbC9dAG+TuiGShQgUhUgAJKNEISo0gGDURCA1QMYBZrMYFITGCLQ5giGMEAgf8AQGCMQhAjGrvAgQBwYI1AUCMct3DGOfpAjnbM4/70yEfg4LGPbrKeIAcZCRb+EZDa0l0GD4lIRu7AkQmBJB8liQNKosOSdsTkqQyJyJ+1j5Od9IImDfY/FYzyGKdE4y2GxaRx4WAypEtBLAtjAgi9DZSh5AIthiaQovEgliyY5S9sKb4NpnKMtGDaCJYikAGYaXWxMZNNNoaAjdQkI8MShz1WEhBrimeZ4fBmS3jTGgI4BZrH/FAuzecmVy6zXwlcYWy8cbFFOQSWAsjKQAoykW3wh38vW4BfklQXtQREZ8Zcpy5LYESYbKwlGUmhm+jxqFntB5/e9NIpcPXPlD3/xExdsaidTvNN+DUwnVvcJdF0EzQfRVSefNJJd4Z2E03FQ58llBlENRW1g+jFTyE9y0Q0hNBFKlR9JngogCDqDYk+Yj6B+0lHrAkReq6mMBylamoWlM2Q+mMjCPBPUR+I0iyuCGULTehRs3DWrLEVl2u1QllbMNdY1FWJdzUlXONKhc0Q0xRu1aJR+SrXGvyVWwSgZQoKc9gTeBNNeVVFZHfo11Ii1gWKhUE9TSrAybqQFgqkmF/AIc7XpIwmCmgAJKByzruANLENMlOTJueZn/AmtDZxxlRi1pq2DZawfWWoBZPjjGB1hpj2oAevNGIegzLgalg7jGX5QZhT8AaH/xdkjGMcCpSxnhS4VQCaCg0AoSQZBbmnyMhtPrOeedwGOrMRHGP3RTKv9sYmTvVuZ8EbXBLgcFYCVQ9UsETe/xVGvc0tjjHQI1176m08QbsuPYmrHgZyFoCe3StuTUsZmhTYo/9sCkgNwICpuDe2kChIWWgCGq4ScYEc9k1+L6y/DKsVeHvlrxNsrF8M61gKPKbx/YL8XUWS9cdRIDIIb4zkJihZyYyAco0/yeQmL4GQWL5ela3sOy771stdBnMixXw8Mi/ZzHWQsonUjGQ2fw/NewSzm3U85wrVGbx3fk+eCbvn9vQ5rn8OTqCPOmj5nTTLiE60ohfN6EZzwhGFzv9DpCE26TNzLhh2WhbP4FzJWuLLVoGo9BecAQ1pOIzTPDSYAij2EkCI+gvbeEk2x0Gbc8AO1dyqZTeSI+vDGflz/PCHPglCntPh2hS6jgk38jkl+0n6dhnJaEckh8NbHxsGq+zIsATQW8OQqsyxw8pBtyLPMV8b27ruDX6sZtk0Q/sdrDxAl6Bp7nN3z2Cu2YhVifXr83Xwg6QQIQntjYJ/g1Dginh1HGQYwxgSXAUMn2HC9fdDSQTx4SioeCQuDiP9MdGJUMT4CT4OiSeqCIBWhAQWRY6ClAdg5RPXXxch8UWWn2DmAah5zPVXxjra/AQ9b4TC5dDGN/78BEUXegP/fX50EzB9502POhSGLvUcg8LRWM96lqOs9a57HcsOtIacIk31/nY6FWVXAtndVqK0px1/UWZ72EvxdubF3Wdtl+zY776zvKPdBaRrLAqAeQTCh2HtOhC8ChSv9BbSHQWsbFLg2z14wBABrR1FQZkuc5p2YwlZK+6lNB/J98UGgFP2YCopZcB4FWz+9CbIaGA1yxIHSAs5Epn7KE7Ay7voafIvMHwRhK8RqNRrPSdQlAhwGCnEUE33h8iGZTQG+1pSfvHXXwECjN9sEnQ78cIm2QB4WjzoX/0EyozOM0274dF2RbXzwhppkrKxjsA/Kdv8iUCGdS57DMNHQxUJ+9Zd/zTTbD5BOQCFNweBD0yDeTkBCQ9oaqzUboinAvYQDzHhUvuWMNTUMmFlJg/iD9R0Ez4Rge6kNwXjTVtCghCIWtMwgcISEQnQVN0HMj4RVs1mELMWG61RDhQVNPeWao8nJK5EKVojYcwiUAvDGP+EVtQlAgaAG0ByEDNoD9rRAPVCQX8SEfPAhDd1ULVSAuOnKwkwW5CAEvFSQvwQGCUVHV81Ed3AFxz2ZYggfcZyK/50UxNBTDMjAlN4HorBh/f0hsq1gtEBFdZEKhuRLUZoQLYih38FIV3zV1NzDv6UFsNmDJ/GURy1aY63eybQUP+UQn7hVPblHZySEfMQX6gBEP/TJAnyZl24YTKuURSIMg+dGA/SRjM+EoMUIQJcsYCk0IDBgmDRwW2u0VgVaHpROCV5iIx+6A8WBTjf4VO5sRvSWBYuY4yZJym9mAIOqC7pBY1zGI2SMiXIdx+SYADskkK7iDLtWG7FdHZiZwJDQx+/R4Mf9l8U5ofPoBSAMTPhgQAAcTRUkVPWgR3NdjWjYoRYQ2oAiVP5YkQEMAALoCCGWB4jwHwO4XxAeIwayR/sdgLLiAIVNRRMxW5PSFMURAwL1oX0NQw0xY2kwy4W1gA2cUGJIo7HOJKrRwyDgkGiKBXCNm6+8CXOlDaeSI9DmFR281If1n4RoSAf8RLutWL/4kEbkKAs8jU5L3g4VqgULTEPVKkAvXYZMgOLTmGRJqCVgxN6rsUxI0CT3jAgy2Vt0ccCinMTqjcg0RJVUtEl+OEgpkUbUhFi48gcsCgs5oAmdFk3BGI41Ycl9KYfgOOISzKWX4IlsweO5gdpW5BZc0BU9ZaXhkCaRNB6JPmZjZcFovkGInKCJfkHsZkEmCYDflePOzKb25KbTdkivJkqvgmKM6CKnZkymHd+gDABIbeasJaRfjCcLlIDxqkCGTGDNAN/T2EZz9BsWCIQgSI5FkZAPkF+PCOAI0CZIyA5LHGRtQadE6l/dMgHEhAAFzBwdCh7LfCa7KCNCCiG70B8/3qZNyeAnX6IFBjkKOEQDYjCDwUzeOaQNcpAATp3S39HA9XJAoQCLVQhGiGJnQ7AfMYwKZaVJCsYKgSGm3EBhJTiHNEwDWViAJYCET2BHcI1EKJjaX5QRmbEcfX2fUgQKskXoPDJAgBBoMj5DvUipDZQGIXTOi9gKRcmARcQAPhpobp5oPyGEwEiOE14QBExhnN5K/sBjB+JkH0yg8aAnSsjjwxQFDbqHf1XP6AHY1zqJrllaw7qG9EQLM8CeQlgoMEYkkKWBxoXABVgATWHJOjpJj7hlxqpW2YRM1EIFQ2RoErBQI/lTDzRWpJ6kFAIF63WlvAWJMQkH2ZhJsNgmf+gdQq21xtb4kx+YpTFgU4lEAE8+nTz+JtZOBT/OTPGmUIzlqE2SECnABAxkazNNobCVw4tIRpFsYLYlRzO5EqTY5AcBiRj4lAAY2GWwY73AFMW8XWCBHAosIhuUpc6sYb4oF0NFQwNoBNOeX2wFE8GYBdr4a7QEYXe8BKJOKbm6BYjwBj8UJc3BBWZFTIwwy4YVIYb6n0/Ya0iMAEW0EQbh24XWjLFOhnT2BHVGQ8OAE3EijeuREsgsaZd0zLfJjCnpxWuEhN0Y4p5YojiARAjtY4kYLMQi0FAIqhBk1lnVQaHmqiLCo7BsodcCFsxhiYbQTcmgJodBZUkhY33NQL/GYWkO+mHpvo/EIK0EpWwrDCDneg0ewN53xZwOaJ3IzCSLyWTHmt5M0GrX1oCgToNHkpLDcB8CvAgQQKz3megG2l86ceP5ECzcREQxTZ+t3IQBQk2SagwcbqR3iClpYlEZZCrPqqjOPm45MJhJ7a0ZROv44I2IlCGeFOMNqWPGgIh6bhM0DkZS0p+XUsPSAgOCRgVDzsCZYh5KgEptlY6FGuxkJC51EAL/NdMARoOb4s1pWtZI+t75uAA3Hmg4Nkdo+o4ELuYClS2dUoxwFRSzjAASokcooGeqJoz4ISzCkSAlbtJY1Cf9+mcA9uYF0K7SduuFZYSL9EAoPp6I/JX/1QFlf7Bugw0qlFTpvwHNbNrWokILmVaJW1pDLPSKMoBVd6Fq5Cgq8iQIqGxwRZBBszpmVSQAMfZBW0hRSdApVY6OztAucvwwW5Qd5KZu2GUAhTKwkYStDEsd8IhwyhMejuMd362d0DcBiXCn5c0xDkMw0YMWEeZWRW8WtzJNt85q0LThijAjt62WtzSqECVK+x5eu7pDow5qSAGA59nbIJGxKz5LU4cNXTboQ5RGCAqojChAA55As9FKCgqj2+zoojSogfxopcjo0FCo2vbbExKqIC3lWrsR2z8iWrACy+RQvkXEBvDrq8wqCCWpgKAsswyYyDjTI0zp1CzYXf6CP95CoXoeLh++p8Du7UKc1EQmKBnjJdgAWWqCQQCisvu28QmUMldkVx8ybzRJTHGCozJscxsw6wruBHQBK1YW0FJWK0XghTYKoncBCVkcSY/ecIICZGA6xIcg8Q+LISm5MVNCjdp/JNDMF/dSFdMPCd5oY9YpZlPvMnlZrKfbB0pazn5QsobOQx+y8rj9b0EyTQkNS46a7Uf2TropVN+SG+3PJ+57AqAjANI3APK585CkFm9bNG/TM9tOU7DvFFjaSefy6F2O8eskLeTu7dNc8dOu7Z5Sw8y3dDLN2GFKySHywCJKyuf0rjHoUOxmzIHAZEGnMyPbGh0tcqeWgAAcxD/97cA81dbpGKZOCgQOhgOxdKDE1FscCwsUmHGtGGRa6gRb5sTgkEPvcWpsLcUvBHSPTbSa8ALlrES4CrRA6LJhVJr0ovA3mm9jaOUJqDF22ueqGy4/ii+VqsYIEVPkFPGoAoTCxJVbAmhclnXEOQK2HwzdxEQSi0AU+jPglFdoXi4xYyJYKiJacOJlZltjQEX4iwAaf3W/3nbHmuv8EzXhYqbR8LDa/zUOju1ELING9OybplZf8OOzWIA7xgY8ehOoknAnXgruh3P2Q2VvV2k8ivJqiLckPzUs/pcq8MbwbAboCqQ4iHWy4cmRJkY2YJWSfmLvhgho82DJBjP+s3W/9wdYbCBsW1cBufsZEr8x/44wJGQNto5HljZYoBjg2WKmfFmzEDlVm75k75x1kmNFMtL2cubQlTZDQG+lOC9C+Lt1Diwy0LA4hEzz3ed4gMUH9lHBLcJBzoMzH134MAJ45Ms4xe9xEU8J+Ra5EZeIzzOIjkunIQGA6/XDcNyALViuqZtHX5sMFoqivsZCegrnpLynpeDFI6JlgELA68q4Cfe4wq1EIbihxLsD3IRE+fANuwyzmTtD+Hhtgq6NV7jkDOKKZpyK/hm1enn4r6QMGjOlKZS4B3nAlA6sHg+JQ/AvwwQKI4DpOvpKV5RAA0gUIZNGefCg8eihsqSNm26Nf/j8pcn0ACpWzmnt2HYd2pDvuhN7uj0BiHGISu6PqLC0MGz7EpAkhPB0qux8en6wi//9C/e/KYQyIgBet4RMa2UahRlHoSKHsmhtBDgDOlufi6TngDDkFH0FqIHgBKDKtbddjKJozKmprIBxRyiw+ogye0yG+uJjs7Y3klsnlpuzmEAMedlcRBi6t4Du1xyWB1mqh33su5bI1B9+zVFrSCP0ZL+SOhO2zqEa+8mfu1Cvk4VUb5mQdqXwe/W4RAO6ropAG/0K5mhnpyKQynX+zhQFcawTBvQdKTyVkTjGRvUbu343vG5xOhp5OMnYnABN0LZnu+WayoR53BJD/QcfyL/hxoAxDtJSm/XLUJyiNqcjXT1yJYqLgdz+u71uZYqOFehXQ/1P98iQefxR/72cF9Is24kSVd1Pwx1pqLBdh9Hpbf3v9Xofr9lhvBqcW/k9hacdTj4h9/3J6cOi9/4oOn454b4prkKuDYBA3cKEoD2CjGdks9pFNCjVF9GXG/5ypkGzwugeoVrVSoJFwD4rRkd6ty5Gz1Rw1HCcytLtr0aIi1m9SkJV/r5sV/MVlgx2Ib7nYP7qZ+1Cc/ZYsajZoT3kB8dnCKqXk1NKAZ7n6oaZ4gsPmHbIFge3MTsZ2gsOW+nllfVXBl/Bu38YKZxVd/5p0/9zLXpUBHWCZavOrFd/8kJAooAkE0DMApBBAQwHEBLBicgAoiyDGMrJBaAhEBQMLxGAIECQXoGntIptWq9YrPaLbfr/YLD4jFZWglUyuo1+xptw+Pt93MQuCMWh3sgNmMBFPAFIAgMkBQ4zTwZBCAhOr0gAAIc+LnIuDQ+OvZk7vFZxiRBUtHJoaaqrrK2ilkEWLjOpp7S3sbZwjwhBAgl+D0AADaMkhiWBghL4ZScMLRQWsosL+Iw8fgQAAkdFywsFChZ2eKan6Onr04ETKi/c5XDz7tN7ZIYJNwVxID2AuTjYwBZICegHg1TcEdAwAAOhr2ZdnARAYVNSM1owCePPgXiSk2RR28kyZLmMP+YNCky5byVLF25fClzJs2aM2PapIUz5xyePn/SGCR0KNGiRo8iTap0KVM+LYGm2wl1jNSpVtFVvSonqyquWst4/ZolrNiyuczeInsW7Sq1bKG8jTvLrdwtdNncrWtKb5i8fP/CBbz2nV/AhcseFlw3sWDGfRWraSp5MuXKSyFjBuMYC6Wrm798zqxTNGmeO1kEKKCmsxSCBLssIvNaS2jYpafWvq0bLBfWY3wfOyQm9pjZY5/u9pk7OXMvUik54MPgCY87CoYJIoTdaa87Bxp5R1YxwMUB+vpIAeUoe4HphPgRyB6l4fdQdpE3r7k8P/96WygpQwUL3dzgxAPX4cD/Wi8LuHYIDjrwcAgLCGUyRQEP1UCCAg8RE4MBCjBgHBb7HdffTSaimFZvbxjRB4EARCcCeAI5AlEO5znS4CY0GODJjlC4oId9M+wIiHyEiOgfYSm+RCKT/T1ny0VTQPNhJBqOIEAUFwLwQI4JBHdDljv4WCMUwiw4xCVYLhFFMa2BGQ9+T5LkJJ3NnbbPAgoFEMQTqKEX3z453KFPm6k5kkIf4lnkRJkUHnQePxUSiihAOBqgqDEjznlnp56CShVmRkT2aahYnZrqcIJpSR4mZNhJjqpLzlrrfanGWkWutsrAq6+y4mpqXJYRW6yxxyKL1K91euFJG7MB99tnu4bU/9iyPV0rrBXOhlmccCREWwWg304RbhczbtorPNSC8eEyJoCW7RrlaGnDR/K21ew4a0DLlbvi+gXNdIHRapMRCxxI4a34ijoFExfdyzAqtrA3XasBMGCed0tImB0CjUw3YKvtHRoAuSzo0x6ES8RJpZngynfpHQ8xcN4JGvW5QM132ADQy+oWbBMMH43MQHXk6Spxw62JswPRhQ6sNG9VXAjNqwNImKODBl63SzEpTOdAA1ZzLAUL08GbSEFUCLKvmDbCm8I2LXMzRBEtHzMlweqwG0Yjh4ANYwMDKim1c1QcrMAB4ghcCbmGP0adegcgoFodI2xiyIx3GFDRJt3tU/95t+CyqJohD1hORThXFrllJAN8rFECCKjXhwGyR6J2tev+5AnoqcFInts0QB6vw6YvJDp2xS9N6C8HkE3Co8jojUgBgIP4ROMNnPwGMADsScQUB2DeDJtaAhB3bEbUfTynvPvkSeAuKww087Qhbnnb2z9+v5yMSCoGF8sY5rS2HeARChMX60ehuleoRzhgB1OoHM8mWKj5nOchF3MCzpC0EZBIoW/Ei58SFgiodI3QfyViGgl6kSWoqdB4MuHWSERov7dMQAIjlIA7YkiCHO6whz6Egw2x4KUX0cOGRVQFBQIAgQgEIAIQCAAFhgiAJj4xilOsohWxdSol8uUCQrn/QBcBIMZBkLGMeFEVGPUiAaHosItvHEQc1ViqYMFPL1O8AwTsuEcn2nGNeAyaXKB4hwjY0ZBRDOS82KgttJwhDYGMJCPnlaxLYjKTTsmjXmAhi0B6spKLedISWcEOIarxlKKUSylZ0spVoKSSsVzlW16pElriMpf4YxJONOnLXwKzMqwIJjGPosu5kHKXdqyNLe94zGEmc4VqZGYtn9mKZjJLmmWkJluweT9vJlGZ04RmN61JzhT1kpHcRAs4i9dOTgILHkla0VfWORUa3tCcg0FROssQHe8g8QnIwOfo7DG8cr1TnBObYHYS8KoRYYI4qGgQKULov2JiFKPZfN8Y/xKGggTUz6BVmCdBEVrPc3ZJO5U4qCkeygrj4DOhiPFUKfvZURVIQXxPaIADDAG6SWSnCAUQhJ9auJHxVA8QDeFQCwjBhyCoB3mpcc95nFCxF2RnAIJQQEgPl6+dPkQKS4VIRxignkasoE/kYQBac6AaQanUqCSYhsZsF4qBuk2m9PhX+nr2PzqV4w7T+cdotBkGIAhPcC+IAYjwyiZvGGBPV6rogyRIur6iQAUs2FcjlmGARARObDIYkxS4hLUEBoKltvmq9CaLWbmxwAW7WEQ0ZgCDtoruIgeSAmHpmrWBCMexFg3VwTzqVcCaYqiEUpFhx5CCBxyoEAnYrWN/VP+2tV3OZ5xAiJFeN4k3ZOyDKXDC71TzB4xNjhSUKOlxayGFN5XWu9JYUybmi9sjCAUhvY3B9IJ7iJimamgvnOrRrrOXOwWWCQL4x1i7olAwCOAAQpDbDbjKhBMMNKzmI4jupKfhMRGIGM+o7VzBtABCUDizUauQAxLhCzWp9w3sXa2Dn+AlJZBPfWmdazBosONK+MFRqqnenxyRD/4WcCBxEu7ePPU3FQuOcPGMZggLEQD0xQ2n7m2uFwiAIyVwD3zaQUZ3JsGnIginw5UyM3kmq9QM2ighiEKAHZyyQBnsgwANmZQn1qvav25ZoHwagJ7hPN9KcI7EQD5UAt7KHnv/kOd7j9IUk1MYKt8NQjUxOqheCSmDPGQHu7CrMUfzI1GYoHSmAR7B/KRQpQMjNyTkvcNrT+3FwuHJpahmrVk6PRJnmdA+sKYyFHKHwZnxesrbTLVYfA0UIKqLh/2B9huk7elhLzvZzYYcFqEoRSr2p9taBPe1d5cFO/SPHLpWBWoIgG6r2LMk7dZM8c7IhzT2x953wDffHkyFAwXUDetOhfgAroUZ6wAPVthsoBuehd+5oFVFhYNO6Q25OfKhjvzB+B00HhV/OyzdAqcFTucpUis4wAlMqIKi/gwrZl9BeSRoXALCCgctWxxyf+xjinYeTi4zYiMSd0/lNmXbOwxg/wEoW2vJOqbwHmi1Nfsw61CsPNWSbdCIBhZrEyJGg+yAIk4ddHk+9/lwPmRpyeRqUZ/OIwy42mLooEhde6WmSESm6O4/L7UVkNG4AxwiQyHZxjcWQITYLhYawqAe114AUldnT7Qz8HvkxxabGeOjAMIAxXc+4vXRVuIIaGUCEjBv6YV+oRchCi7djWCARowA8Ddgqqsx5jhK5RxylHzS7h95+pEeQnnxwT2QprGEA8xXeZrLLz7LWyEyZ1rmFbXCeKnwuyuHMOLCaYHxTV92IvZlbgUlyOQH0DreWm74tl4Y5EL5JPf7/vutAZztw3zqHxReHPPlX4GkgM9WPx/2RP9N9LxAWGED06wY1eSV9vnYwYQD2cUbFjQAee0AzdncdZXf26CP9tRf4A0cyDGMKj2JCMYfTrgGDN2fbCGd0kUEA6WG0wEPQd1ZBpaMAElHmTWA2xyJaz3B59FgCxjePkAgzPWddUSCxL0I+TFgdwiCw6DgBwIdw8zSk0whPCXNO8DXLexJwKHC6oCgIJkDqTicPl3UF7JCnT3esCAd+6EeLbQKzm3FX2TUHCKLG9DhHQ4FG17hMhGhZ8ghlOCaXuyETY2Ttp0UXzjbNQXiKJmh/MVQBMqGyGGBya0KIgKisgmiHmKbF7TKATjAt+gAK+zJA8kZyfyHVKyf2cXhGND/ECX2nSRWYibyx0okYizy3R4eFv09wgBcICvU3Ns4AN7gBRTeWhvyCyy+oipW0ywuIitpornlIgmID8iYjcdQo8hM3addz3kF1OpAgxD4BqL0QaHYiBEQ1QLs11kVTYE1kiEeT6G4HSlczCGox8cMwsfAGTLUI1Yh3VZ1FTQ641u44i022RmSnTsCJC5CWHCBiXHoVtfEwNdUngzYgESg0B5kDelQCPYtzuuRmOtJ1n5VSGgNzouB4Rjmj0fG3n8JANnMxgHQTRBk2TaQC0y+QPDNwOdh4jJ6AQX1CTH6WFBuxY8NZDM6ohQU2EFWgfeBBlAWpEJCJScKx4kxgJpt/44jeI4jOB9FcNXPvBf0vFg4MmB9RQGHIYBIzoDzbVo7ktoVKGHZ9IDyHQITDEol+InuwA4y0GUMjoCfPSM7fYGXRAL52IVTrgaLICNB/h7KxQmdiQFTOodhHuViJqRU7lQCWNYTENlQCWD21UEC+FUO2ABoAqMw/uCOmeWEHBk1QBn9EGDuGWMyBmAS8E9nwYhqyJ4zoMAPmF+AtFiMSc9B1mLdaQFPTcFYmWPOnBX+neN9HdBkiZZAgUkLsEdyThygVWYVBCOkpNl3pQxVPd2AkYw4hl0JFAqDDJVyCsRfDpdibkEnkoCXoBBcWU4vKNCQvIqXuNTO9AkSjIcpAv8JBqJmd75ApLngQITCCV2XLcYm8AWlY4Xdf+1DAQDKlSGnhKaGavSZjAnnHzaLa80kSF4EbRFeZDWBcz6kFOyW7OUgWUKWZMnQJlqBHijE7NxeQZwNZmHfyvUASYJeR46enxCBiCqCZA5iI75DUdKDQ70cQsKbh3ZBFoJEXhIoiZrlfV0lQpzYA/CiDrgHURIocT7l2elBd1ICqZxXjyxYps3mJwwC+VSpkbInZe6VAiwDlKKkVgwnjXHBjc2VAOiYWbJmJgiqdkQdke1UE6SAgdWWEAiqmNLpFLRoDuwAqVTEd0njmvxmj2ZPgCph+1yX2gQIdu5kdvoQJOopnnL/wV4S2oWWwkTQZClInKPVpaA9j48FoTiEKZ+a6jumhiYQVRMAyuPxAYXKI34KaPoIHYEexJxG6rOWoZPihqomBy22gVhulHsW5GdhX7S25TtAJpKmKjOWahhgaw05azl8Yk82lLvhQXSSpt1Io5nwp40WJwx9wcWk4RDQ63nYaMKZTAJuy8ZoK1uOXBwIV7gKZa+qmqkZJU8WbD5N6hYI5p+Swm7tyXVQZULo1C8eH9dJmIpyFYzlq+V4bEV0rAFKWIAswATyVsV5wwLwVbme5Dk4i8IS35gCJrlGZUBG4emBTo+sYGzFlXGKFFU+QAMkAAPsViVMoMlKoh5cTyTA/970yYxDQAQLXAmpPOBcPa00ksuJqRbVQU8JhJUnbCDDOtNOod0n2AAv0scSpOfEbaxmPoBPbURdeQic5WYinJXaHmJdeEIqmipZEO4pgoG5ICkhBqfcgsPhdWsd8KCz5GBPWe4J7MkD7IkLUF3AFqHlmEAC7OtraVbkHoOwZe7mogAoDMBg1VnILiV63KwN9mwxkh5GpFWmOMKbfEiIHAGMPgERfBYCpABcKsFpTchM9m2R1m6vzSgaCgHEUcGHXA3BIuEtDK5hWuvBacPCrmr3JK5aHKlheYLxRRhwSGnjLoHSMq3Sosmbjo8wSu2oscwx4A1eYqr72GSlEOwT7P8vCRheL5LtwBgt5sVb93VvDzhADOzgo5KA2BwA6gCq8TbuJuDv8uYstAbucSZd10qfEy7CwbiLBWJv9/5lVpBoGSjuwolvulIB2uafAACHn65URS0q+CiEEPAi6RjeYJLLh8Bu3iDB/9baj7EQjO0wRPTwXBFa64IPzCIAzDruv3hJ/cSbA35EWioATkmpA2eWajTANfzX2SZZoL7ViN5pezIiFogP6LDUIhTw3RQUC2wVzjxEQxDH0CWBVu1j9uZmEsuopdWthnBphNFIVYUE2JGjeMQM6DCwfdRZ0gGCI8stPN5BGk/mZJbDzQ6tPLCqu6qUAowmmFAjIgjAP/X/p1gJheWg4YqNFXCI4WdpSdSIAyqD1O3wQWhe3yi87gOjUCY3KXVIiglfDz5gihe/TRWXTZk9ylhxK2YaBOcA7ri6pTCqHucFaEXBgGvQHeIV8z8o7cL+3X+Nrk1m7yZYV+FOgfCCVteY8I7S3Y+KHm++jYKYZEX47uPK8CksiOtVbW7qrBrTrMQwaSAXI3WomWlQa3pcp/dmcxwDwRxzqI3oTmwIn4aWEJ9gdIUo8C/TqS1AsASfQPYG5Qef5vL5ZxRE8XpWznSYL/Kp9DFv31gGdE0DszsxGx8kZpMs9KVsisuuTEvF7AjbnsdeFnDqGAeiDUv6jDBsavfGR6fW/64tpAAY48DgVoMLmPRY0vM1bMlDVHHlPAIW73MggLUBtalNa7I69eGTWmIVON8b8uCdFSh6MNqL+CUgVCWiPJQec3KG4i7Yumc54IAyl2+iaXU8nzROqtWhCMLmYKgkl+U+oDUNqjXjdhGq+uFbz8SrrYHqGuWexujDavBM4CxPSytUiLazqgOgKOUWBCPQrTavDvRNC4hds4BHI24WAMdpuxKzKSm4vnFP38b2GoYLiwFqCMEe6LYWrHCc+d9rn0hqvwR7zfbPioZxE7dANy9vm4wAhM8jT9XKRDQvnBl7ULIhXAwCNa5fGwI/bMTm4OPGGEGNoqN9sJ3oXrLBNv/oQGWVPy7deBYdUtljyPgCXAlZP5IHEhTN0oHITxm08/JshJdTI6qF1ooD4G0Kl6iNmgGyb/SzsfZ2S9qe7JkHpMRky3pIY8UwL/iCP3PkTotr84TJadlnauUovAheZfFARDJW49l4TrZk5SHeLlj3dquEZAazQfMnCkmvbHjHurbQ1mmBl2D3Wif3emAMDAgJfQ8A6pSLPrQuJaw05xDEiF90Re2l5cCkEDSwcMBAmVc2TS95fzO1n52peWmCmWBlV3rkIKhpnMVlph3akXO2fig5jXM3L9CM7aEfHPidmQDyudFaxGK5uRpQnL/Y94QPSxUD4XBJFZ+5SV4O/5X/iVPj5rd08SFYSajP+YLW+SrOH3AmASV8jzWAWCAUc/9ll5+1WqH3olpTM4ShICJrj82Q93Qqcp+Q1VSdVSQLAXmSI4Mu+hQMslEthD3894I3XchJYwFFzWc9RDAi0QqPr6WzMELcVgA9cGZKz9Tl6sigda5GN6NNx18PVYUyxDHnsmO/enCju6I7Fp4/FRJwZZsZFSbQJ62jbYK24JpR+LaFwTiDnhjab3ytDUfOc1qhzQlMXuGJj8Z7ZKLrLE7sMBPylqNLD066AOMEiHG4RkM+zoc0wBHc9pVjNir4NjoAPPhRt0nJxHUHPEPBTIVIHy7b6OlYzmnmeYW8dJse/25oY4HhNTfxbWhwyqW3i1lV8mAvYPJRkza05sYR5UTPH7Qyevd0yyIY8F9axrM34LBOMb339BhZQz3Jf/QVXKoVALW7Xz1tdqDWpw9mIhHN2zzQh/2lF+K3SvzaE3uffKlbSZ3CwYhlzT0pHgS03z2162ztpItci5Rfzt3aEax8HudHKO2L1FlcRbziZxvjb7DPlrBz74p200L6IpOFf8G8XQWVtgG3Sne1n/2wy/4skH3an4PtnyEpmsO5L2K4SLG6kUH0F1nwH2elyjhsZ393r23DrjGeJL73hz1XwCEqoAZLtZxsCND2Z8HERg7sE/+wXCL3Szh2ywMgWGeX8/9Dd/InCDRAQABDEAwLESSBwgDyTA8CPRsKUtx0UEAdUAlZAxXwFUqCQjCxMKFUBhKAZxIMCjgE0nBKrUgBBA4XOKvXbDTyDY/L5/S6/Q5v6/f8vr+d9ifYZzVoWOOjFqh42Oj4KLMIuCc5wwLQZLCwM1JyMCBTgCBQNEPStLCQIMBSMnDQZiPjBWTQA3D7c3NQYFBFIKBgkAXwUJq5OVqQuvp7xTWQMHwmi6rKmkQJuc0d2f0NHs5WWYgoHllyWP4nu1b5cx7/+M6oR3+pFWpm9alvcJRgH4EDsDAduASAYKxEM2ghYWglXyeFxBr4kCiKooADzrC0o7ar4EaE9uT/mXR3MqVKbT/SrVwnCGafj2foeVuJEyXLSWfwgcIlEBMXApxkNOlkrQdChcGi4KB5JpcpJj9PLVvQY0EApxiVpbpVxgS0G03NJcXGx2bOb2rXugUnaQiKKjw+kUUCikAQFAAMuAgAS4uAAP+ILPCLxKWJv4FtEA6jQu7jKVEGo2BA9IUZWa3QjMMDOrTo0aDT7qThU1+nvk92WA5rBfIYGQot4mCBgssaqegwVSWgKrcAASKM/hQlRQwmImMB2DaXXAVJnm/Fta2O3RG5dAGK22AQ4IFvAAocALjUAJYOBk2YQAGwqsHvGiLAs18ilNmNiFdXgXepwA0IKLAAZzBd/+cWgtUhqGA8mzh1ElYIJCDeIw/ClV04DWbI4WmrfWgDFr5VMcwle6Ewyk+SAYbchzK0U4ZEGsHCj0gHiNgXYZGAwZBnHZryY00eBsnWFEQKeaR2SS7pYXi9ZWGfc6AEuJxzBRln1HtG1LeOLA8QJtFZI4h31n8zUNmULFqZAQ+RG67FIJNyxvPmnDfZiWclcjlDjFwFgEJLEH39BeZPziGBAANPdPnQeC9SltBcsi13WWaceKlbm0HWiVOceH4KCadzigpqTqKmR8NR3EAljwM9jnAkqSl5Wqoa0/1hSzYZyrokr7We9GYY0lCqgGKPsGpqrEzSKohEyIJ0Tmp/OP9gqDwyIfnrONn2uq1Jvlq37JB9SOTHs5Dc6sdz3hpbT7fYutvht/DqtGm4JakRjRBXIMERv9XkFkMLKDqEgANIxGDKX2boheJ5ey184nj5AjZoYg0hSsYoAFOaAi43kIgYxU08sYBk09A7750pZycvrkG8Wi+HEmyAAawYbCCBm+KawCXC+y7grAAMwACAAyJkcxSMFaJBFhecPKAAeWZATd4NqQ2QF2ENlNKl1dkMHYPRZuZzC4morocMJ9f6uDKsbbN8iLlq5EPtGa81UMVlAcTwJd9RF0MxHyGrQF2GGQRweOLK3gvtCAhM+EXQDgGxmkcXBXEAhJX3AkfeX+j/ePXHhLXY9XmBTC6KbmSLniuiXbmo7dstv93I7H2oK4MDBcQARglWrFI0lUa/OACBXQBPgwNF6MAmytlFAEcEixduzpe2mGc9KS8KTfRUz5hgHg1F9YbF+FKLf5fErDfApWIGygD2DFHKZ0JgWl/pKHJOMr6y7bQP0qDXgCJEf9OeZXaXqgE45GQKWJr3hhcf+IhOUc2T3xAOgDAeIGATPmtXhihQASRUgALTix01GnVAwgwNMP/SlxWwQItgGKYl32MY5WzIBVq4QH05MoCigFA6krwGFn7KmsB8QSgDvG5P1JuX//73BwWBh0wDFEAypBa/4c0gH1DRERpKMLQH/xFob5goArlOqJ4EHEABxTEhhzSABA0kiVnQeRt4TjaIM2qIdk+EIiH4ICIukmUAD8jhGzLFQ/FV8EkBEsEqSnEiL1oQMAhrQPgGED7nZWcCSJjAHHcmt1rhRleH0COGZOfHBPFhflXM0S3iZ7dWJg8/vftQA4RXHtM5BZM0mFCPtgYAVWTSgxyCQAAgwC3+pRJUfcROM5fpxjYUkRgJMR7H8CfIM0imX3NZDt+cdIA2DqiXcEgjpKKZIQ4EgAPJbCI0R8XHd75EEKiC5jMbgcx2ojNbwalWtu6pSnnOaiZEwKMfARpPZebRn3xA10KNggQH/gqhyRIosCwaRYyGav9nfjDlHhzarJ+8RqK1ominNGotlJrGDaRpqUtfGhqFvmsQnjuAYLRmGM9BYS892EsC/iIeG26GMTXtpww6kyoixMAGW/jBXuSyPCTs9AabIKk6EqrSPWa1iSb9pDvZVkqR4ocUUUBejh6AkExUYRdTmlrUsGY6JTL0qOuIUj+iYdBs8MIX5ajCA2CIyHlgdavdQOhrhiUDF0yDAX8JyBUUMIUOsiEM+DPEO7paQmJqNqRYihS/GBCGMqR1PlrwnKRY59E1iEgv1KShREgAWkRtggCO5QZmB0pYtpxEVQkIH1GQ11ujZM5JC2hABX2JA1TowKp+uOxWr0PHPB5DpFr/SkgR1sSCypC2reYgkfbUsCYasLK13nvtQK4bFlL8zbaDze1GHSGbVoTFKFzAig/CKaIEVEsrMIPfBSt5yf7+EawahS5H+7BCmxrqCCjKTBA26IIebNdhuSEGiRJ8hkLaTank7Y15HRwW/uoWle5lbyOssQoW9GiIMqjqbAHAALkMIAYIoKzmakCxdrxCSQTGqIFlOi9XnYQoNxYsiUv83kPMCF1HOUApJldZJ9NAmDiIMSWNEGAea+otoaQTkLeMZD8Ed8Rtu+0yeXUWJutGjeCjqyrY9AkCzDiYZr1CnfOzXC0DaRBhWKQhkGUFkCZZkzMN81vM7C1DG7kR8X2H/6psMRif9cBgBS0MCto4i3I+KnC1K/RMBMwOmK2tsF/es6IX1N5TZ/TUzv3zDRh76V5CNhsMfg+Dk6DTkmGsYgEwDwtc0L2YlFpl4bjVqJM7V5Wk1rIEEDSxnajqq7La03yoRimekkmySjATrfXratBTn2J1ZscAHLbb2LDsj25nXLKUB03SHZNm/7jM0basqlvN548BpIK0TYGV+UWR74Q2KCZikwKXUtkB77PH3zA2u9YAb3lEvLnyNndJ613uaTO82gxRFQ7So236fmUj6N1HUNPAPhiTAOH2/iqYbZiG0pIxuwfsYMga8OsXBMwVlJGvxowkC54yYHIGEOpi9P8VMvNEoxgwaGHHjI5jMfhc6J0wEVUbCGZoY3zVisY3O1D0mgqGAYG3hvALlALZB3vWC7z2dSAoImyXm1oGubwaLNKTRUzTj66uoBEw+oONV0ek3bjI5I6f9taepXxoJUjALV0htMGfj2pbBLyKcVAA86w8DYDdeLcQfdB7U1ue83YjiUw3HqKQCHU0aBHqE+L3JZ9OdVXUtb5UoZ7OwUiDLzJDFQIcyAGYVpKyb/E2q56G2dZ27ikDPRSdLyevF9jclUBTzI/zJxgHmwZ7f71CrDJyhIw3RFuBT+bMaj4vaa198DkC5MdrvsqH/3TlZ/Pms7Re5mt964SAqf//D4D/dTB671R6zhMo15dp6cBiOfAXOPd2fhcds0EbRFBFIVMANvUGzcZTyZENScczmNB0u0CBFEY5UScdgWCBfocQIuZ52wJ9/Bd6WVWAmyUU7tJl1UFkA/hPMPgrNWMvGTJxfuBs50ZoBGYZxWKDoJYdY9aCO8iDoMJJnqRPjuIIQxhLqMErl+AnkjWDOviEJkZvX4gnFhAAFvCDnVWFdRKEfTAdKZd1TUiEYggu8zIBOeM2EiCFcngkIVQBZ1hTDtEYg2FpSAMwGzgDkgExKDAcTtACsxEysHALVfWIJBgXldWFcKiHnTYvFHBM0BMBxkRCmRgk0IMC0uNVW+RPXgA0/2MlDFBCNEYjaFJGJfSlCTuAHuoBA0dxFGcDA1QiftFwY5f4hqI4aO5yAXBwAcQYJMaEAvmUWRIBOXMhIwVBfkiwBI42a5xzMl1hIm+wQcXiWJHkBSUyezSof16ojHE3LxIAB3aYjtnBjm/gjjGzRZCEPYUicvYFS7pEA96mO1WDivpwizjAC8ZTT3SXPnIXh4oQgA3pkA8JkXTQNsx4TO/IIcf4BsmYWQmWQnLVYn9xC0MUHIg0dkMxa8NxHAhwCSGjI2slAyxpADpUjjr4gha5LaQYAKZok2/BiRDgiaCYWYIgIS5ocfPigzvJDXyIlNVRhzeBh0HZfx1DlAqZMv9RuJTbQIZmeJXOFH3PVZTukpVb+QhWKZaH1pUy+JXdopRl2QhHyZYVNYU+lpbZgpM6+ZZ3CU9nOH1UCS8U6Yx4CZinKJh7uXArE49IMI+EFZGLyZhzsJM1CQiNKZkAOJe1gpFIoJHuBZk6Y5ObOZicCUU9+ZMBEIq55Zk/cpr7p3Fx2TZNeYd5qJir+Y6pSY+f+XxdJ5vpSJuoeZb2hJu/aZG7GS+9eWbACS/SsgZDKJxTKXp6GYNhJgmjhFgJtD18sIYQl2xYSIW2kgZbiIlPuJy7QpypFJ4BRVfDMACYhobs9ggRh5zcyX3qWZ4XF23hOZ/bcJ8nZQk60gSAWFP/LYRAAlMGNcV9KBA1lpEAS0VU/HJTYNBzCGh0MEcDcPdsxJif5mmb/3OhKhGdhIF7FwM0P/Edr3g0TbOdQrFYZHRXWeORQsEEloeAiAeQv1hdFSqKGwqXGZpqpomFhhGN+JgFrPdCXKBHcLdazeFdIqUiNuITw3d6CIEjw5iJOKqfrKmhxskCJ5N5gKNEpTCiHTSkZZRcvQA/ZEQ/suBd05WPShGjFWR9lYlx9jmZc+pSBxaG0ImF25gbKgRZdnFNm6N9nJYcB8phaMqngEEujZZ6GyiTsxBYNjql42lR0bUkeeYc6gmnxWmcuimpAkWpS4IKUGNQmUqeuamM9omW/6TqFq8QkgBTIAaKjnK5qafaqaRnp0RSBaCQd9lVhF45qxZaqwR4q0QiC6xnMLMopalqaFQarBzCrPg5rEEiC/soP5IEqcqKp53ZrJrKl9J6EfwySgn3rF72qze6raWqqszUdXTKrgH4mEfimoHwlNAUrzIwr7EKL+MqrIHJoUcimjkJlND0r59Imr16ZPy6UgibaEdymSiQmdDUsAHwsN+ZrwqrcBZ7Drt5mCiQmKm0sQHQsed4pRibriTbrWvhlxiVsoV5sCaLry7LdURSlxg1syx7pzBLsTh7sUSylhjVswZ7szp7rUKrjkcSlhp1tDbbP0SbrEzbXExClhgVtf9Au7ROu5BWW7RH4pYYtbXm2LJCq6/1Fra+6ptWO7bNGZntqrYS6Q5ry5h54rZxK7dz+wY6+6nc+rLnirUjC7N3i65eWypnu7cxOwMnIDoPt5R++5x565yDi7eFGwR8hbhIqbi3SbWfIriOm7A18AnCFxvnRLnR+rUiO1Ga66n4chBJAH7XcJWVy7eMa6Wmu6M7xmADYSOtexqiGky8sQeK9SiHa1rD9GnVuQesohaVYLg5MrnVYbyyu69PkXury7vB6SEppzx/8Fs+sAWE8QtP6niCcIN1RLrIG7l84q2w67yBi7oTyHPKkbgesgkGEwO1tgCw1h0EaVy68QpY073/XgQemiOgZoCIBAOgAaMwBCOlyNu5zjApDIgC5tGglrAXAgCIQkEyOUc0lvI4iNK06Zst9QoA92qx0eUFZPEeq/BdOOBiSPgKKkYCp/ckkUAW+SdlOsY9YVOiNdi8ztPCqvt3+hGf2vd3xoKsIJo2KhkbsEAlA1Igr5K5HiwDAxuwGEup/PAGHLFv5MQv9XMoL+y/5ec9WSpDlGPDQloCljN6CtzFtitcrWdwKYIDMGxnkZOSCAfDj+HEUEw7ETuxClvF7lFkHtdmurRjeUMA3muJJaA7/ggNAUatYcpLnqfGhiwmM7B4p8BQyLql2VPHDwiQaSK8V6vH3fKxIcuv/39sBK7DwS9JRqGgBQUxBIf8Bk6cG+3rBPtSBk4HgTDUMOMLvewbgf34FxDMUJmRBB3JjZ6swbhcQU88yitrsq7LoctLapebJ6P8NjUbzaILLNQMhugLldislgHQh33LzVULuOoqziuTtNGMByh1vOi8zvAytYPbVVaYb7DjcrISvkKIgIQ7z93StXvrPyCFz+C7H94MqdfxLP3Mhv/8tAEt0ZgLDgb9RLJwbAmsBw2thIPwnpuLzXQr0iOdB897BgwWNVQXwK2XG7l2CYpyA/SbVC2wVFpwgRyM0QMhoqG80G1AMIjYJ9JQc8L8wKbDAg4BBU0aaGBszY7rzO7y1P80yG2Yp3kmup9xHB4soCiALEHVGgN3NZ3WRQxezFej2tMLQZBFYAP9kHdBzHiXlwNZjYAKQaHpbLpRzZyPe4hXYnsUE6ZXDWMDxwK55Fn64qhH1RwgWGE5nQUOkHC+jNaKTcYK0IqsNwMtcnCBEFsNBqHCYK12rbl47YRlazdk+jPmB6j7GQVShl0kgCY1Wqbz20qMPNYloBfbJ8kbbR60jUl7Ra2W3D5LUXLSEg2YCs5EK9qla9JPYaApmNofCQQghsTad3erDFE0TU0lWduJlZ2i7N2Zlsu50Ry8wB5b7MC99nrSLS1f4s3JLavmvNzz8mKFWZ4T596TuhYn0N3/D53R6kzaK3O9+ywnllqyOHsdk8MXFIcDUFNkhnBnlKDQbeC7WvFNfvNYkQXSi3u6TZ2X69wgDh3D6+kISBhFEZ6cCgBcN+AAwtMAWiEexeVnoF2xhHnctRnSw+tzQy10JsPKYMdhZXCB+3nUNecnDSpVUYDSJjMpQH4Cts3UCZG/ueNIxCFBLBjR/73hMt7h4vzhXvNqJNp6mmcs+WBXoHC/WPjlOLwa7dGP4THVaw54I1AcdI0/KwxGBILnFH4FNpbhlvveNc6b89zlr4c6fQ2B1Hmk+gylh7TmP7HZZUChNdLGhaB61gplCDnl1/aRPA3o10zjOau3oY3jmh1s/6qI2vsTkOMFE+K3fZIn1mvy5k4iJuVQ3NjmZs6BS742Z6x7zi5I0mr7Gb/ufwE96ELEL87NRJ2FoDt3G4vAYq4u3YPqWQ6qHOXA3m0uaXfxTeIxiMat5RMN7jOuaNf5zeFu7n4eZgQ+T+fO7q+7ze0O7/L87vFO759nt/WO76Ptsved73rM7xTd7wFvJ//u6QJv8DoKCe/W3QeNbvtNQ7Zl4hx+8BOPW45gMH6m8G3A8Nip4IWb0O6AuP1d4BRP8sU4CJsAV0/RcQvvK2t4LWsD8xH/7SVP82R2CAMCw7d2F0aynxGGGQKTwQ9zdBTjgU0AWVDg0hmz0mv9BTve9P8bI/InW/NTX+58pnRNg56RRxVYOL8O2HeT91YsunjFUslnBddI81YfH+b6vKVRr7RUD/fQ2gimxQUBR8G0p50u+oBOaqi28MbOgkGCvQhLzSOrYeiGf3xuL/Fxz/gA/QffVVVlYqbVghBqxHLptz7tkw/Mw9qiNfiK3BxOYur2Jx6jf+ia2PipX82HIBXhFBwKcAtQRflSVXTKvIF9X/RIIALqPfi13CdzAZJEBPy5cfrSpvrHv2hrsfHxjfzNf+XKT/B97vzTL/VsGf3UD5jXH+rYP/3a37jcD/5DG5jeH/5bSf4IX/7df+/pz/4F3aH2IPPYYRlzyP7lLwl3A0D/FQfY4xD/IACII1ma5ykM5xIQKEkEMDzTN57rO9/7PzAoHBKLxiMyqbzZRIICwFAQ/GSxJsq1XDKwSe82LB6Ty+YzOq0GYp+ixsGQCAQcAISCLmDMAw2Ai8xcAYOVHN1BidYA3cACIELBQQEdIQIdnQEBZQACwEBf4gGm5xNdQt8DicpnKADnJJVBgAGenmGf3RNlwiMJ2Fqw8DBxsfEx8kgbFIMCQsNfM8GAnVPCL4EMAwC0FVyUwrYywdPCQgKVX0lB9WeiM8CDwmd0gDjAwfWTwSzVwcoIVgNWyNBkY0oUWtRGeIumgFwBAwvg/Upm8SLGjBo3EmuDKVEBT58Q/xCYM4CBgQYBEngKZOOJFU50RIpwcSARAAGJtCwYhQjAuUSzMCmkAklAngBQWAF6wdTJigGyaFl5NVWTyUIzQooYgIAp14ocx5Ita/Zs2WUkoAHo8uINzpxQXIpIcMBbXEUQzSHUcumR3XNGAVDsSuUBrQCqHCwFqOVpzqhXqw5IJIDWCDgN27oAS7Mm2tCiR5MufUTtiEN1PlVicHlmUxmnDEbpg3kc6wCOmtaudOA1nWycoDDSk7tA45pOAUL9NNmG7DkGihPCRUcXwLDKTHPv7v27aGCmpYYHb/48+vRqxJcmH5q9+vjy59PPUp8s/Pv69/Mfnb+/MP8BOCCBBf8OI6CBZiCYIIMNOkjEgg8uEaGEFVp4IWgYokGhhh162B9RIYo4IoklmngiiimquCKLLdLxIYwxyjgWhzPaeCOODtaYI489+ijfjj8KOSSR7xV5JJJJlhakkk06+WQYTEI5JZVV8iCllVlqqSWWW3r5ZZETSJChBBOAeSaaVVIQAAQRBBABBAFQkCaddSZ5QYgX2Lknnz5KEOKYfQo6aIxx0gEBoYkqeqGbdESwKKSRJlhBABVIeimm+1kQgAWZevppehMEYCaopZpqGganqroqq6266p+Lsco6K62YvHrrj12apyuuvQLI63fA+jpsfcJ2ZyyxyaaHrGnMKvusd87/kiYttNX6550VkJlQVQ3WessgFrKtZIAJTLl3g7Y+pLvtDOsyNINPhCjyLb0EhovZAH+U4C4M/OrgrwjZMncCt9zou129Ce93L7lPXILIUAH8Q8Vr8q40U8R5qRTAPK8lsA0oEH+kwmXTNbKAwABsAtvKL45w07wKy0wfw0GN8Je5e4QDgAN/BEBxcqtEJEIX2/zzCUG0MAWTXOagkzI88hBGRVUMgOILwjNrvewVpyyAgG0G5PxwJbxFElkJMItwtsrEXbU0QGrrJHDEmWBWFdsxb703eAyPwE48Sl/jXDP3mL3U4AENzdk2DUiWkNiDL10AXwJA/ZkCFOdHbRa1/3r+Oeihiz466aWbfjrqqROVjN9OVEJLMxKTB9xOL5wde17FdXwKyFfh/lRxjqTcMhQPz7E2FCZwfsLyfHvZvA7QmyV91s63Sj0TEmIPiPWvbt/tg9t/372T4zOv/Rrmk5+k+no3KP76rLYvlo7px19MF4nzOH/14NpvoAOCI4YWzKMH+QvDHAxHg8u0AwcHXAUmHqKUgE3QBA/sEf9qoroNku5/BYIFRi5IDAbuQIQiQIy+KPGCADZwBCbEUQYtEsP1GAgxCVCAAh4RwFzw7GKrCWADFOCABVBHFYyw3EomMo8ADiAPB1DJzpKiDik+wGqNINcIFrCxAqiCbHUgYP9O1KESBuzwOkApYhcw8TVO/IGJefgDFUmAQtfZgRKGYwAl8nANPlyxh3T4QyT+eEZMDGZAM0TGITdkIJUIgJE9pMIcCBBASLoggNdRyQMWUIAcAmAOChgaDh9JGFpcIi8qfOAmvyaxtShmFoSYIAPBeJk/jHGSnXQBJjWZQxIecBQIsGUeGPDCOSaEi7pZhz0OmEpB2NCFK8FHJwKYlwIl0hjVVFCB6vZMW2KSm4qx5SgBo5jA/UwEoQRmABYwR0vSoYrPTCMm9CfFdqojlhwLIy3t4U15pPOWDyAhcK5jywQOUx1dUUonSADG/B2wBekszs8CWgc80mFn1LTQNcv/kNEyzFIEKpykJvX5s5CSsZzcUIwunfZJBZDrnOXMgzr9cJkVYLILydskFkugEpoIIoxD5NgCOlrLkdoxl6m8TCJEONBkVlCOBr1DRU2AQ5Q9c5nPPKFSXtjDaYIIo/b64Di3GsCkeGKssAEnEU9hxE7IgHIupQJMUXgOjs1BFRurIkQPBpSN3dOSjLCDX8UoUrIOciWqmGs6A6mHpTaunQGJ4AicaALEXGyPfRiA2OLZRZk0EhOYNdBGA2SCIybkLegJ7RrAKQLVooWENGDtrVDrwREMgBL80ALXJMRa2JrFtTDgratkS8MSVGYgs3hB8LDGHeHez0PMJYOYyESq/8rI4DJ7EUywmnuq545hTW16U5zm5I6T2gQnOsmudkvF3THgiSh66opQglMOTRayWelV74P+RJRAjReayD0Zeu/rqfWOwVBs+pWAP0VgMTTqTQjGyAPkdYOFDOlcO7AwoRYsBkpZ6sGuE2S5BnYl0+aAi2GUmAOYgwegPAQGZEOIc4SRYobkQcJhuIxIcMwb2tY3BxjeAXB6rIS8YcQALU7b6iBUoU11ysNyiQKMVyHiLYAtICvoAhYp7ACu3ix5SBHyho5pTio4QH9LuMzgKPEZHvvgxz1AjHKXQGSLvIbEIlCbETQcBlGRqquKg4tqHJAx1SQiZKsk7zy0sLFe2P/CpHduB1PQkRBxSA1pJcibAK5BnuEwwIua4ERL+uAJnyS0to3IY06tTLR+FqytHNuYHVSD2xzsggAPYERLXsBXKnDa0wTIAzw23RpAwOIUKHADCUytG1ST19E5IPKvOeYJqdSW1Aio27Vd8QQ9LiBivXC1AmDNPDtDUykkBre4ZW1nPYchVYYUWlucwRZpMOUbRrZa0sS2uKZkGjAqaGFXaLI0fTBnFl0Rcd6sYGHAwZcwnpBaOZFCgnxY+hIviLKqVQad22j84iu4BDcGN2scPEEnDbhErvcR47+1ozJTu0MOF26Hck7itnYeip0HAtWLCwAp5HKzi5M3ZpgTMQH/qaa4NbQolHDMN8qzeIAMPA7VccPgAAWkoNRB3gCRr3trHvlJWLwCFqIggDyzMACem0JqiZVEN4bzSsZbgEeaGBwFmNa0AHryEaDYJSFEOa7GxZYUt2ncMCFe9SNabQPyxEQkI0dXRO6Z0PIaRu8/sdnZazKdvJO6dmjbcQmwnGyqLV4nOAG63YWeeUBs3gmDv3MvXkF2cx3AijOhDOmpjgLFG77xynHfFzgo/OF/bgioeUM9yDG4b7D57CpXTr9NwPxHZzzknDxhAXVOArYhZdoC+EsnD4Bdc35GC4x5Os8Ij/vDD73MV+j9DOb9+AVCoQHpSDnl6Av+wEh66Egh/+L39VPfPYZjkNgAvABivF3uOUfTgVnqkUDm5ETMTcViQMHRwIWUgQMCUFwLkETpFZ7yvAXIdZLRDMz6bYZbAB8SsNu0GB+8pQYP4Y6stV7m6Q5v8FXZDdvNSM5PBE5ebNnBXRomhJ0AqIYkBJRwlM0Q/pdSqN8H/gImkEu02RgIMt4MUJQKAZnQQUJTzNUnFWEfHCFRZAOweZ8Reh5TjFyQEdcCSgViYRwOeJHllOHKUUcBiMvPzCBw/MEUstUHFsyJrdIILprhnOAVUkIW0o8SsOC1CEE1mRgOTAS5TcgkCoPoDYgmrVkwAIwlclyGTMiWSEk1RZgCnQCFkcH8rf+BuDjgfHjWMXBiGqyi8kRJKLpggmWKszBieTjiLeIiLW7ilIlBKooWL/bipeQiEbwGlwGdvwCi8VXi59GAMwaBKO5LUjRAnEUPNAbDjLFLI+zAMO5LMBJDN5aAuIyj7qELOqZB3QhZOXpMNh7bOr4LMYJiMo4jM67jNFIjNHLiPv5ANY4AYniCHOgVOG7jeogZChiZKiABLIbZOjJkEjwkGawe84hZ0XQSwA3BP6LiLw5BGooa2UTC22xSEnlbSE3QoimXtbXCT6gbCbATPB0A2ViGVBDFFlKjLb5BO3RBUCFHEvFRPbUGqRkEQnLUOl6iE3ACKjiWS3jSNiDE2X3/BKHBnHGggb8opVycQirExsXsjFQmBsS4QqOx4hFEjEFmXKY1x7vkkbgJhCtcYEgMB3n1glCmZZ59pBCkIdCsXFjqW+WkhmJURfT1X9poWr45zu8pQ0NG49qkE9N0ZA8EpEcNhvNFxER8ReIUDs/4zFtEXTEwRcRgESXU1z70Az6sgEsgF0i8DUDYWzicYhqIZhR6lLPJxW35g2pmwyK0JuTU29JZzUaSQTMUYW1+3uRcQda1S1Tkm1x6YNJ1Us+Z2SLqZRCkoe0QnlX8JkBUhu354Z0RRV4gRdmYHS2EhRpSgvgxBdhEIVNI5pXsJDf0JGRmx7WpBEt40Vwc5Wyu/2MmZiBvsAJd4INvOl92kF3bnUR/0sB/ZhwBeuWdFajSHCgpJGgpjoGbDRxbUhD8oY15op19VsXaxQF+amJebkGXYOcdEEc1uFzJsIKRbeA1dKAMPEL0lQD6MUaMnZ38TaIzrOUr2AFiiA1A1OiJ6uTNJFRBfp52PAFnMibWhWYw/gY4FJKKCihvRuh4vejycdn0mcG6UKmRWWkBos2AwoyLCg4GSh+XKYEA2IE0pABAZGQCNJAhemhJqowzGOmNvmB1omgy/oRfFM/tnYLSYAIf1lgnzFX9kUKyVQLhnR1FRVIWJYVdOlHFTKgIMGoRUKbr/ZGN2idwlMLe+YRRdv/EcXYZiDnockAogWrcxRiADIYNdVxolKQq8qwqWz7omSZCdMCOE81grZZBy2zk351Y7NFjjKXMh0rBSjgDp+LgqAIqtWaJpxrjoiAjl8gntiqKtlort3ZrhlknlVyruA7Ktw6Ds9YXfFJQOF6EufIA6p1rkaSrjAUjIKaiYdLAu+JAu+aAp+6hj5nlMZRj1ygkDvTrhhpDO+rAvFbfRpxjwNSYrbJfwvLncNkjMdgfwSDIkY3BvyasfLqBFBDsw1oTwpqARDrkPLKjJ7LsWUhkBLrfF2BsGtjrhWnbTZqMblDVIGyDx3RaFCZXvvImVMbLc6aV5DHhbvjQZ6AkXYb/62S+IBxUZUuSRz6Qy20aQ1Z6oimsRFc+JcdE5VVQJVkmBcGeJaLuC1N2JXk47XZO5Vj+RFkiA5b5JAhSkFuaEVzSrQ3cRFFWjDD1AV56ZLX2QL4wDtPM19PYg8Fk5NHMTv41rl6ApstpwXMaKfRNbjr0pcoOpq4ELDPIW3C+DN5dICCk7YL63W2UJtvmZmp6JWvGraZyQ3DKZhoUp9DAbuR27pP9JXCCg3BahOtWRUG8y3J6aL6NIMxoAWf2DJAGA846rFF0AlPIzV28xFwGDOFhb9GKqOc9Zw9FIOXlhOcR2XdCZ6eO7N7JhPW+XhOxFEf4S4Puaqv2Ku0SqW1W/2hWrIGFXenjDGr+jh3/uh0yZCLe8t6yMueOktLfni9OpsRKmKjhaiziHkbtNmBV2EVGKqbkVs73PnCAQsGv0QSWdUb+9UV2TtyM+mE8+oDorkVc5CiL1lxNqC5WTqksRCCrmmmWvmqaRs6a6lSbnhmcfuznPejbrnAQA+mXZkYRn4GYRuDM6s+dCsRz8MMAqsKT+qkiHa68ElI0Em08NQzv1OHJhLCWaoGz3pAHCirTPoIA0xhCIQCnSm18/hkMDi2kxtgkbMPWomomXBobiePvYSn4wqp0zCofZ9UZFKshB2gAr/Cvymqw0qoODoNi6csUFuIfMvCHsoYC9J2p0v/OtGbsn7aZ6oasfsQrve7J9A6sDrDyfbjyK9dJLD+JLd9ymuRy+eAxL/cyuRLDROhvfOwygVCkrygzjQzzCQglTshEy+5A2TnmIyPIyfKrfL4YDisrLYuBwbqQKwCoeZTj2p0AYiQpJjBhFLMhrU2zD0AzwfRBJEeLM5vALzHOK1CwEMAdM6tBNoMPkiKP63Vz3iJSyq4NnDouxEaLQqYdcbnMigpNtylAYxrBPz/bQivQLHBZRmuEL7OA4zJlqqGbGalGA8CkkYXqiiahRNeEqLUNbFDbFiKUxBhbtgAloz3wSAouOG6z0K3lX0ZdJ8RTSt7hDASaXPCCjVIL/TL/9FIydW44AvPuRCQcgEzSGXPEyyRyC9lQQQO0qJW2rWO9bUz/pdnSLdoGgdyVQDgrjlQnV1VDgiRktTXdMwrI5jnoFWgWwMfFH3Ns3e85QDWoANi0lB3kK8XMQ9TMAyikWuriQ0QcV05LhDPMNXk8b+GeTzESNIcOtbM9nfHGn0NAhGWT6hjQ5iB3RQvtQ2YybgCusb6E1UWki9XJXkId9GNajVG4nOLwbgD3JfC+5u0Op7zG2tBaaqq59o9y7lwbFG0fQ0grVN/VcxXmnnag5wtYFHmqQuYVbeCFSOvpRRJnqWdgNhXo50939kRbQ/5WDUSpr++NhGeA6TjaTCSH/wT2PvdbmIL4aTW7dOy4hbXh9TAWH84AU+jt9a8P4LdOGUV1s6V+mxdNijBu+fcLo/IXzHJhTIPTFNKdKibycYatJU6mWdzLXQZ562hhrBw2lHfK7HNByEGhHXHFCjQbbJ+XBZtlUMXftrAHJh5pk3h9q7gYrEsJy6lHfUUKI5EWex4E8jMwjsDHxG6Av4En4MFPVvRFA3CMCXATd+kJPHEOJHkKxF6dAmhIaDAt0DjokZ904/XEiadq7IayWmFv+AEW4tJgsALKPQwlKEIlvADxuDhuYGeMcwUjjHIiPMxX7F30bPMQikQlG6+i2vEgWMdqFLm0HOucQ7qETxuALaz6AL7ARHgN69QmIY6Wo74GRRTHNHn5Ek90JTNyJgxrD4yo9AFYxin6qNOV5516EsU5GK9B0fQT5JG3kbB3MNvJdIeBLKJLRa2bzbIOMDc7mDw7kiAzttdisU8Jt3c7uH47lIS7uFeJth+JuZ87uMu5kogi8cW7vM87vde7vd978aEovu+7vLO7v/87wAe8wA88wRe8wR88wie8wi88wze8wz88xEe8xE/8v4cAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AWS: alcohol withdrawal syndrome; CIWA: clinical institute withdrawal assessment for alcohol scale; RASS: richmond agitation sedation scale.",
"    <div class=\"footnotes\">",
"     * Doses are for adults. Medications and doses may need adjustment based upon comorbities (eg, liver disease), patient age, or other factors (eg, coadministered medications).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Lorazepam infusion is titrated to effect, and additional symptom-based bolus doses, 2-4 mg IV, are given when titrating the infusion up.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert S. Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24641=[""].join("\n");
var outline_f24_4_24641=null;
var title_f24_4_24642="Knee pain";
var content_f24_4_24642=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Knee pain (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24642/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24642/contributors\" id=\"au5319\">",
"       Bruce C Anderson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24642/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24642/contributors\" id=\"se7143\">",
"       Karl B Fields, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24642/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24642/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24642?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      KNEE PAIN OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The knee is a \"hinge\" type joint that allows the leg to bend and straighten (flex and extend) (",
"     <a class=\"graphic graphic_figure graphicRef70435 \" href=\"UTD.htm?42/54/43873\">",
"      figure 1",
"     </a>",
"     ). Of all the joints in the body, the knee is at the greatest risk of injury, age-related wear and tear, inflammatory arthritis, and septic (infection-related) arthritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      KNEE PAIN CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     There are many conditions that can cause knee pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Patellofemoral pain syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is a group of symptoms most commonly caused by overuse of the knee. It affects many running athletes, and is more common in women than men. It causes pain in the front of the knee, and pain may worsen with squatting, running, prolonged sitting, or when climbing or descending steps. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link\">",
"      \"Patellofemoral pain syndrome\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Bursitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The knee is lubricated by joint fluid that is produced by the lining of the joint and by six lubricating \"bursa\" sacs. The bursa sacs can become irritated as a result of injury, excessive pressure, or overuse; inflammation of a bursa is called bursitis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      \"Patient information: Bursitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Joint effusion",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a knee injury, excessive fluid can accumulate inside the joint. This is called \"water on the knee\" or a joint effusion.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Arthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cartilage covering the ends of the bones and the undersurface of the knee cap (surface or articular cartilage) can become worn down, irritated, or irregular, a condition known as arthritis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"      \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Meniscal tears",
"     </span>",
"     &nbsp;&mdash;&nbsp;Specialized \"shock absorber\" cartilage located between the thigh and leg bones (meniscal cartilage) can be damaged, a condition known as a torn meniscus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Cruciate ligament sprain or tear",
"     </span>",
"     &nbsp;&mdash;&nbsp;The knee joint is held tightly together by four ligaments: the inner and outer fan-shaped hinge ligaments (medial and lateral collateral ligaments) and the crossing (cruciate) ligaments, which sit in the middle of the joint (the anterior and posterior cruciate ligaments) (",
"     <a class=\"graphic graphic_figure graphicRef69611 \" href=\"UTD.htm?34/27/35251\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The collateral ligaments are firmly attached to the far end of the femur (thigh bone) and the near end of the tibia and fibula (lower leg bones). They function to hold the two bones together and prevent side-to-side motion. The cruciate ligaments are firmly attached to the far end of the femur and near end of the tibia. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1797?source=see_link\">",
"      \"Patient information: Anterior cruciate ligament injury (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Muscle strain",
"     </span>",
"     &nbsp;&mdash;&nbsp;The quadriceps muscle (in the front of the thigh) and the hamstring muscles (in the back of the thigh) support and move the knee joint. Loss of strength in these muscles from injury or disuse causes the knee joint to become unstable.",
"    </p>",
"    <p>",
"     Significant weakening of muscle can cause the knee to \"give out,\" potentially leading to a fall and further injury. Excessive use or a rapid contraction (ie, from sprinting or jumping) can strain the quadriceps or hamstring muscles.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Knee injuries",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain in the knee can also occur after an injury:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Acute injuries may be caused by breaks in the bones, torn cartilage, ligament rupture, or increased joint fluid due to a severe knee strain, infection, arthritis, or bleeding. Most acute injuries cause severe pain and swelling.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More subtle injuries, such as partially torn cartilage or tendon, and ligament sprains cause less swelling, pain, and minimal difficulty walking or bending the knee",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Overuse or excessive use of the knee can cause patellofemoral pain syndrome, arthritis flares, bursitis, or a knee strain and effusion.",
"      </li>",
"      <li>",
"       Wear and tear over time; painful knee caps and arthritis are the two most common causes of knee pain in people without knee injuries.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      KNEE PAIN TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Physical therapy is essential to the treatment, rehabilitation, and prevention of many of the conditions that affect the knee joint and its surrounding supporting structures. Physical therapy for knee pain often includes ice, elevation, and muscle-toning exercises.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Activity limitations",
"     </span>",
"     &nbsp;&mdash;&nbsp;To speed recovery and protect against future knee damage, activities that cause pain should be avoided temporarily.",
"    </p>",
"    <p>",
"     The following positions and activities place excessive pressure on the knee joint and should be limited until knee pain and swelling resolve:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Squatting",
"      </li>",
"      <li>",
"       Kneeling",
"      </li>",
"      <li>",
"       Twisting and pivoting",
"      </li>",
"      <li>",
"       Repetitive bending (multiple flights of stairs, getting out of a seated position, clutch and pedal pushing, etc.)",
"      </li>",
"      <li>",
"       Jogging",
"      </li>",
"      <li>",
"       Aerobics, dancing",
"      </li>",
"      <li>",
"       Playing stop and go sports (basketball, sports that use racquets)",
"      </li>",
"      <li>",
"       Swimming using the frog or whip kick",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The following types of exercise equipment also place excessive pressure on the knee joint and should be limited until knee pain and swelling resolve:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stair stepper",
"      </li>",
"      <li>",
"       Stationary bicycle",
"      </li>",
"      <li>",
"       Rowing machine",
"      </li>",
"      <li>",
"       Universal gym utilizing leg extensions",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The preferred exercise equipment for the knee should provide smooth motion of the knee, maximal toning of the front and back thigh muscles (quadriceps and hamstring muscles), minimal jarring and impact to the joint, and the least amount of bending to accomplish toning. These activities are acceptable alternatives to the above:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fast walking",
"      </li>",
"      <li>",
"       Water aerobics",
"      </li>",
"      <li>",
"       Swimming using the crawl stroke",
"      </li>",
"      <li>",
"       Cross country ski machines",
"      </li>",
"      <li>",
"       Soft platform treadmill",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Ice and elevation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ice is useful for the control of pain and swelling. It can be applied to the knee for 15 to 20 minutes as often as every 2 to 4 hours, particularly after physical activity. A bag of ice, frozen vegetables, or a frozen towel work well. The swollen knee should be elevated above the level of the heart while icing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;If needed, a non-prescription pain medication such as acetaminophen (Tylenol&reg;), ibuprofen (eg, Advil&reg;, Motrin&reg;) or naproxen (eg, Aleve&reg;) can be taken. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .) No more than 4000 mg of acetaminophen is recommended per day. Anyone with liver disease or who drinks alcohol regularly should speak with his or her healthcare provider before taking acetaminophen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Strengthening exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rehabilitation of the knee begins with gentle strengthening exercises. These exercises are performed",
"     <strong>",
"      without bending",
"     </strong>",
"     the affected knee.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Straight leg raises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sit on the edge of a chair or lie down on the back. Bend the opposite leg (",
"     <a class=\"graphic graphic_picture graphicRef78695 \" href=\"UTD.htm?10/31/10736\">",
"      picture 1",
"     </a>",
"     ). Keep the affected leg perfectly straight and raise it 3 to 4 inches off the ground. Hold for 5 seconds. Repeat 10 to 15 times (one set). Perform a total of three sets.",
"    </p>",
"    <p>",
"     As your condition improves, perform straight leg raises with weights at the ankle; begin with a 2 pound weight and gradually increase to a 5 to 10 pound weight (pennies or fishing weights in an old sock, 2 cans in a purse, or Velcro ankle weights).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Hip abduction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lie on your side on the bed or floor. The affected leg should be on top and should be held straight. The bottom leg should be bent. Hold the top leg straight and raise it 3 to 4 inches towards the ceiling. Hold for 5 seconds then slowly release. Repeat 10 to 15 times (one set). Perform a total of three sets.",
"    </p>",
"    <p>",
"     Be sure to avoid rolling forwards or backwards while lifting the leg.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Hip adduction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lie on your side on the bed or floor. The affected leg should be on bottom and should be held straight. The top leg should be bent with the foot placed in front of the bottom leg. Lift the bottom leg 3 to 4 inches. Hold for 5 seconds then slowly release. Repeat 10 to 15 times (one set). Perform a total of three sets.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Quarter squats",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stand 18 to 24 inches from a wall. Lean back against the wall. Bend both knees slightly (the buttocks should not be lower than the knees), keeping the back straight (",
"     <a class=\"graphic graphic_picture graphicRef64474 \" href=\"UTD.htm?30/40/31361\">",
"      picture 2",
"     </a>",
"     ). Hold for five seconds then slowly stand up straight. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of three sets. To increase the difficulty, bend the knees more deeply, hold for a longer time, and increase the speed.",
"    </p>",
"    <p>",
"     Alternately, use an exercise ball to perform squats. Stand up straight, holding the ball between your back and the wall. Slowly bend the knees and lower the back (roll the ball down the wall). Hold for a count of five. Stand up. Repeat 10 to 15 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Stretching exercises",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Hamstring stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sit on the floor or bed with the affected leg extended straight out in front of you. The opposite leg may be bent or may hang off the bed. Keeping the affected leg straight, lean forward and reach for the ankle. Hold for 30 seconds but do not bounce. Sit up straight. Repeat 10 to 15 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Quad stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stand behind a chair, holding the top of the chair with one hand. Bend the knee and grab the foot with the hand on the same side of the body. Stand up straight. Gently pull the foot towards the body. Hold for 30 seconds, holding constant pressure on the foot (do not pull-release-pull). Release the foot. Repeat 10 to 15 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Runner's stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Face a wall and stand 18 to 24 inches away. Place hands at head height and lean into the wall, keeping legs and back straight. You can rest your head on your hands, against the wall. You should feel a stretch in the muscles in the back of the calf. Hold for 30 seconds. Repeat 10 to 15 times.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287529743\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600269\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/36/7747?source=see_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=see_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=see_link\">",
"      Patient information: Meniscal tear (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/10/18594?source=see_link\">",
"      Patient information: Patellofemoral pain syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/37/11858?source=see_link\">",
"      Patient information: Chondromalacia patella (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/27/5554?source=see_link\">",
"      Patient information: Iliotibial band syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/6/35937?source=see_link\">",
"      Patient information: Baker&rsquo;s (popliteal) cyst (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600306\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1797?source=see_link\">",
"      Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=see_link\">",
"      Knee bursitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=see_link\">",
"      Medial collateral ligament injury of the knee",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link\">",
"      Meniscal injury of the knee",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21157?source=see_link\">",
"      Patella fractures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"      file://orthoinfo.aaos.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"      www.niams.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Rheumatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"      www.rheumatology.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Arthritis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.arthritis.org/\">",
"      www.arthritis.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24642?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_4_24642=[""].join("\n");
var outline_f24_4_24642=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           KNEE PAIN OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           KNEE PAIN CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           KNEE PAIN TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/54/43873\" title=\"figure 1\">",
"           Lateral knee anatomy adult",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35251\" title=\"figure 2\">",
"           Anterior anatomy of knee",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/31/10736\" title=\"picture 1\">",
"           Straight leg raise PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/40/31361\" title=\"picture 2\">",
"           Quarter squat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24643="Breast MRI for evaluating extent of disease - case 2";
var content_f24_4_24643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Breast MRI for evaluating extent of disease - case 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be used to determine the extent of disease in newly diagnosed cancer patient. Architectural distortion was detected in the central left breast on screening mammography. Diagnostic mammography confirmed persistence of the abnormality (A) and biopsy under ultrasound-guidance confirmed invasive ductal carcinoma. Preoperative MRI confirmed the large invasive cancer in the left breast (B) and a second suspiciously enhancing lesion in the outer right breast (C). Subsequent biopsy of the right breast finding revealed an invasive ductal cancer confirming contralateral disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24643=[""].join("\n");
var outline_f24_4_24643=null;
var title_f24_4_24644="Diabetic kidney disease (diabetic nephropathy)";
var content_f24_4_24644=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24644/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24644/contributors\" id=\"au5420\">",
"       George L Bakris, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24644/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24644/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24644/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24644/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24644/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24644/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24644?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     People with diabetes have a lot to juggle when it comes to their healthcare. Having diabetes puts you at risk of other health problems, including heart attacks, strokes, vision loss, nerve damage, and kidney disease. While all of that may sound overwhelming, there is some good news; many of the steps you need to take to prevent one of those complications may actually help to prevent them all.",
"    </p>",
"    <p>",
"     This article will discuss the early signs of diabetic kidney disease, or what healthcare providers call diabetic nephropathy. People who develop diabetic nephropathy usually have no symptoms early on, although the condition puts them at risk of developing more serious kidney disease. More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"      \"Overview of diabetic nephropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The kidneys play an important role in the body: they filter the blood, removing waste products and excess salt and water. If the kidneys become diseased, they falter in their task, leaving the blood polluted.",
"    </p>",
"    <p>",
"     Finding out that you have early diabetic nephropathy can alert you that your kidneys are in danger. It is important to take steps to protect your kidneys before the problem advances. Information about advanced kidney disease is also available (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In some cases, diabetic nephropathy can eventually cause the kidneys to stop working altogether. If that happens to you, will need to have a kidney transplant or dialysis, a procedure that filters the blood artificially several times a week. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     .).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Diabetic nephropathy usually causes no symptoms, and people who have the condition often produce normal amounts of urine. To detect diabetic nephropathy, healthcare providers rely on tests that measure protein levels in the urine and blood tests to evaluate the level of kidney function.",
"    </p>",
"    <p>",
"     When the kidneys are working normally, they prevent protein from leaking into the urine, so finding protein in the urine is a sign that the kidneys are in trouble. Often people who have diabetic nephropathy also have high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are several factors that can increase your risk of developing diabetic nephropathy. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Having chronically elevated blood sugar levels",
"      </li>",
"      <li>",
"       Being overweight or obese",
"      </li>",
"      <li>",
"       Smoking",
"      </li>",
"      <li>",
"       Having a diabetes-related vision problem (diabetic retinopathy) or nerve damage (diabetic neuropathy) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"        \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Having a family history of kidney disease or belonging to certain ethnic groups (African American, Mexican, Pima Indian) can also increase your risk of diabetic nephropathy. But the factors listed above are the ones you can do something about.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Urine tests are recommended once per year in people with type 1 diabetes, beginning about five years after diagnosis, and in people with type 2 diabetes, starting at the time of diagnosis.",
"    </p>",
"    <p>",
"     The urine test is looking for a protein called albumin. If there is albumin (protein) in your urine, it means you have diabetic nephropathy. You may be told that you have \"microalbuminuria\". That simply means that you have trace amounts of protein in your urine, but it still means that you have nephropathy, assuming you do not have kidney disease caused by another condition. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"      \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"      \"Microalbuminuria in type 1 diabetes mellitus\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"      \"Microalbuminuria in type 2 diabetes mellitus\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The same urine test that is used to diagnose diabetic nephropathy will also be used to monitor your condition over time (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Monitor for signs of change'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The key complication of diabetic nephropathy is more advanced kidney disease, called chronic kidney disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Chronic kidney disease can, in turn, progress even further, eventually leading to total kidney failure and the need for dialysis or kidney transplantation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     People with diabetes often focus on keeping their blood sugar levels in the right ranges. And while it is important to control blood sugar, it turns out that controlling blood pressure is at least as important. That's because high blood sugar and high blood pressure work in concert to damage the blood vessels and organ systems. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"      \"Treatment of diabetic nephropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     For these reasons, the most important things you can do to stall kidney disease and protect against other diabetes complications are to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Make healthy lifestyle choices",
"      </li>",
"      <li>",
"       Keep your blood sugar as close to normal as possible (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Manage blood sugar levels'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Keep your blood pressure below",
"       <span class=\"nowrap\">",
"        130/80,",
"       </span>",
"       if possible (see",
"       <a class=\"local\" href=\"#H9\">",
"        'Manage high blood pressure'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Lifestyle changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changing your lifestyle can have a big impact on the health of your kidneys. The following measures are recommended for everyone, but are especially important if you have diabetic nephropathy:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Limit the amount of salt you eat (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       If you smoke, quit smoking (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lose weight if you are overweight (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"        \"Patient information: Diet and health (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"        \"Patient information: Exercise (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"        \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Manage blood sugar levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Keeping blood sugars close to normal can help prevent the long-term complications of diabetes mellitus. For most people, a target for fasting blood glucose and for blood glucose levels before each meal is 80 to 120",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (4.4 to 6.6",
"     <span class=\"nowrap\">",
"      mmol/L);",
"     </span>",
"     however, these targets may need to be individualized. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A blood test called A1C is also used to monitor blood sugar levels; the result provides an average of blood sugar levels over the last one to three months. An A1C of 7 percent or less is usually recommended; this corresponds to an average blood glucose of 150",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (8.3",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"UTD.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ). Even small decreases in the A1C lower the risk of diabetes-related complications to some degree.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Manage high blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with diabetes have hypertension (high blood pressure). Although high blood pressure causes few symptoms, it has two negative effects: it stresses the cardiovascular system and speeds the development of diabetic complications of the kidney and eye. A healthcare provider can diagnose high blood pressure by measuring blood pressure on a regular basis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The treatment of high blood pressure varies. If you have mild hypertension, your healthcare provider may recommend weight loss, exercise, decreasing the amount of salt in the diet, quitting smoking, and decreasing alcohol intake. These measures can sometimes reduce blood pressure to normal. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"      \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If these measures are not effective or your blood pressure needs to be lowered quickly, your provider will likely recommend one of several high blood pressure medications. Your provider can discuss the pros and cons of each medication and the goals of treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A blood pressure reading below",
"     <span class=\"nowrap\">",
"      130/80",
"     </span>",
"     is the recommended goal for most people with diabetic nephropathy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Blood pressure medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with diabetic nephropathy need at least one medication to lower their blood pressure. Several medications can be used for this purpose, but a medication known as an angiotensin converting enzyme inhibitor (abbreviated ACE inhibitor) or a related drug known as an angiotensin receptor blocker (ARB) are used most commonly. ACE inhibitors are generally used first because they have been available longer than ARBs.",
"    </p>",
"    <p>",
"     ACE inhibitors and ARBs are particularly useful for people with diabetic nephropathy because they decrease the amount of protein in the urine and can prevent or slow the progression of diabetes-related kidney disease. In fact, the kidney benefits of ACE inhibitors and ARBs are so robust that healthcare providers sometimes prescribe them for people with diabetic nephropathy who have normal blood pressure.",
"    </p>",
"    <p>",
"     Still, despite their kidney-protecting abilities, ACE inhibitors and ARBs do have their downsides. For instance, ACE inhibitors cause a persistent dry cough in 5 to 20 percent of the people who take them. Some people get used to the cough; others find it so disruptive that they cannot continue taking an ACE inhibitor. For them, ARBs are often a good alternative, because ARBs are less likely to cause a cough.",
"    </p>",
"    <p>",
"     In rare cases, you can have more serious side effects with ACE inhibitors and ARBs. These include a decrease in kidney function or a condition called hyperkalemia, in which too much potassium accumulates in the blood. To monitor for these and other side effects, healthcare providers sometimes run blood tests soon after starting these drugs. In some people, the medications will need to be stopped.",
"    </p>",
"    <p>",
"     More information on the risks and side effects of ACE inhibitors and ARBs is available (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"      \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Monitor for signs of change",
"     </span>",
"     &nbsp;&mdash;&nbsp;After beginning treatment and lifestyle changes to stall kidney disease, you will need to have repeat urine and blood tests to determine if urine protein levels have improved. If the urine protein levels have not improved or your kidney function has worsened, your healthcare provider may need to adjust your medications or recommend other strategies to protect your kidneys.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PREGNANCY AND DIABETIC NEPHROPATHY",
"     </span>",
"    </p>",
"    <p>",
"     If you have diabetes and are interested in getting pregnant, it is important to talk with your healthcare provider well in advance, especially if you have diabetic nephropathy. Diabetes and its attendant problems can increase the risk of complications in pregnancy, especially in women with decreased kidney function. However, many women with mild diabetic nephropathy have normal pregnancies and healthy babies. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"      \"Pregnancy in women with underlying renal disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     To ensure the best outcome with a pregnancy, the most important thing you can do is to keep your blood sugar and blood pressure under tight control. However, women who are pregnant or attempting to get pregnant should not take ACE inhibitors or ARBs, as these drugs can cause birth defects. Instead, other medications (such as calcium channel blockers) are used during pregnancy to keep the blood pressure in check. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      DIABETIC KIDNEY DISEASE AND OTHER DIABETES COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     If the steps you need to take to protect your kidneys sound overwhelming, keep this in mind; controlling your blood sugar and blood pressure can help to reduce the risk or severity of several other debilitating diabetes complications, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Vision loss (due to diabetic retinopathy)",
"      </li>",
"      <li>",
"       Nerve damage (called diabetic neuropathy)",
"      </li>",
"      <li>",
"       Stroke and heart attack, both of which can be fatal.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      DIABETIC NEPHROPATHY PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The same measures that are used in the treatment of diabetic kidney disease are also useful in preventing it. That's true for the lifestyle choices mentioned above, as well as for the tight control of blood sugar levels and blood pressure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784950733\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18611001\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18611009\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=see_link\">",
"      Aldose reductase inhibitors in the prevention of diabetic complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10614?source=see_link\">",
"      Dialysis in diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=see_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/4/24644/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24644?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24644/abstract/1\">",
"      Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24644/abstract/2\">",
"      Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24644/abstract/3\">",
"      Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24644/abstract/4\">",
"      K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(Suppl 2):S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24644/abstract/5\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_4_24644=[""].join("\n");
var outline_f24_4_24644=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DIABETIC NEPHROPATHY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIABETIC NEPHROPATHY SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DIABETIC NEPHROPATHY RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           DIABETIC NEPHROPATHY DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DIABETIC NEPHROPATHY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DIABETIC NEPHROPATHY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PREGNANCY AND DIABETIC NEPHROPATHY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           DIABETIC KIDNEY DISEASE AND OTHER DIABETES COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           DIABETIC NEPHROPATHY PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24645="Testicular cancer";
var content_f24_4_24645=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Testicular cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24645/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24645/contributors\" id=\"au5259\">",
"       William K Oh, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24645/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24645/contributors\" id=\"se5258\">",
"       Philip W Kantoff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/4/24645/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24645/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24645?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Testicular cancer occurs when cancer cells develop in one or both of the testicles. Testicles are the male reproductive glands located within the scrotum (",
"     <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"      figure 1",
"     </a>",
"     ). The scrotum is a sack of loose skin that contains the testicles and hangs directly below the penis.",
"    </p>",
"    <p>",
"     Testicular cancer is the most common cancer arising in young men. Fortunately, it has become one of the most curable of all cancers. More than 95 percent of all men diagnosed with testicular cancer survive their disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF TESTICULAR CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Approximately 95 percent of testicular cancers develop from a type of cell in the testicle called a germ cell. Thus, they are called testicular germ cell tumors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Seminoma versus nonseminomatous germ cell tumor (NSGCT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two major types of testicular germ cell tumors: seminoma and nonseminomatous germ cell tumors (NSGCTs). Approximately one-third of all testicular germ cell tumors are seminomas; the remainder are NSGCGTs. Both seminoma and NSGCT affect men between the ages of 15 and 35 years old, although seminomas occur in a slightly older group of men (",
"     <a class=\"graphic graphic_table graphicRef62949 \" href=\"UTD.htm?38/15/39163\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     For most men, the first symptom of testicular cancer is a painless lump or swelling in the scrotum. Some men also feel a dull ache or heavy sensation in the low belly, or around the anus or scrotum. Pain is the first symptom in about 10 percent of men.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Men who detect a lump in their testicle should see a healthcare provider as soon as possible. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If testicular cancer is suspected, several tests may be ordered. However, the only way to be certain of the diagnosis is to remove the testicle.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Testicular ultrasound",
"       </strong>",
"       &mdash; Testicular ultrasound uses sound waves to measure the size and characteristics of the testicle and mass (lump), and can determine whether the mass is inside or outside of the testicle and whether it contains fluid or is a solid mass. Testicular cancers are solid and develop inside the testicle. Often, the ultrasound will strongly suggest the diagnosis of testicular cancer.",
"      </li>",
"      <li>",
"       <strong>",
"        Orchiectomy",
"       </strong>",
"       &mdash; The only way to confirm the diagnosis of testicular cancer is by surgically removing the testicle. This procedure is called a radical inguinal orchiectomy (see",
"       <a class=\"local\" href=\"#H11\">",
"        'Radical inguinal orchiectomy'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER STAGING AND CLASSIFICATION",
"     </span>",
"    </p>",
"    <p>",
"     Staging is used to determine if there is spread (metastasis) of the cancer beyond the testicle.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stage I testicular cancer is defined as cancer that is limited to the testis only.",
"      </li>",
"      <li>",
"       Stage II testicular cancer has spread (metastasized) to the retroperitoneal lymph nodes (located in the abdomen).",
"      </li>",
"      <li>",
"       Stage III testicular cancer has spread to other organs",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Blood tests and imaging (eg, CT scan) are used in the process of staging.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Substances produced by a testicular cancer (called tumor markers) can be measured in the blood. The three most important markers are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Alpha fetoprotein (AFP)",
"      </li>",
"      <li>",
"       Beta human chorionic gonadotropin (beta-hCG)",
"      </li>",
"      <li>",
"       Lactate dehydrogenase (LDH)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     High levels of these tumor markers are suggestive of testicular cancer and can help determine the specific type of testicular cancer that is present. These markers are also used during and after treatment to monitor a patient's response.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      CT scans",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most men with a suspected testicular cancer will undergo a CT scan (sometimes called a CAT scan) of the abdomen and pelvis. A chest x-ray or CT scan of the chest is also commonly done.",
"    </p>",
"    <p>",
"     These tests are done to determine if the suspected cancer has spread beyond the testicle (metastasized). The most common site of metastasis in testicular cancer is the lymph nodes in the abdomen; metastasis to the lung, liver, bones, and brain is also possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Prognostic classification",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men with stage II or III testicular cancer (both seminomas and NSGCTs) can be classified as having a good, intermediate, or poor prognosis (chance of survival and recovery) based upon the stage of disease and particular type of testicular tumor. Men with stage I testicular cancer have an excellent prognosis and are not included in this classification system.",
"    </p>",
"    <p>",
"     Following radical inguinal orchiectomy, testicular cancer is treated based on the type of tumor (seminoma or nonseminomatous germ cell tumor), the stage of the disease, and the prognosis.",
"    </p>",
"    <p>",
"     All men with seminoma are classified as having a good or intermediate prognosis. Men with NSGCT may have a good, intermediate, or poor prognosis, depending upon the stage of their disease.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Good prognosis",
"       </strong>",
"       &mdash; Men with seminoma have a good prognosis if the tumor has not metastasized to organs other than the lungs and if they have a normal AFP level in the blood.",
"       <br/>",
"       <br/>",
"       Patients with NSGCTs have a good prognosis if the tumor is located only in the testicle or area outside or behind the abdominal wall, if the tumor has not metastasized to organs other than the lungs, and if their tumor markers in the blood are only slightly elevated.",
"      </li>",
"      <li>",
"       <strong>",
"        Intermediate prognosis",
"       </strong>",
"       &mdash; Patients with seminoma have an intermediate prognosis if the tumor has metastasized to organs other than the lungs and their AFP test is normal.",
"       <br/>",
"       <br/>",
"       Patients with NSGCTs have an intermediate prognosis if the tumor is found in only one testicle or in the area outside or behind the abdominal wall, if the tumor has not spread to organs other than the lungs, and if tumor markers in the blood are not significantly elevated.",
"      </li>",
"      <li>",
"       <strong>",
"        Poor prognosis",
"       </strong>",
"       &mdash; Men with NSGCTs are classified as having a poor prognosis if the tumor develops in the center of the chest between the lungs (called the mediastinum), if it has spread to organs other than the lungs, or if any of the tumor markers are significantly elevated.",
"       <br/>",
"       <br/>",
"       Even for patients with a poor prognosis, approximately one-half are cured with aggressive treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of both seminoma and NSGCT generally includes surgery to remove the affected testicle; this surgery is called radical inguinal orchiectomy (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Radical inguinal orchiectomy'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     The need for further treatment depends on the type of cancer, the stage of the cancer, and the prognosis. Chemotherapy and radiation therapy are often used in combination with surgery, and can improve the chances of curing the cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Radical inguinal orchiectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical inguinal orchiectomy is required for diagnosis and is the first step in treatment. During the surgery, the entire testicle is usually removed to avoid the risk of spreading the tumor within the scrotum. Tissue from the testicle is later examined using a microscope.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      What is chemotherapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (like cancer cells) to divide or multiply. Because most of an adult's normal cells are not actively dividing or multiplying, they are not affected by chemotherapy. However, the bone marrow (where the blood cells are produced), the hair follicles, and the lining of the gastrointestinal (GI) tract are all growing. The side effects of chemotherapy drugs are related to effects on these and other normal tissues (see",
"     <a class=\"local\" href=\"#H24\">",
"      'Chemotherapy side effects'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Most drugs are given intravenously (IV) rather than by mouth. They are not usually taken daily, but periodically, in cycles. A cycle of chemotherapy refers to the time it takes to give the drugs and the time required for the body to recover. For example, a typical chemotherapy regimen could include a one hour IV infusion of two chemotherapy medicines given once every three weeks. This three week period is one cycle of therapy. If this regimen were repeated for a total of three months, four cycles of chemotherapy would be given.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Adjuvant chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The term adjuvant therapy refers to additional anticancer treatment that is given after surgery to get rid of any remaining tumor cells in the body (often termed micrometastases). Adjuvant therapy decreases the chance that the cancer will return (or recur), and also improves the chances of surviving cancer. As a result, adjuvant therapy has become an important component of treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Chemotherapy for testicular cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy is sometimes given to men with early stage testicular cancer. Men with more advanced stages of cancer and those who have a disease relapse after radiation therapy usually undergo multiple cycles of combination chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Lymph node removal",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common sites of spread for testicular cancer are the lymph nodes in the back of the abdomen, called the retroperitoneal lymph nodes. Surgical removal (called retroperitoneal lymph node dissection or RPLND) of these nodes is sometimes recommended.",
"    </p>",
"    <p>",
"     There are alternatives to RPLND, including periodic physical examination and CT scans (called surveillance or watchful waiting), a short course of chemotherapy, or, in the case of seminomas, low-dose radiation therapy.",
"    </p>",
"    <p>",
"     Men with stage II or III testicular cancer may not undergo RPLND at all or may only have it if there is still cancer present after chemotherapy.",
"    </p>",
"    <p>",
"     RPLND requires specialized knowledge and training; men who require this procedure should seek care in a facility where the surgeon is experienced with RPLND. Risks of the procedure depend upon the amount of surgery needed to remove the lymph nodes and whether you have had chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy (RT) refers to the exposure of a tumor to high-energy x-rays in order to slow or stop its growth. Exposure to x-rays damages cells. Unlike normal cells, cancer cells cannot repair the damage caused by exposure to x-rays, particularly when it is administered over several days. This prevents the cancer cells from growing further and causes them to eventually die.",
"    </p>",
"    <p>",
"     RT for testicular cancer is given as external beam radiation therapy, meaning that the radiation beam is generated by a machine while you lie on a table underneath or in front of the machine. The high energy beams are directed at the lymph nodes, not the scrotum (",
"     <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Exposure to the beam typically takes only a few seconds (similar to having an x-ray). In general, treatment is repeated five days per week for approximately five to six weeks.",
"    </p>",
"    <p>",
"     Radiation therapy (RT) is often recommended after orchiectomy for men with seminoma to decrease the risk of relapse. RT may also be used after orchiectomy for men with non-bulky stage II seminoma. However, there are potential risks of RT, including impaired fertility, second malignancy, or late cardiac disease (see",
"     <a class=\"local\" href=\"#H28\">",
"      'Radiation therapy side effects'",
"     </a>",
"     below). For these reasons, RT is usually reserved for older men, men who could not tolerate chemotherapy, and men who are not good candidates for surveillance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Surveillance",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, men with small stage I testicular cancers do not require more treatment after orchiectomy. However, these men do need to follow up regularly with a healthcare provider to monitor for signs of relapse. This approach is called surveillance.",
"    </p>",
"    <p>",
"     Surveillance is only appropriate for men who are willing to have follow-up visits over a period of years. Men who are not able or willing to undergo this active surveillance may require additional treatment with either radiation therapy or chemotherapy (see",
"     <a class=\"local\" href=\"#H20\">",
"      'Seminoma'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     During surveillance, you will be seen every few months for a physical examination, blood tests, and imaging studies (eg, CT scan of the abdomen and pelvis, chest x-ray). This schedule is recommended for the first three to four years, and then visits may become less frequent (eg, twice per year for several years, and then once per year until at least 10 years after diagnosis).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Testicular cancer treatment recommendations",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Seminoma",
"     </span>",
"     &nbsp;&mdash;&nbsp;In general, seminomas grow slowly and do not spread rapidly to other areas of the body. Surgery (radical inguinal orchiectomy) is recommended for all men with early stage seminoma. Following surgery, three treatment options are possible, all of which have an excellent cure rate (98 percent). Treatment options include surveillance (watchful waiting), radiation therapy, and chemotherapy.",
"    </p>",
"    <p>",
"     Retroperitoneal lymph node dissection is used in some situations after chemotherapy but is not usually performed initially (see",
"     <a class=\"local\" href=\"#H16\">",
"      'Lymph node removal'",
"     </a>",
"     above). A short course of chemotherapy or radiation therapy is sometimes used to treat patients with stage I seminoma who are not candidates for active surveillance.",
"    </p>",
"    <p>",
"     Not all treatments are suitable for all patients; a physician will work with you to determine the most appropriate option based upon your situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Nonseminomatous germ cell tumors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery (radical inguinal orchiectomy) is recommended for all men with NSGCT. NSGCTs are not as sensitive to radiation therapy as seminomas. NSGCTs are also more likely to spread through the bloodstream to other areas of the body, such as the liver, lungs, and brain.",
"    </p>",
"    <p>",
"     Treatment with one or two cycles of adjuvant chemotherapy, usually with cisplatin and another chemotherapy agent is usually recommended. Men who have a mass remaining after chemotherapy may require surgery to remove it. Patients who require this type of surgical treatment are best treated at a cancer center that treats a large number of men with testicular cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER TREATMENT SIDE EFFECTS AND COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Side effects and complications related to treatment depend upon the type of treatment used and the severity of the disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Fertility issues",
"     </span>",
"     &nbsp;&mdash;&nbsp;Testicular cancer frequently occurs in younger men who have not begun or completed having children. Treatment with surgery, radiation, or chemotherapy can reduce or eliminate sperm production, causing infertility. For reasons that are not well understood, up to 50 percent of men with testicular cancer have a low number of sperm, even before treatment.",
"    </p>",
"    <p>",
"     For these reasons, men preparing to have treatment for testicular cancer should consider storing their sperm for future use. The storage process is called semen cryopreservation and involves storing semen at very low temperatures. Cryopreservation requires that a man give several samples of semen. Ideally, a semen sample should be collected in a clinician's office after masturbation; if this is not possible, the man may be allowed to collect a sample at home in a sterile laboratory container or chemical-free condom. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If possible, collection should be started before surgical removal of the testicle and before chemotherapy or radiation therapy; this allows the greatest number and healthiest sperm to be stored.",
"    </p>",
"    <p>",
"     Even men with very low sperm counts (before cancer treatment) should be encouraged to store their sperm. Intracytoplasmic sperm injection (ICSI) is a type of infertility treatment that requires a very small number of sperm.",
"    </p>",
"    <p>",
"     Men who are unable to store sperm before treatment may still be able to father a child after treatment, depending upon the type and amount of treatment used. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"      \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Chemotherapy side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of side effects and complications that can develop as a result of chemotherapy. These can be divided into acute side effects (that occur during and shortly after treatment) and long-term risks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Short-term side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men who undergo chemotherapy can have side effects such as fatigue, hair loss, and nausea or vomiting. Nausea can be prevented or treated with oral or intravenous medications, and hair regrows after treatment is completed. Low blood cell counts can occur in the first few weeks of chemotherapy, which can increase the risk of infection. This generally does not require that the dose or schedule of treatment be changed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Long-term complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy can cause serious problems in a number of organ systems within the body, especially when given in combination and if multiple cycles of chemotherapy are required. The type and severity of these problems depends upon the type and dose of chemotherapy. A few of the most common include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Kidney damage",
"      </li>",
"      <li>",
"       Damage to nerves, causing pain in the arms and feet or hearing loss",
"      </li>",
"      <li>",
"       Damage to blood vessels in the heart, potentially increasing the risk of cardiovascular disease. This typically occurs many years after treatment is completed.",
"      </li>",
"      <li>",
"       Lung scarring",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Another serious long-term risk of testicular cancer treatment is the development of a second cancer. This is not a metastasis of the testicular cancer but is a new cancer that develops in the blood or blood forming organs (leukemia), lung, colon, pancreas, bladder, stomach, or other organ system.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Retroperitoneal lymph node dissection",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effect of RPLND is decreased or absent semen with ejaculation. Advances in surgical techniques with nerve-sparing retroperitoneal lymph node dissection have reduced the incidence of this problem. For those men who do have decreased or absent ejaculatory volume, infertility treatments are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Radiation therapy side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;During radiation therapy, fatigue is common but usually not debilitating. Gastrointestinal effects, including nausea, vomiting, increased stool frequency, and rapid gastric emptying, have been described but are not typical. Anti-nausea medications may be used for control of nausea and vomiting. Suppression of the bone marrow can occur (potentially causing anemia) but is usually mild. Mild tanning of the treated skin occurs in the weeks after radiation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      MONITORING AFTER TESTICULAR CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Relapses of testicular germ cell tumors usually occur within two years of the end of treatment, although they can occur later. As a result, all patients who have been successfully treated for testicular cancer should be monitored for cancer recurrence with blood tests, x-rays, computed tomography (CT) scans, and other imaging tests. Monitoring is generally more frequent in the first few years after treatment is completed.",
"    </p>",
"    <p>",
"     Blood tests such as the beta-hCG and the AFP are used to monitor for early signs of a relapse. In 30 to 50 percent of patients who relapse, increases in blood tumor markers are the first sign of cancer relapse. A man who relapses may have no changes in their tumor markers, and for this reason, the combination of blood testing, CT, and x-ray is recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Stage I follow up",
"     </span>",
"     &nbsp;&mdash;&nbsp;The optimal schedule for posttreatment surveillance is controversial. Most experts recommend frequent monitoring with blood tests and imaging studies (eg, x-ray, CT scan) every few months for the first few years, decreasing to twice per year for several years then once per year for the man's lifetime.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      After RPLND",
"     </span>",
"     &nbsp;&mdash;&nbsp;For men who undergo retroperitoneal lymph node dissection (RPLND) for limited stage disease, most experts recommend blood testing for tumor markers and a chest x-ray every few months initially, decreasing to once per year after several years. CT scan of the abdomen and pelvis may be done less frequently because of the decreased risk of retroperitoneal relapse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32\">",
"     <span class=\"h2\">",
"      Advanced disease follow up",
"     </span>",
"     &nbsp;&mdash;&nbsp;Follow up of men with advanced disease is similar to that of men with stage I disease. Follow up does not begin until after the man has a complete response to chemotherapy. More intensive surveillance may be recommended for men who undergo chemotherapy for advanced disease followed by an RPLND.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H33\">",
"     <span class=\"h1\">",
"      TESTICULAR CANCER PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Men with stage I, good prognosis disease have an excellent chance for cure when treated appropriately (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Testicular cancer staging and classification'",
"     </a>",
"     above). Patients who have an intermediate or poor prognosis also generally respond well to treatment and require a more aggressive treatment regimen. Even for those with a poor prognosis, approximately one-half can be cured.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H34\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"      www.cancer.gov/clinicaltrials/learning/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H35\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196606\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196613\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=see_link\">",
"      Patient information: Testicular cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/57/11154?source=see_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196621\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1196629\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42425?source=see_link\">",
"      Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/4/24645/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/4/24645?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24645/abstract/1\">",
"      Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 1997; 15:1444.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute. Testicular Cancer (PDQ&reg;): Treatment: Patient Version. file://www.cancer.gov/cancertopics/pdq/treatment/testicular/Patient (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24645/abstract/3\">",
"      Amato RJ, Ro JY, Ayala AG, Swanson DA. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004; 63:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24645/abstract/4\">",
"      Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005; 23:9290.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Testicular cancer. file://www.cancer.org/cancer/testicularcancer/index (Accessed on March 16, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_4_24645=[""].join("\n");
var outline_f24_4_24645=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TESTICULAR CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF TESTICULAR CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TESTICULAR CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TESTICULAR CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           TESTICULAR CANCER STAGING AND CLASSIFICATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           TESTICULAR CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           TESTICULAR CANCER TREATMENT SIDE EFFECTS AND COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           MONITORING AFTER TESTICULAR CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H33\">",
"           TESTICULAR CANCER PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H34\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H35\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\" title=\"figure 1\">",
"           Male anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/55/24439\" title=\"figure 2\">",
"           Lymph nodes body PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?38/15/39163\" title=\"table 1\">",
"           Testicular tumors PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24646="Foscarnet: Pediatric drug information";
var content_f24_4_24646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Foscarnet: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"    see \"Foscarnet: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/11/37044?source=see_link\">",
"    see \"Foscarnet: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14934198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"      see \"Foscarnet: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cytomegalovirus (CMV) infection (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CNS disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment; induction: I.V.: 60 mg/kg/dose  every 8 hours in combination with ganciclovir; continue until symptom improvement, followed by chronic suppressive (maintenance) therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance therapy: I.V.: 90-120 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Retinitis, disseminated disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment; induction: I.V.: 60 mg/kg/dose every 8 hours for 14-21 days with or without ganciclovir, followed by chronic suppressive (maintenance) therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance therapy: I.V.: 90-120 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Herpes simplex virus (HSV) infection acyclovir-resistant; treatment (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009): I.V.: 40 mg/kg/dose every 8 hours or 60 mg/kg/dose every 12 hours for up to 3 weeks or until lesions heal; repeat treatment may lead to the development of resistance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster virus (VZ) infection (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chickenpox not responding to acyclovir; treatment: I.V.: 40-60 mg/kg/dose every 8 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Zoster: Progressive outer retinal necrosis; treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 90 mg/kg/dose every 12 hours in combination with ganciclovir intravenous and intravitreal foscarnet and/or ganciclovir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intravitreal: 1.2 mg/0.05 mL per dose twice weekly in combination with systemic foscarnet and ganciclovir and/or intravitreal ganciclovir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cytomegalovirus (CMV) retinitis (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment; induction: I.V.: 60 mg/kg/dose every 8 hours for 14-21 days",
"     <b>",
"      or",
"     </b>",
"     90 mg/kg every 12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy: I.V.: 90-120 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Herpes simplex virus (HSV) infection acyclovir-resistant; treatment (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a): I.V.: 40 mg/kg/dose every 8-12 hours until clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster virus (VZ) infection (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chickenpox not responding to acyclovir; treatment: I.V.: 90 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Zoster:  Progressive outer retinal necrosis; treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 90 mg/kg/dose every 12 hours in combination with systemic ganciclovir and intravitreal foscarnet and/or ganciclovir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intravitreal: 1.2 mg/0.05 mL per dose twice weekly in combination with systemic foscarnet and ganciclovir and/or intravitreal ganciclovir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cytomegalovirus (CMV) retinitis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment; induction: 60 mg/kg/dose every 8 hours for 14-21 days",
"     <b>",
"      or",
"     </b>",
"     90 mg/kg/dose every 12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy: 90-120 mg/kg/day as a single daily infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Herpes simplex virus (HSV) infection acyclovir-resistant; treatment:",
"     </b>",
"     I.V.: 40 mg/kg/dose every 8-12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CMV Induction",
"     </b>",
"     (equivalent to 60 mg/kg every 8 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.4 mL/minute/kg: 60 mg/kg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1-1.4 mL/minute/kg: 45 mg/kg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.8-1 mL/minute/kg: 50 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.6-0.8 mL/minute/kg: 40 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.5-0.6 mL/minute/kg: 60 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;0.4-0.5 mL/minute/kg: 50 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/minute/kg: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CMV Induction",
"     </b>",
"     (equivalent to 90 mg/kg every 12 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.4 mL/minute/kg: 90 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1-1.4 mL/minute/kg: 70 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.8-1 mL/minute/kg: 50 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.6-0.8 mL/minute/kg: 80 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.5-0.6 mL/minute/kg: 60 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;0.4-0.5 mL/minute/kg: 50 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/minute/kg: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CMV Maintenance:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.4 mL/minute/kg: 90-120 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1-1.4 mL/minute/kg: 70-90 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.8-1 mL/minute/kg: 50-65 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.6-0.8 mL/minute/kg: 80-105 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.5-0.6 mL/minute/kg: 60-80 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;0.4-0.5 mL/minute/kg: 50-65 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/minute/kg: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      HSV Infection (equivalent to 40 mg/kg every 8 hours):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.4 mL/minute/kg: 40 mg/kg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1-1.4 mL/minute/kg: 30 mg/kg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.8-1 mL/minute/kg: 35 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.6-0.8 mL/minute/kg: 25 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.5-0.6 mL/minute/kg: 40 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;0.4-0.5 mL/minute/kg: 35 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/minute/kg: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      HSV Infection (equivalent to 40 mg/kg every 12 hours):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.4 mL/minute/kg: 40 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1-1.4 mL/minute/kg: 30 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.8-1 mL/minute/kg: 20 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.6-0.8 mL/minute/kg: 35 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.5-0.6 mL/minute/kg: 25 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;0.4-0.5 mL/minute/kg: 20 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/minute/kg: Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]: 24 mg/mL (250 mL, 500 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foscavir&reg;: 24 mg/mL (250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: For central I.V. administration, may administer undiluted 24 mg/mL solution; for peripheral I.V. administration, must be further diluted with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a final concentration &le;12 mg/mL. Administer using an infusion pump at a rate",
"     <b>",
"      not to exceed",
"     </b>",
"     60 mg/kg/dose over 1 hour or 120 mg/kg/dose over 2 hours (1 mg/kg/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: Prehydration prior to initial infusion: Children: 10-20 mL/kg (maximum: 1000 mL) of age-appropriate fluid (usually NS); adults: 750-1000 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Subsequent foscarnet doses: Concurrent hydration: Children: 10-20 mL/kg (maximum: 1000 mL) of age-appropriate fluid; adults: 500-1000 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W; concurrent hydration volume is dependent on foscarnet dose",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose 30%, LR, TPN, and I.V. solutions containing calcium, magnesium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amikacin, aminophylline, ampicillin, aztreonam, cefazolin, cefoxitin, ceftazidime,  cefuroxime, chloramphenicol, cimetidine, clindamycin, dexamethasone sodium phosphate, dopamine, doripenem, erythromycin lactobionate, fluconazole, flucytosine, furosemide, gentamicin, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, metoclopramide, metronidazole, morphine, nafcillin, oxacillin, penicillin G potassium, phenytoin, piperacillin, ranitidine, ticarcillin/clavulanate, tobramycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, diazepam, digoxin, diphenhydramine, dobutamine, droperidol, ganciclovir, haloperidol, leucovorin calcium, midazolam, pentamidine, prochlorperazine edisylate, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, ceftriaxone, lorazepam, sulfamethoxazole/trimethoprim, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from temperatures &gt;40&deg;C and from freezing. Diluted solution is stable for 24 hours at room temperature or under refrigeration; incompatible with dextrose &ge;30%, LR, TPN, vancomycin, digoxin, ganciclovir, midazolam, and I.V. solutions containing calcium or magnesium",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative to ganciclovir for treatment of CMV infections; treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (FDA approved in adults); treatment of acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised patients and acyclovir-resistant herpes zoster infections (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F174213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, ECG changes, edema, facial edema, flushing, hyper-/hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, aggressiveness, amnesia, anxiety, aphasia, ataxia, confusion, coordination abnormal, dementia, depression, dizziness, EEG abnormal, fatigue, fever, hallucination, headache, hypoesthesia, insomnia, malaise, meningitis, nervousness, pain, seizures, somnolence, stupor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythematous rash, maculopapular rash, pruritus, rash, seborrhea, skin discoloration, skin ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hyper-/hypophosphatemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cachexia, constipation, diarrhea, dysphagia, dyspepsia, flatulence, melena, nausea, pancreatitis, rectal hemorrhage, taste perversion, ulcerative stomatitis, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, nocturia, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bone marrow suppression, granulocytopenia, leukopenia, lymphadenopathy, thrombocytopenia, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, hepatic function abnormal, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess, injection site pain/inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, involuntary muscle contraction, leg cramps, myalgia, neuropathy (peripheral), paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, eye pain, vision abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Abnormal renal function, acute renal failure, albuminuria, BUN increased, creatinine clearance decreased, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, bronchospasm, dyspnea, hemoptysis, pharyngitis, pneumonia, pneumothorax, pulmonary infiltrates, respiratory failure, rhinitis, sinusitis, stridor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, infection (bacterial and fungal), malignancies (lymphoma/sarcoma), sepsis, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Cardiac arrest, coma, diabetes insipidus (usually nephrogenic), erythema multiforme, hematuria, hypoproteinemia, myositis, neutropenia, pancytopenia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal calculus, rhabdomyolysis, Stevens-Johnson syndrome, syndrome of inappropriate antidiuretic hormone (SIADH), toxic epidermal necrolysis, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to foscarnet or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, patients with altered electrolyte levels, and patients with neurologic or cardiac abnormalities; adjust dose for patients with impaired renal function; discontinue treatment in adults if serum creatinine &ge;2.9 mg/dL; therapy can be restarted if serum creatinine &le;2 mg/dL. Anemia and granulocytopenia have been reported; monitor CBC; foscarnet is a venous irritant, infuse only into veins with adequate blood flow",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal impairment occurs to some degree in the majority of patients treated with foscarnet",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal impairment may occur at any time and is usually reversible within 1 week following dose adjustment or discontinuation of therapy; however, several patients have died with renal failure within 4 weeks of stopping foscarnet. To reduce the risk of nephrotoxicity and the potential to administer a relative overdose, always calculate the Cl",
"     <sub>",
"      cr",
"     </sub>",
"     even if serum creatinine is within the normal range. Dosage adjustments are recommended for renal dysfunction; safety and efficacy data in adult patients with a baseline S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2.8 mg/dL or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute are limited. Adequate hydration may reduce the risk of nephrotoxicity and prehydration is recommended; foscarnet use is not recommended in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/kg/minute.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Foscarnet is deposited in teeth and bone of young, growing animals; it has adversely affected tooth enamel development in rats; deposition in human bone has also been demonstrated; safety and effectiveness in children has not been fully evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serum electrolyte imbalance occurs in 6% to 48% of patients (hypocalcemia, low ionized calcium, hypo- or hyperphosphatemia, hypokalemia, or hypomagnesemia). Patients with a low ionized calcium may experience perioral tingling, numbness, parasthesia, tetany, and seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Seizures related to electrolyte/mineral imbalance may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; incidence has been reported in up to 10% of HIV patients. Risk factors for seizures include impaired baseline renal function, low total serum calcium, and underlying CNS condition. Some patients who have experienced seizures have been able to continue or resume foscarnet treatment after their mineral or electrolyte abnormality has been corrected, their underlying disease state treated, or their dose decreased.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3051197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Associated with an increase in skeletal anomalies in animal studies at approximately the equivalent of 13% to 33% of the maximal daily human dose. There are no adequate and well controlled studies in pregnant women. A single case report of use during the third trimester with normal infant outcome was observed. Monitoring of amniotic fluid volumes by ultrasound is recommended weekly after 20 weeks of gestation to detect oligohydramnios.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine, calcium, phosphorus, potassium, magnesium; CBC, ophthalmologic exams, clinical signs of polyuria, and polydipsia",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1047495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic serum concentration for CMV: 150 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrophosphate analog which inhibits DNA synthesis by interfering with viral DNA polymerase and reverse transcriptase",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.5 L/kg; up to 28% of cumulative I.V. dose may be deposited in bone; CSF levels are ~",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14% to 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, plasma: Adults: 2-4.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% to 90% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/11/37044?source=see_link\">",
"      see \"Foscarnet: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any numbness in the extremities, paresthesias, perioral tingling, or seizures",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aweeka FT, Jacobson MA, Martin-Munley S, et al, &ldquo;Effect of Renal Disease and Hemodialysis on Foscarnet Pharmacokinetics and Dosing Recommendations,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr Hum Retrovirol",
"      </i>",
"      , 1999, 20(4):350-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/4/24646/abstract-text/10096579/pubmed\" id=\"10096579\" target=\"_blank\">",
"        10096579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Butler KM, DeSmet MD, Husson RN, et al, &ldquo;Treatment of Aggressive Cytomegalovirus Retinitis With Ganciclovir in Combination With Foscarnet in a Child Infected With Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(3):483-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/4/24646/abstract-text/1311378 /pubmed\" id=\"1311378 \" target=\"_blank\">",
"        1311378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/4/24646/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/4/24646/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13325 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24646=[""].join("\n");
var outline_f24_4_24646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708811\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047493\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047485\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174148\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174134\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047497\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174214\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047488\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047496\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174213\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047500\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047484\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047483\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299364\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174143\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174145\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3051197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047492\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047495\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047482\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047499\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047490\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=related_link\">",
"      Foscarnet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/11/37044?source=related_link\">",
"      Foscarnet: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24647="Lymphocutaneous sporotrichosis leg";
var content_f24_4_24647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65985%7EID%2F50115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65985%7EID%2F50115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocutaneous sporotrichosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphocutaneous sporotrichosis on the right lower extremity of a young man who overturned his dirt bike and inoculated soil in multiple places in his leg. Following a plastic surgery procedure before the diagnosis of sporotrichosis, new lesions developed at the edge of the skin graft and extended up into the thigh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A. Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphocutaneous sporotrichosis on upper limb with ulcerative fungating lesions typically spreading upward",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52:451. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24647=[""].join("\n");
var outline_f24_4_24647=null;
var title_f24_4_24648="Nonselective NSAIDs: Adverse cardiovascular effects";
var content_f24_4_24648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonselective NSAIDs: Adverse cardiovascular effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24648/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/4/24648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective (ie, non-COX-2 selective) nonsteroidal antiinflammatory drugs (NSAIDs) may have several adverse effects on the cardiovascular system, including interference with the beneficial antiplatelet activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , an increase in cardiovascular events, and exacerbation of heart failure.",
"   </p>",
"   <p>",
"    The cardiovascular effects of nonselective NSAIDs will be reviewed here. The cardiovascular effects of COX-2 selective NSAIDs and an overview of the adverse effects of NSAID therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERFERENCE WITH BENEFICIAL EFFECTS OF ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial antiplatelet effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for secondary or primary prevention of cardiovascular disease result from irreversible acetylation of the active site of cyclooxygenase (COX) in platelets; these effects may be attenuated by prior or ongoing administration of some nonselective NSAIDs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, regular NSAID use should be avoided, if possible, in patients taking low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for cardiovascular protection. In patients who require NSAIDs on an occasional short-term basis, we suggest that aspirin be taken at least two hours before the NSAID, although the data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies of healthy controls, the antiplatelet effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is attenuated by prior or ongoing administration of at least two nonselective NSAIDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      on in vitro platelet aggregation was evaluated in a study in which healthy volunteers were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      two hours before or two hours after ibuprofen [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/2\">",
"       2",
"      </a>",
"      ]. When ibuprofen was given before aspirin, thromboxane B2 production by activated platelets was approximately twofold higher and inhibition of platelet aggregation was negligible at 24 hours. Ibuprofen had no effect on the action of aspirin when given after two hours after aspirin and neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      affected the activity of aspirin.",
"     </li>",
"     <li>",
"      Similar effects have been described with a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      two hours before the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/5\">",
"       5",
"      </a>",
"      ]. This was consistent with in vitro studies in which preincubation of platelets with naproxen prevented aspirin from irreversibly inhibiting thromboxane production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presumed mechanism is that nonselective NSAIDs compete with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for a common binding site on COX-1 and prevents aspirin from binding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As a result, aspirin is unable to acetylate a serine residue on COX-1, an irreversible reaction that inhibits COX-1 for the remaining life of the platelet [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/7\">",
"     7",
"    </a>",
"    ]. This pharmacodynamic interaction is not seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blockade caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is less complete than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at the doses used, and declines rapidly between doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/10\">",
"     10",
"    </a>",
"    ]. The inhibitory effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    on platelet function is greater than that of ibuprofen and its half-life is significantly longer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H11#H11\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Nonaspirin NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical relevance of the inhibition of the antiplatelet effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has not been confirmed. No randomized trials have been performed to directly address this issue and observational studies have shown conflicting results as to whether concurrent use of aspirin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or other NSAIDs affects cardiovascular risk. Some reports showed an increase in risk with aspirin plus ibuprofen compared with aspirin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/4,11\">",
"     4,11",
"    </a>",
"    ], while other showed either no change [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] or even a reduction in risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/14\">",
"     14",
"    </a>",
"    ]. Three of these studies found that the effect or lack of effect of ibuprofen was similar with other NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps the best data, which suggest a frequency-dependent relationship between the use of any NSAID and the protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    on a first MI, comes from a subgroup analysis from a five-year randomized trial of over 22,000 apparently healthy male physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alternate day dose of 325 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      conferred a statistically significant 44 percent reduction in the risk of first MI in this low-risk population.",
"     </li>",
"     <li>",
"      Among those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , the use of an NSAID for &ge;60 days per year was associated with a significant increase in the risk of an MI (multivariable adjusted relative risk 2.9 compared with no NSAID use, 95% CI 1.3-6.6).",
"     </li>",
"     <li>",
"      In contrast, there was no significant increase in risk with NSAID use for 1 to 59 days per year (multivariable adjusted relative risk 1.2, 95% CI 0.8-1.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with the possibility of an adverse effect of regular, but not intermittent NSAID use on the protective effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . No information was available on the type of NSAID used, although it is likely that the majority of patients used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    during that time period. An association between adverse cardiovascular outcomes and the frequency of NSAID use, particularly ibuprofen, has also been suggested in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    may be an effective alternative to NSAIDs in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT ON CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of NSAID therapy on cardiovascular risk has been evaluated with both the nonselective and COX-2 selective NSAIDs; medications within both NSAID classes appear to increase such risk. The degree of COX-2 selectivity, even among nonselective NSAIDs, may be related to the level of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/16\">",
"     16",
"    </a>",
"    ]. However, some analyses have failed to show such a relationship, and additional factors may also be important, including effects on blood pressure, renal function, endothelial cells, and nitric oxide production [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonselective nonaspirin NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of most nonselective NSAIDs is associated with an increased risk of adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/17-26\">",
"     17-26",
"    </a>",
"    ]; absolute risk is low, but risk increases with higher doses or frequency of use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/18,24-26\">",
"     18,24-26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     Naproxen",
"    </a>",
"    appears to be the safest with respect to such risk, although an increased risk of myocardial infarction or stroke with naproxen use has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/11,17-23,27-32\">",
"     11,17-23,27-32",
"    </a>",
"    ]. Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , when taken at high frequency or dose has also been associated with increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are insufficient data to guide NSAID usage in patients at low risk of cardiovascular disease, in whom the absolute increase in risk of adverse cardiovascular events (if any) from use of nonselective NSAIDs is likely to be small. The author prefers to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    at the lowest effective dose in such patients, based upon the available data and clinical experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of the nonselective NSAIDs on cardiovascular risk are best illustrated by a 2011 network meta-analysis based upon 31 large randomized trials of three nonselective NSAIDs and four COX-2 selective NSAIDs, including 116,429 patients with individual followup averaging over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/17\">",
"     17",
"    </a>",
"    ]. Among the nonselective NSAIDs, when compared with placebo, the risk of myocardial infarction (MI) was lower for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (rate ratio, RR, 0.82, 95% credibility interval, CI, 0.37-1.67) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    (RR 0.82, 95% CI 0.29-2.20) than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (RR 1.61, 95% CI 0.50-5.77). The risk compared with placebo of the composite outcome of nonfatal MI or nonfatal stroke plus cardiovascular death was lower for naproxen (RR 1.23, 95% CI 0.71-2.12) than for diclofenac (RR 1.60, 95% CI 0.85-2.99) or ibuprofen (RR 2.26, 95% CI 1.11-4.89). Similar findings have been noted in patients with underlying coronary heart disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The effect of nonselective NSAIDs on cardiovascular risk is less clear in patients with systemic inflammatory disorders such as rheumatoid arthritis (RA). Cardiovascular risk is increased in patients with RA, while disease-modifying antirheumatic drugs (DMARDs) can have a protective effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\", section on 'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link&amp;anchor=H16#H16\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\", section on 'Control of inflammation due to RA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     COX-2 selective inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several COX-2 selective inhibitors (eg, rofecoxib) have been withdrawn from the market because of an increased risk of ischemic cardiovascular events. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXACERBATION OF HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of NSAIDs may cause worsening of heart failure and an increased risk of new events, including myocardial infarction, in patients with established heart disease. We thus suggest that nonselective NSAIDs be avoided in patients with an acute myocardial infarction (MI), unstable angina, or heart failure; during the perioperative period in patients undergoing coronary artery bypass graft surgery; and in patients with a history of a prior MI, based upon the available data and recommendations from major groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/16,33-36\">",
"     16,33-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Heart failure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Coronary heart disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Recommendations by major groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If NSAIDs are required, they should be used at the lowest effective dose and for the shortest duration necessary for the given indication. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    for patients with known cardiovascular disease or increased cardiovascular risk who require treatment with a nonselective NSAID, when an equivalent therapeutic intervention is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonselective nonaspirin NSAIDs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID use has been evaluated both for a first occurrence of heart failure (HF) and for exacerbation of preexisting HF. The data on COX-2 selective agents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H8#H8\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several large cohort studies evaluated the relationship between nonselective NSAID use and either a first occurrence of or first hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one representative study, the adjusted relative risk for a first occurrence of HF was not significantly different from that in individuals who did not use NSAIDs (adjusted relative risk 1.1, 95% CI 0.7-1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are also available for the effect of nonselective NSAIDs on the risk of exacerbation of preexisting HF. The best data come from an observational study of over 40,000 patients in Denmark who had survived a first hospitalization for HF and had subsequently used NSAIDs as determined by a nationwide registry of drug dispensing by pharmacies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/39\">",
"     39",
"    </a>",
"    ]. The outcomes in these patients were compared with over 70,000 controls with HF who had not received NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/39\">",
"     39",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adjusted risk of rehospitalization for HF was significantly increased in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , and to a numerical but non-significant level for users of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (adjusted hazard ratio 1.35, 1.16 and 1.18, respectively).",
"     </li>",
"     <li>",
"      There was a dose-dependent increase in risk of death, which was highest with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (adjusted HR 2.08). Higher doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (&gt;1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      (&gt;500",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      but not lower doses, were also associated with an increased risk of death (adjusted HR 1.31 and 1.22, respectively, for the higher doses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major mechanism for HF exacerbation is an increase in afterload resulting from NSAID-induced systemic vasoconstriction, which can lead to a further reduction in cardiac contractility and cardiac output in advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients at greatest risk for this complication usually are hyponatremic at presentation. The fall in plasma sodium concentration in this setting is a marker for advanced disease, which is associated with increased secretion of antidiuretic hormone as well as angiotensin II and norepinephrine. The ensuing renal ischemia and increase in water reabsorption combine to impair water excretion, leading to water retention, hyponatremia, and increased intravascular volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the vasoconstriction associated with NSAID therapy (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at a dose &ge;325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may partially or totally reverse the unloading effect of ACE inhibitors or angiotensin II receptor blockers in patients with advanced HF and therefore minimize the improvements in cardiac output, diuretic response, and patient survival often induced by angiotensin inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk of cardiovascular events described for nonselective NSAIDs has also been reported in patients with coronary heart disease (CHD) in large observational studies, although these effects have not been directly evaluated in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. NSAIDs should NOT be considered a substitute for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the primary or secondary prevention of cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Interference with beneficial effects of aspirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of NSAIDs in patients with CHD is illustrated best by the following study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of death and recurrent myocardial infarction (MI) was evaluated according to the duration of NSAID treatment following survival of a first MI in a nationwide Danish cohort of 83,677 patients; 42 percent of the patients had received NSAIDs during follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/43\">",
"       43",
"      </a>",
"      ]. NSAID use was associated with a significantly increased risk of death or recurrent MI, compared with nonuse of NSAIDs, even within one week of beginning treatment, and risk remained elevated throughout the treatment course (hazard ratios, HR, 1.45, 95% CI 1.29-1.62, and 1.55, 95% CI 1.46-1.64, respectively). Risks were significantly elevated both for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      , which showed the highest risk for use within the first week, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ; the risk was least evident with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      among the NSAIDs analyzed individually.",
"      <br/>",
"      <br/>",
"      The absolute increase in the incidence death or recurrent MI for all NSAID users was very low, approximately one per 5000 person-years, although it was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of COX-2 selective NSAIDs in patients with known CHD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ELEVATION IN BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonselective NSAIDs can raise the blood pressure and worsen control of hypertension in patients already being treated. The supportive data are presented separately. Nonselective NSAIDs should be used with caution in such patients, and if required, they should be used at the lowest effective dose and for the shortest duration necessary for the given indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS BY MAJOR GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     FDA warning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA) requires the following warnings for all NSAIDs based upon observations such as those described above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including myocardial infarction and stroke, and the risk may be increased with duration of use or preexisting cardiovascular risk factors or disease.",
"     </li>",
"     <li>",
"      Individual cardiovascular risk profiles should be carefully evaluated prior to prescribing.",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , and potentially other nonselective NSAIDs, may interfere with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      's cardioprotective effect.",
"     </li>",
"     <li>",
"      Use of NSAIDs is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft surgery.",
"     </li>",
"     <li>",
"      Use of NSAIDs should be avoided in heart failure.",
"     </li>",
"     <li>",
"      The lowest effective dose should be used for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events, and alternate therapies should be considered for patients at high risk.",
"     </li>",
"     <li>",
"      NSAIDs should be used with caution in patients with hypertension, as they may cause new onset hypertension or worsening of existing hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the FDA warnings, major professional society guidelines have addressed the issue of NSAID use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     AHA advisory",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 advisory from the American Heart Association (AHA) on the use of NSAIDs (both nonselective and COX-2 selective) addressed many of the issues discussed above regarding their effect on the risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/16\">",
"     16",
"    </a>",
"    ]. It was concluded that more long-term data are needed to assess the cardiovascular risks of nonselective NSAIDs and that prolonged use of any NSAID (including over-the-counter NSAIDs) should only be considered in consultation with a physician, particularly in patients with or at high risk for cardiovascular disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     Naproxen",
"    </a>",
"    was considered the NSAID of choice. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonselective nonaspirin NSAIDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ACR white paper",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 American College of Rheumatology (ACR) white paper on the use of NSAIDs (both nonselective and COX-2 selective) also noted the limitations of the available data and reached similar conclusions to the AHA advisory, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    being the nonselective NSAID of choice in patients at increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, it was recognized that some patients with arthritis would accept a modest increase in cardiovascular and gastrointestinal risk if relief from persistent pain were attained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ACC/AHA guidelines on acute MI or unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of acute myocardial infarction (ST elevation or non-ST elevation) or unstable angina strongly recommended immediate cessation all nonaspirin NSAIDs at presentation and made a weak recommendation for avoiding their use during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At hospital discharge, the guidelines concluded that it is reasonable to use a nonselective NSAID, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , for patients with chronic musculoskeletal disorders if initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , nonacetylated salicylates, or small doses narcotics is insufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Nonselective nonaspirin NSAIDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The guidelines also suggested administration of other NSAIDs of increasing COX-2 selectivity in patients with persistent intolerable discomfort despite use of the above medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/35\">",
"     35",
"    </a>",
"    ]. In this setting, the drug should be used at the lowest effective dose for the shortest possible time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of acute myocardial infarction and unstable angina are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ACC/AHA guidelines on HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the adverse effects of NSAIDs in patients with HF cited above, the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the diagnosis and management of heart failure (HF) concluded that NSAIDs should be avoided or withdrawn whenever possible in patients with current or prior symptoms of HF and a reduced left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24648/abstract/36\">",
"     36",
"    </a>",
"    ]. Data are limited in patients with HF due to diastolic dysfunction but one would expect similar adverse effects. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Heart failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) have a variety of effects on cardiovascular disease. They may interfere with the beneficial antiplatelet activity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , increase blood pressure, increase risk of adverse cardiovascular events unrelated to their effect on aspirin, and can exacerbate heart failure.",
"     </li>",
"     <li>",
"      The beneficial effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may be attenuated by prior or ongoing administration of some nonselective NSAIDs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      . Thus, regular NSAID use should be avoided, if possible, in patients taking low-dose aspirin for cardiovascular protection. In patients using NSAIDs on an occasional short-term basis, we suggest that aspirin be taken at least two hours before the NSAID (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interference with beneficial effects of aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NSAIDs may worsen heart failure, increase the risk of recurrent myocardial infarction in patients with coronary disease, and increase the risk of death in patients with preexisting cardiovascular disease. We suggest that nonselective NSAIDs be avoided in patients with an acute myocardial infarction (MI), unstable angina, or heart failure; during the perioperative period in patients undergoing coronary artery bypass graft surgery; and in patients with a history of a prior MI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Heart failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'ACC/AHA guidelines on HF'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonselective nonaspirin NSAIDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with cardiovascular disease who require treatment with a nonselective NSAID, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Any NSAID should be used in the lowest effective dose and for the shortest duration necessary for the given indication. Patients with cardiovascular disease should be cautioned regarding the risks of regular use of over-the-counter NSAIDs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonselective nonaspirin NSAIDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NSAIDs may raise blood pressure and can worsen control of hypertension in patients already being treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"       \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/1\">",
"      Do NSAIDs interfere with the cardioprotective effects of aspirin? Med Lett Drugs Ther 2004; 46:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/2\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/3\">",
"      Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/4\">",
"      MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/5\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/6\">",
"      Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/7\">",
"      Patrono C, Garc&iacute;a Rodr&iacute;guez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/8\">",
"      Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006; 80:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/9\">",
"      FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/10\">",
"      FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003; 361:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/11\">",
"      Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/12\">",
"      Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/13\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Varas-Lorenzo C, Maguire A, Gonz&aacute;lez-P&eacute;rez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/14\">",
"      Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004; 164:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/15\">",
"      Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005; 32:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/16\">",
"      Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/17\">",
"      Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/18\">",
"      J&uuml;ni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/19\">",
"      Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/20\">",
"      Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/21\">",
"      Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/22\">",
"      Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/23\">",
"      Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/24\">",
"      Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/25\">",
"      McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/26\">",
"      Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/27\">",
"      Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/28\">",
"      Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/29\">",
"      Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/30\">",
"      Solomon DH, Avorn J, St&uuml;rmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/31\">",
"      Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/32\">",
"      Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/33\">",
"      American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008; 59:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/34\">",
"      Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, J, Adams, C, Antman, E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1. Available at: file://content.onlinejacc.org/cgi/content/full/50/7/e1 (accessed July 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/36\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/37\">",
"      Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002; 162:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/38\">",
"      Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/39\">",
"      Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/40\">",
"      Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med 1984; 310:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/41\">",
"      Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/42\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/43\">",
"      Schjerning Olsen AM, Fosb&oslash;l EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/44\">",
"      Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24648/abstract/45\">",
"      Solomon DH. Searching for a safe analgesic in patients with cardiovascular disease. Circ Cardiovasc Qual Outcomes 2009; 2:146.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7968 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24648=[""].join("\n");
var outline_f24_4_24648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERFERENCE WITH BENEFICIAL EFFECTS OF ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT ON CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonselective nonaspirin NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COX-2 selective inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXACERBATION OF HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ELEVATION IN BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS BY MAJOR GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FDA warning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AHA advisory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACR white paper",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACC/AHA guidelines on acute MI or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ACC/AHA guidelines on HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24649="Overview of deep small bowel enteroscopy";
var content_f24_4_24649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of deep small bowel enteroscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Hiroto Kita, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24649/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/4/24649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H388475148\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the small bowel is difficult due to its length, intraperitoneal location, and contractility. Methods used to evaluate the small bowel include push enteroscopy, video capsule endoscopy, and intraoperative enteroscopy. These techniques all have advantages and limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Push enteroscopy has both diagnostic and therapeutic capabilities, but typically only examines that part of the small bowel that is 50 to 150 cm distal to the ligament of Treitz",
"     </li>",
"     <li>",
"      Video capsule endoscopy is capable of examining the entire small bowel, but lacks therapeutic capacity",
"     </li>",
"     <li>",
"      Intraoperative enteroscopy permits examination of the entire small bowel and therapeutic interventions, but is much more invasive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative endoscopic approaches have been developed to overcome these limitations. Deep small bowel enteroscopy permits visualization and interventional therapy throughout the small bowel by using insertion techniques that pleat the small bowel onto an overtube. The techniques used for deep small bowel enteroscopy limit stretching of the small bowel (as occurs with push enteroscopy), permit better transmission of maneuvers designed to position the tip of the enteroscope, and stabilize the enteroscope, thereby facilitating therapeutic interventions.",
"   </p>",
"   <p>",
"    Options for deep small bowel enteroscopy available in the United States include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Double balloon enteroscopy (Double Balloon Technology, Fujinon, Inc., Wayne, NJ)",
"     </li>",
"     <li>",
"      Single balloon enteroscopy (Single Balloon Enteroscope System, Olympus, Inc., Tokyo, Japan)",
"     </li>",
"     <li>",
"      Spiral enteroscopy (Spirus Endo-Ease Discovery SB System, Spirus Medical Inc., Stoughton, MA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional option available outside the United States is the NaviAid Balloon Guided Endoscopy Device (Smart Medical Systems, Ra'aana, Israel).",
"   </p>",
"   <p>",
"    The first report of double balloon enteroscopy (DBE) appeared in 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/1\">",
"     1",
"    </a>",
"    ], followed by the introduction of a dedicated system for DBE in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of DBE has subsequently grown worldwide, and the first international workshop on DBE was held in Japan in August 2006. Single balloon enteroscopy (SBE) became commercially available in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/3\">",
"     3",
"    </a>",
"    ], and a spiral enteroscopy system was approved by the United States Food and Drug Administration for deep small bowel enteroscopy in 2008.",
"   </p>",
"   <p>",
"    This topic will review the indications, techniques, and complications of balloon-assisted enteroscopy and spiral enteroscopy. Wireless video capsule endoscopy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475156\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep small bowel enteroscopy has multiple diagnostic and therapeutic applications, the most common being the evaluation of obscure gastrointestinal (GI) bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wireless capsule endoscopy is often preferred as an initial diagnostic test because it is noninvasive, well-tolerated, and can view the entire small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/4\">",
"     4",
"    </a>",
"    ]. However, deep small bowel enteroscopy is required in some patients such as those with findings that require biopsy or therapeutic intervention. Deep small bowel enteroscopy may also be preferred when a small bowel stricture is suspected since wireless capsule endoscopy in such patients is associated with an increased risk of capsule retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link&amp;anchor=H15#H15\">",
"     \"Wireless video capsule endoscopy\", section on 'Capsule retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475164\">",
"    <span class=\"h2\">",
"     Diagnostic applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic applications for deep small bowel enteroscopy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of obscure gastrointestinal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evaluation and tattooing of suspected small bowel malignancies (eg, adenocarcinoma, lymphoma, gastrointestinal stromal tumors, metastatic tumors) or abnormal findings on other imaging studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/5-11\">",
"       5-11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evaluation of suspected nonsteroidal anti-inflammatory drug-induced small bowel injury [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/12-15\">",
"       12-15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evaluation of suspected or established small bowel Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evaluation of refractory celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Detection of polyps in patients with polyposis syndromes such as familial adenomatous polyposis or Peutz-Jeghers syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assistance with difficult colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Examination of the gastric remnant in patients who have undergone Roux-en-Y gastric bypass [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475172\">",
"    <span class=\"h2\">",
"     Therapeutic applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advantage of deep small bowel enteroscopy compared with capsule endoscopy and radiologic methods to visualize the small bowel is the ability to perform a wide variety of therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/23-30\">",
"     23-30",
"    </a>",
"    ]. Therapeutic applications for deep small bowel enteroscopy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of gastrointestinal bleeding (eg, angiodysplasia)",
"     </li>",
"     <li>",
"      Small bowel polypectomy",
"     </li>",
"     <li>",
"      Stricture dilation",
"     </li>",
"     <li>",
"      Stenting of small bowel obstructions",
"     </li>",
"     <li>",
"      Foreign body retrieval (eg, retained video capsule) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Placement of direct percutaneous jejunostomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with Roux-en-Y reconstructions (",
"    <a class=\"graphic graphic_figure graphicRef52350 \" href=\"UTD.htm?25/10/25761\">",
"     figure 1",
"    </a>",
"    ), endoscopic retrograde cholangiography with biopsy, lithotripsy, dilatation of a biliary stenosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475180\">",
"    <span class=\"h2\">",
"     Advanced techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel approaches involving balloon-assisted enteroscopy continue to be reported. These include a modified double balloon enteroscopy (DBE) technique to access the proximal side of a stricture in the distal colon (anterograde colonoscopy) by using a long transnasal decompression tube as a guide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/38\">",
"     38",
"    </a>",
"    ], balloon-assisted intubation of the ileocecal valve to facilitate retrograde DBE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/39\">",
"     39",
"    </a>",
"    ], and balloon dilation of obstructing small bowel strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475188\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients deemed fit to undergo endoscopic procedures are candidates for deep small bowel enteroscopy. However, some authors suggest that surgically altered gastrointestinal (GI) anatomy (eg, an ileoanal or ileocolonic anastomosis or an ileostomy) should be a relative contraindication because of a higher perforation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H388475260\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the risk of perforation, we suggest that the examination be carried out cautiously by providers who have significant experience with these procedures when patients with surgically altered GI tract anatomy require deep small bowel enteroscopy (eg, a patient who has undergone Roux-en-Y gastric bypass who needs an endoscopic retrograde cholangiopancreatography).",
"   </p>",
"   <p>",
"    In addition, the balloons used for double balloon enteroscopy (though not for single balloon enteroscopy) are latex and should not be used in patients with latex allergies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=see_link\">",
"     \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475196\">",
"    <span class=\"h1\">",
"     BALLOON-ASSISTED ENTEROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon-assisted enteroscopy includes double balloon enteroscopy (DBE) and single balloon enteroscopy (SBE). While similar, the systems vary with regard to whether a balloon is attached only to the overtube (SBE) or also to the tip of the enteroscope (DBE), resulting in differences in the techniques used to perform the procedures. Limited data suggest that the systems have similar efficacy. (See",
"    <a class=\"local\" href=\"#H388475228\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H388475300\">",
"     'Single balloon enteroscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475204\">",
"    <span class=\"h2\">",
"     Double balloon enteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three DBE systems available. The standard DBE system includes an endoscope with an 8.5 mm diameter and a 200 cm working length (Fujinon EN-450P5), a 145 cm soft overtube with an outer diameter of 12.2 mm, and a specifically designed pump (",
"    <a class=\"graphic graphic_picture graphicRef53187 \" href=\"UTD.htm?40/35/41524\">",
"     picture 1",
"    </a>",
"    ). After the overtube is backloaded onto the scope, a soft latex balloon is attached to the tip of the enteroscope. The balloon can be inflated and deflated using a pump through the air channel in the enteroscope. The flexible overtube also has a latex balloon at its tip that can be inflated and deflated. The pressure in both balloons is monitored and regulated at 5.6 kPa.",
"   </p>",
"   <p>",
"    A therapeutic double balloon enteroscope (Fujinon EN-450T5) is also available. It is similar to the standard enteroscope with a 200 cm working length, but has a larger outer diameter (9.4 mm) so that it can accommodate a larger channel (2.8 mm in diameter). A shorter double balloon endoscope with a working length of 152 cm is also available (Fujinon EN-450B15). This endoscope will accept both endoscopic retrograde cholangiopancreatography (ERCP) length and colonoscopy length accessories and is primarily used for cases of incomplete colonoscopy and for ERCP in patients with surgically altered anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475212\">",
"    <span class=\"h3\">",
"     Patient preparation and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should fast after midnight the evening prior to the examination to allow time for food residue to clear the small bowel. In addition, patients undergoing retrograde examinations should receive a bowel preparation to cleanse the colon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Balloon-assisted enteroscopy can generally be performed under conscious sedation, though some centers prefer to perform anterograde procedures under general anesthesia. One reason for using general anesthesia is that it can be difficult to maintain adequate sedation throughout what is often a prolonged procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475220\">",
"    <span class=\"h3\">",
"     Technique for DBE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double balloon enteroscopy (DBE) can be performed from either the mouth (anterograde approach) or the anus (retrograde approach). The insertion route is chosen according to the estimated location of the suspected lesion(s). In a study of 60 patients undergoing DBE, an anterograde approach was used for lesions noted in the first 60 percent of a capsule endoscopy study (based on the time at which the lesion was noted in the small bowel relative to the total small bowel transit time), whereas a retrograde approach was used for lesions in the distal 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/41\">",
"     41",
"    </a>",
"    ]. Using this cut-off, the lesions were reached on the first examination in all patients.",
"   </p>",
"   <p>",
"    With an antegrade examination, the enteroscope is advanced using repetitive cycles of balloon",
"    <span class=\"nowrap\">",
"     inflation/deflation",
"    </span>",
"    and scope advancement (",
"    <a class=\"graphic graphic_figure graphicRef50391 \" href=\"UTD.htm?14/3/14392\">",
"     figure 2",
"    </a>",
"    ). During one cycle of the procedure, the scope is advanced until no further forward progress is made. The balloon on the tip of the scope is then inflated, anchoring the small bowel. Once the small bowel is anchored by the enteroscope balloon, the balloon on the overtube is deflated (having been inflated during the prior cycle) and advanced until it reaches the inflated balloon on the scope. The balloon at the end of the overtube is then inflated, and with both balloons inflated, the scope and overtube are gently withdrawn to remove loops and pleat the small bowel onto the overtube. The balloon on the scope is then deflated, and the cycle is repeated until the scope can no longer be advanced or the lesion of interest is reached. The procedure is carried out in reverse during withdrawal of the scope.",
"   </p>",
"   <p>",
"    The procedure is the same for retrograde examinations, except that the cycles of scope advancement and withdrawal are carried out in the colon as well as in the small bowel to ensure that there is no colonic looping prior to intubation of the terminal ileum.",
"   </p>",
"   <p>",
"    The point of maximal insertion is frequently tattooed so that it can be identified on subsequent video capsule endoscopy, deep small bowel enteroscopy from the opposite approach, or at the time of surgery. The maximal insertion depth may be limited in patients with adhesions due to prior surgery or inflammatory disorders.",
"   </p>",
"   <p>",
"    Fluoroscopy may be used when initially learning balloon-assisted enteroscopy to permit the endoscopist to observe advancement and reduction of the enteroscope and to identify looping (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54636 \" href=\"UTD.htm?16/33/16916\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475228\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the published data on balloon-assisted enteroscopy are from studies of double balloon enteroscopy (DBE). Multiple reports have described experience with DBE, and a few have compared it with other methods to visualize the small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/23,42-53\">",
"     23,42-53",
"    </a>",
"    ]. Most of these studies focused on patients with obscure gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of obscure gastrointestinal bleeding\", section on 'Enteroscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported mean procedure times with DBE range from 73 to 123 minutes, with average small bowel insertion depths of 220 to 360 cm for antegrade examinations and 124 to 183 cm for retrograde examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/23,48,51,54,55\">",
"     23,48,51,54,55",
"    </a>",
"    ]. In a majority of patients without a significant history of abdominal surgery who undergo an antegrade examination, the mid to distal jejunum or proximal ileum can be reached within 40 to 80 minutes of examination time (not including the time to set up for the examination, which can be significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/45,55\">",
"     45,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrograde examinations are more difficult, and even in expert hands, the failure rates for ileal intubation during retrograde examinations range from 7 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/51,55-57\">",
"     51,55-57",
"    </a>",
"    ]. Even if the terminal ileum is intubated, adhesions may limit subsequent advancement to only 10 to 15 cm within the small bowel.",
"   </p>",
"   <p>",
"    The reported rates of complete enteroscopy (ie, visualization of the entire small bowel, often through a combination of an anterograde and retrograde approach) vary widely. Rates of 70 to 86 percent have been reported in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/1,23,58\">",
"     1,23,58",
"    </a>",
"    ] compared with 4 to 92 percent reported in the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/44,54,55,59-61\">",
"     44,54,55,59-61",
"    </a>",
"    ]. Lower rates of complete enteroscopy have been noted in patients who are obese and in operators with less experience with DBE. Typically, complete enteroscopy is accomplished by performing both an antegrade and a retrograde examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475244\">",
"    <span class=\"h4\">",
"     Diagnostic and therapeutic yields",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic yield of DBE ranges from 40 to 80 percent, with therapy being performed in 15 to 55 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/23,48,51,54,55,57\">",
"     23,48,51,54,55,57",
"    </a>",
"    ]. A meta-analysis of 11 studies that compared DBE with capsule endoscopy estimated that the overall yield for clinically pertinent small bowel findings was similar with the two examinations (60 and 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/62\">",
"     62",
"    </a>",
"    ]. The yield was also similar when comparing specific types of findings such as vascular malformations (",
"    <a class=\"graphic graphic_picture graphicRef70270 \" href=\"UTD.htm?24/38/25186\">",
"     picture 2",
"    </a>",
"    ) (24 percent with both), tumors (",
"    <a class=\"graphic graphic_picture graphicRef78991 \" href=\"UTD.htm?1/61/2003\">",
"     picture 3",
"    </a>",
"    ) (11 percent with both), polyps (",
"    <a class=\"graphic graphic_picture graphicRef59056 \" href=\"UTD.htm?30/11/30911\">",
"     picture 4",
"    </a>",
"    ) (11 percent with both), and inflammatory lesions (18 and 16 percent).",
"   </p>",
"   <p>",
"    A few studies have compared DBE to push enteroscopy and found better diagnostic yields with DBE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The better diagnostic yields with DBE were in part related to higher rates of complete visualization of the small bowel (ie, total enteroscopy).",
"   </p>",
"   <p>",
"    A study of 2245 DBE examinations in 1765 patients found that the diagnostic yield varied with the indication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peutz-Jegher's syndrome: 82 percent",
"     </li>",
"     <li>",
"      Mid-gastrointestinal bleeding: 53 percent",
"     </li>",
"     <li>",
"      Crohn's disease: 47 percent",
"     </li>",
"     <li>",
"      Abdominal pain: 19 percent",
"     </li>",
"     <li>",
"      Diarrhea: 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with mid-gastrointestinal bleeding due to angiodysplasia, DBE allows for effective treatment with argon plasma coagulation (APC), though recurrent bleeding is common [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In a study of 50 patients with small bowel lesions, 44 patients (88 percent) were treated with APC for angiodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/63\">",
"     63",
"    </a>",
"    ]. After a mean follow-up of 55 months, hemoglobin levels increased from a mean of 7.6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    prior to treatment to 11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    following treatment. In addition, there was a significant decrease in the number of patients requiring blood transfusions, from 30 patients prior to treatment to 8 patients following treatment. However, small bowel bleeding recurred in 21 of the patients (48 percent) treated with APC.",
"   </p>",
"   <p>",
"    In a second study that included 98 patients with small bowel vascular lesions who were followed following treatment during DBE (primarily with APC), rebleeding occurred in 45 (46 percent) at 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/64\">",
"     64",
"    </a>",
"    ]. Factors that increased the risk of bleeding included the total number of observed lesions and the presence of valvular and or arrhythmic cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475252\">",
"    <span class=\"h4\">",
"     Learning curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical skill to perform DBE improves with experience. The learning curve for DBE was evaluated in a study involving six tertiary centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/55\">",
"     55",
"    </a>",
"    ]. A total of 188 patients underwent 237 DBE procedures, mainly for obscure gastrointestinal bleeding. About two-thirds of the cases were antegrade. The mean procedure duration for antegrade examinations was 102 &plusmn; 45 minutes for the first 10 cases, declining to 90 &plusmn; 37 minutes thereafter. The improvement in procedure duration was observed only for anterograde cases, with no change in mean procedure time being observed for retrograde examinations. In addition, retrograde cases failed to reach the small bowel in 31 percent of cases.",
"   </p>",
"   <p>",
"    It has been estimated that the learning curve for antegrade examinations is approximately 10 cases, compared with 20 to 30 cases for retrograde examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/3,65\">",
"     3,65",
"    </a>",
"    ]. However, some endoscopists require more than 100 to 150 cases percent to develop expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475260\">",
"    <span class=\"h4\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall complication rates for DBE in large series have ranged from 1.2 to 1.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/60,66,67\">",
"     60,66,67",
"    </a>",
"    ]. A meta-analysis found that minor complications occurred in 9.1 percent of procedures, whereas major complications were reported in 0.7 percent. Complications include pancreatitis, perforation, bleeding, and aspiration pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/60,66-69\">",
"     60,66-69",
"    </a>",
"    ]. The rate of complications may be higher for patients undergoing therapeutic procedures compared with those undergoing diagnostic procedures (eg, 4.3 versus 0.8 percent in a series of 2362 procedures) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475268\">",
"    <span class=\"h5\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis is the most common significant complication of DBE. The rate of pancreatitis following DBE is approximately 0.3 percent based upon data from three series with a total of 8734 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/66,67,69\">",
"     66,67,69",
"    </a>",
"    ]. The cause of pancreatitis is uncertain, but may be related to physical trauma to the pancreas. It is important to distinguish clinical pancreatitis from hyperamylasemia alone, which occurs in approximately 50 percent of patients, especially following long procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. There are no proven methods to reduce the incidence of pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475276\">",
"    <span class=\"h5\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of perforation is 0.3 to 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/66,67,69\">",
"     66,67,69",
"    </a>",
"    ]. The cause of perforation is likely to be multifactorial. In one report, perforation occurred in two patients who may have been at increased risk due to inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/23\">",
"     23",
"    </a>",
"    ]. One had intestinal lymphoma and had received chemotherapy, while the other had Crohn's disease.",
"   </p>",
"   <p>",
"    Therapeutic interventions also increase the risk of perforation. In one series, 3.4 percent of polypectomies were complicated by perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/67\">",
"     67",
"    </a>",
"    ]. The risk is also increased if stricture dilation is carried out in the setting of active ulceration. Balloon dilation in these cases should be postponed until the ulcer has healed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgically altered gastrointestinal (GI) anatomy is another risk factor for perforation. In one series, the rate of perforation in 219 examinations in patients with surgically altered anatomy was 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients who may be at particularly increased risk include those with an ileoanal or ileocolonic anastomosis and those having their examination performed through a stoma. This has led some authorities to suggest that altered surgical GI anatomy should be considered a relative contraindication to balloon-assisted enteroscopy. (See",
"    <a class=\"local\" href=\"#H388475188\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given these risk factors for perforation, we suggest that further insertion of the enteroscope across the lesion be avoided when fragile lesions such as active ulceration are encountered in the small intestine. In addition, DBE should be performed with caution in patients with a history of GI tract surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475284\">",
"    <span class=\"h5\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding has been reported in approximately 0.2 percent of procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. Polypectomy and biopsy appear to be risk factors for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475292\">",
"    <span class=\"h5\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional reported complications include two cases of aspiration pneumonia in a series of 265 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/68\">",
"     68",
"    </a>",
"    ], one cecal volvulus in a series of 2478 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/69\">",
"     69",
"    </a>",
"    ], and a case report that described severe esophageal trauma from the overtube in a patient with eosinophilic esophagitis, a condition known to predispose to mucosal tearing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475300\">",
"    <span class=\"h2\">",
"     Single balloon enteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SBE system uses a 200 cm high-resolution enteroscope (Olympus SIF-Q180) with a 2.8 mm working channel. The overtube is 140 cm long with a 13.2 mm outer diameter. The overtube is equipped with a silicone balloon at its tip, which can be inflated and deflated with a pressure setting range of -6.0 to + 5.4 kPa.",
"   </p>",
"   <p>",
"    The technique for SBE is similar to that used for DBE. (See",
"    <a class=\"local\" href=\"#H388475220\">",
"     'Technique for DBE'",
"    </a>",
"    above.) Like DBE, SBE uses an overtube with a distal balloon to aid with scope advancement through the small bowel. However, SBE uses the scope's flexible tip to anchor the scope, rather than a second balloon on the tip of the enteroscope as with DBE (",
"    <a class=\"graphic graphic_figure graphicRef63179 \" href=\"UTD.htm?15/63/16374\">",
"     figure 3",
"    </a>",
"    ). Anchoring stabilizes the scope, permitting advancement of the overtube. The overtube balloon is then inflated, and the tip of the enteroscope is straightened. With the overtube balloon inflated, the scope and overtube can be withdrawn, pleating the small bowel onto the overtube. The enteroscope is then advanced. Like DBE, the cycle of advancement and withdrawal is repeated until the scope can no longer be advanced or the lesion of interest is reached. As with DBE, the point of maximal insertion is frequently marked with a tattoo.",
"   </p>",
"   <p>",
"    Experience with SBE suggests that its efficacy is similar to that of DBE. Diagnostic yields have ranged from 41 to 65 percent, and therapeutic yields have ranged from 7 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/56,74-82\">",
"     56,74-82",
"    </a>",
"    ]. Average depths of small bowel insertion range from 133 to 270 cm for antegrade examinations and 73 to 199 cm for retrograde examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/74,77,79,80,82\">",
"     74,77,79,80,82",
"    </a>",
"    ]. However, the rate of total enteroscopy may be lower than with DBE at 0 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/74-76,81\">",
"     74-76,81",
"    </a>",
"    ]. In our experience, this is largely due to more difficult intubation of the terminal ileum with SBE compared with DBE. With DBE, the balloon on the tip of the enteroscope can anchor the scope in the small bowel while the overtube is advanced. This is not an option with SBE, so it is harder to maintain position of the enteroscope within the small bowel during overtube advancement. (See",
"    <a class=\"local\" href=\"#H388475244\">",
"     'Diagnostic and therapeutic yields'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of the data on complications of balloon-assisted enteroscopy come from studies of DBE. Complications that have been reported with SBE include abdominal pain, fever, pancreatitis (following endoscopic retrograde cholangioscopy), mucosal tears, and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/56,74-77,80,83,84\">",
"     56,74-77,80,83,84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H388475260\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475317\">",
"    <span class=\"h1\">",
"     SPIRAL ENTEROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spiral enteroscopy is an alternative to balloon-assisted enteroscopy for antegrade evaluation of the small bowel. The method was developed in an attempt to provide a simpler, faster method for deep small bowel enteroscopy. Spiral enteroscopy uses an overtube with a soft raised helix at its distal end (Endo-Ease Discovery SB, Spirus Medical, Inc, Stoughton, MA) (",
"    <a class=\"graphic graphic_picture graphicRef76104 \" href=\"UTD.htm?15/18/15662\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Like balloon-assisted enteroscopy, spiral enteroscopy can be performed using conscious sedation or general anesthesia. However, if the patient is endotracheally intubated, the anesthesiologist should be asked to deflate the cuff on the endotracheal tube until the spiral is completely within the stomach to prevent esophageal trauma that may be induced by the raised helical spirals on the overtube. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 118-cm overtube is compatible with enteroscopes that are 200 cm long and between 9.1 and 9.5 mm in diameter (ie, the enteroscopes used for double balloon or single balloon enteroscopy, but not standard enteroscopes). The spirals on the overtube are either 4.5 mm (low profile) or 5.5 mm (standard profile) high. The overtube has a coupling device that affixes it to the scope, while permitting rotation of the overtube. By rotating the overtube clockwise, the small bowel is pleated onto the overtube, and the enteroscope is advanced.",
"   </p>",
"   <p>",
"    Data on spiral enteroscopy are limited. Initial reports suggest decreased procedure times and similar depths of insertion compared with balloon-assisted enteroscopy and low complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/80,85-90\">",
"     80,85-90",
"    </a>",
"    ]. However, other reports suggest lower rates of complete small bowel enteroscopy with spiral enteroscopy compared with balloon-assisted enteroscopy. This, however, is not surprising since spiral enteroscopy is performed from an antegrade approach, whereas balloon-assisted enteroscopy can be performed both antegrade and retrograde, increasing the chances for complete enteroscopy. In one study, the rate of complete small bowel enteroscopy was much lower for spiral enteroscopy compared with balloon assisted enteroscopy (8 versus 92 percent), though the rate of complete small bowel enteroscopy with balloon-assisted enteroscopy was higher than that reported in many studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H388475228\">",
"     'Efficacy'",
"    </a>",
"    above.) In addition, the reported yield of spiral enteroscopy in some studies has been lower than that seen with balloon-assisted enteroscopy and varies by indication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 27 patients with obscure gastrointestinal bleeding, 25 underwent spiral enteroscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/85\">",
"       85",
"      </a>",
"      ]. The examination could not be carried out in two patients (due to a Schatzki ring or an inability to advance the overtube into the esophagus). The depth of insertion ranged from 80 to 340 cm (mean 175 cm), and the procedure time ranged from 19 to 65 minutes (mean 37 minutes). Possible sources of bleeding were noted in nine patients (33 percent), including angiodysplasia in eight and a duodenal ulcer in one. All of the angiodysplasias were treated with bipolar cautery. There were no major complications. Superficial esophageal mucosal trauma was noted in 22 percent of patients, and a postprocedure sore throat was noted in 28 percent.",
"     </li>",
"     <li>",
"      In a second report, 90 procedures were carried out in 95 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/86\">",
"       86",
"      </a>",
"      ]. The most common indications for the procedure were abdominal pain with loose stools or diarrhea (72 percent), occult gastrointestinal bleeding (12 percent), overt gastrointestinal bleeding (3 percent), a history of intestinal polyps (11 percent), and chronic abdominal pain alone (3 percent). In five of the patients, the overtube did not successfully engage the small bowel. The mean procedure time was 34 &plusmn; 8 minutes, and the mean depth of insertion was 262 &plusmn; 57 cm. Notable findings were present in 12 percent of the patients. There were no perforations and only two cases of deep mucosal tears associated with the procedure.",
"     </li>",
"     <li>",
"      In a third series of 61 patients, the procedure was successfully completed in 56 patients (92 percent). The most common indication was gastrointestinal bleeding (85 percent). The average depth of insertion was 217 &plusmn; 79 cm, and the mean procedure time was 41 &plusmn; 15 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/87\">",
"       87",
"      </a>",
"      ]. Positive findings were present in 36 patients (59 percent), and therapeutic maneuvers were carried out in 30 patients (49 percent). Complications included bradycardia requiring procedure termination (one patient), mucosal abrasions in the esophagus (2 patients), and abdominal pain necessitating hospital admission.",
"     </li>",
"     <li>",
"      A low rate of complications was reported in a series of 1750 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/89\">",
"       89",
"      </a>",
"      ]. Severe complications were reported in seven procedures (0.4 percent). Six of the complications were perforations, and all occurred as the enteroscope was being pushed through the overtube. Three of the perforations occurred with clinicians who had performed fewer than 10 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The yield of spiral enteroscopy in patients with positive findings on capsule endoscopy has also been examined. One study included 56 spiral enteroscopy procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24649/abstract/91\">",
"     91",
"    </a>",
"    ]. Findings on capsule endoscopy included angiodysplasias (26 patients), masses (eight patients), ulcers (four patients), polyps (four patients), abnormal mucosa (six patients), fresh blood (six patients), and stricture (one patient). The findings on capsule endoscopy were reproduced with spiral enteroscopy in 30 patients (54 percent). The type of finding on capsule endoscopy was associated with reproducibility on spiral enteroscopy. Blood was reproducible in 86 percent of patients, angiodysplasias in 69 percent, abnormal mucosa in 50 percent, masses in 38 percent, polyps in 33 percent, and ulcers and strictures in zero percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388475325\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep small bowel enteroscopy permits visualization and interventional therapy throughout the small bowel.",
"     </li>",
"     <li>",
"      Available options for deep small bowel enteroscopy include double balloon enteroscopy (DBE), single balloon enteroscopy (SBE), and spiral enteroscopy. (See",
"      <a class=\"local\" href=\"#H388475148\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Balloon-assisted enteroscopy (ie, DBE and SBE) can be performed orally or per rectum, whereas spiral enteroscopy can only be performed orally.",
"     </li>",
"     <li>",
"      The most common indication for deep small bowel enteroscopy is the evaluation of obscure gastrointestinal bleeding. There are multiple other indications, including the evaluation of suspected small bowel malignancies and the evaluation of small bowel Crohn's disease. (See",
"      <a class=\"local\" href=\"#H388475164\">",
"       'Diagnostic applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic applications for deep small bowel enteroscopy include the treatment of gastrointestinal bleeding from the small bowel, small bowel polypectomy, and small bowel stricture dilation. (See",
"      <a class=\"local\" href=\"#H388475172\">",
"       'Therapeutic applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that deep small bowel enteroscopy (rather than wireless capsule endoscopy, push enteroscopy, or intraoperative enteroscopy) be used when (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There are findings on wireless capsule endoscopy or radiographic small bowel imaging that require biopsy or therapeutic intervention, including active bleeding from the small bowel that is out of reach of a standard endoscope",
"     </li>",
"     <li>",
"      There is suspicion for a small bowel lesion despite a negative capsule study",
"     </li>",
"     <li>",
"      There is suspicion of impaction of a wireless capsule proximal to a small bowel stricture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep small bowel enteroscopy is generally well tolerated, but has been associated with many of the complications seen with other forms of endoscopy. The two most common serious complications are perforation and pancreatitis. (See",
"      <a class=\"local\" href=\"#H388475260\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H388475300\">",
"       'Single balloon enteroscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H388475317\">",
"       'Spiral enteroscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/1\">",
"      Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc 2001; 53:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/2\">",
"      Yamamoto H, Yano T, Kita H, et al. New system of double-balloon enteroscopy for diagnosis and treatment of small intestinal disorders. Gastroenterology 2003; 125:1556; author reply 1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/3\">",
"      Gerson LB, Flodin JT, Miyabayashi K. Balloon-assisted enteroscopy: technology and troubleshooting. Gastrointest Endosc 2008; 68:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/4\">",
"      Westerhof J, Weersma RK, Koornstra JJ. Investigating obscure gastrointestinal bleeding: capsule endoscopy or double balloon enteroscopy? Neth J Med 2009; 67:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/5\">",
"      Yoshida N, Wakabayashi N, Nomura K, et al. Ileal mucosa-associated lymphoid tissue lymphoma showing several ulcer scars detected using double-balloon endoscopy. Endoscopy 2004; 36:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/6\">",
"      Iwamoto M, Yamamoto H, Kita H, et al. Double-balloon endoscopy for ileal GI stromal tumor. Gastrointest Endosc 2005; 62:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/7\">",
"      Kunihiro K, Manabe N, Hata J, et al. Gastrointestinal stromal tumor in jejunum: diagnosis using contrast-enhanced ultrasonography and double-balloon enteroscopy. Dig Dis Sci 2006; 51:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/8\">",
"      Yamaguchi T, Manabe N, Tanaka S, et al. Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointest Endosc 2005; 62:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/9\">",
"      Ji JS, Choi H, Choi KY, et al. Two cases of GI involvement of Gorham's disease diagnosed by double-balloon enteroscopy: case report and review of the literature. Gastrointest Endosc 2005; 62:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/10\">",
"      Ross A, Mehdizadeh S, Tokar J, et al. Double balloon enteroscopy detects small bowel mass lesions missed by capsule endoscopy. Dig Dis Sci 2008; 53:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/11\">",
"      Yamagami H, Oshitani N, Hosomi S, et al. Usefulness of double-balloon endoscopy in the diagnosis of malignant small-bowel tumors. Clin Gastroenterol Hepatol 2008; 6:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/12\">",
"      Hayashi Y, Yamamoto H, Kita H, et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005; 11:4861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/13\">",
"      Yen HH, Chen YY, Soon MS. Nonsteroidal anti-inflammatory drug-associated ileal ulcers: an evaluation by double-balloon enteroscopy. Gastrointest Endosc 2006; 63:328; discussion 328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/14\">",
"      Nosho K, Endo T, Yoda Y, et al. Diaphragm disease of small intestine diagnosed by double-balloon enteroscopy. Gastrointest Endosc 2005; 62:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/15\">",
"      Kamata Y, Iwamoto M, Nara H, et al. A case of rheumatoid arthritis with protein losing enteropathy induced by multiple diaphragmatic strictures of the small intestine: successful treatment by bougieing under double-balloon enteroscopy. Gut 2006; 55:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/16\">",
"      Oshitani N, Yukawa T, Yamagami H, et al. Evaluation of deep small bowel involvement by double-balloon enteroscopy in Crohn's disease. Am J Gastroenterol 2006; 101:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/17\">",
"      Fry LC, Bellutti M, Neumann H, et al. Utility of double-balloon enteroscopy for the evaluation of malabsorption. Dig Dis 2008; 26:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/18\">",
"      Hadithi M, Al-toma A, Oudejans J, et al. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am J Gastroenterol 2007; 102:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/19\">",
"      Matsumoto T, Esaki M, Yanaru-Fujisawa R, et al. Small-intestinal involvement in familial adenomatous polyposis: evaluation by double-balloon endoscopy and intraoperative enteroscopy. Gastrointest Endosc 2008; 68:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/20\">",
"      Gay G, Delvaux M. Double-balloon colonoscopy after failed conventional colonoscopy: a pilot series with a new instrument. Endoscopy 2007; 39:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/21\">",
"      Moreels TG, Pelckmans PA. Double-balloon endoscope for failed conventional colonoscopy. Clin Gastroenterol Hepatol 2008; 6:259; author reply 259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/22\">",
"      Sakai P, Kuga R, Safatle-Ribeiro AV, et al. Is it feasible to reach the bypassed stomach after Roux-en-Y gastric bypass for morbid obesity? The use of the double-balloon enteroscope. Endoscopy 2005; 37:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/23\">",
"      Yamamoto H, Kita H, Sunada K, et al. Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol 2004; 2:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/24\">",
"      Sunada K, Yamamoto H, Kita H, et al. Case Report: Successful treatment with balloon dilatation in combination with double-balloon enteroscopy of a stricture in the small bowel of a patient with Crohn's disease. Digest Endosc 2004; 16:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/25\">",
"      Sunada K, Yamamoto H, Kita H, et al. Clinical outcomes of enteroscopy using the double-balloon method for strictures of the small intestine. World J Gastroenterol 2005; 11:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/26\">",
"      Ohmiya N, Taguchi A, Shirai K, et al. Endoscopic resection of Peutz-Jeghers polyps throughout the small intestine at double-balloon enteroscopy without laparotomy. Gastrointest Endosc 2005; 61:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/27\">",
"      Yen HH, Chen YY, Soon MS, Lin YM. An unusual cause of obscure gastrointestinal bleeding. Gut 2007; 56:12, 28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/28\">",
"      Nishimura M, Yamamoto H, Kita H, et al. Gastrointestinal stromal tumor in the jejunum: diagnosis and control of bleeding with electrocoagulation by using double-balloon enteroscopy. J Gastroenterol 2004; 39:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/29\">",
"      Kuno A, Yamamoto H, Kita H, et al. Double-balloon enteroscopy through a Roux-en-Y anastomosis for EMR of an early carcinoma in the afferent duodenal limb. Gastrointest Endosc 2004; 60:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/30\">",
"      Kita H, Yamamoto H, Nakamura T, et al. Bleeding polyp in the mid small intestine identified by capsule endoscopy and treated by double-balloon endoscopy. Gastrointest Endosc 2005; 61:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/31\">",
"      Lee BI, Choi H, Choi KY, et al. Retrieval of a retained capsule endoscope by double-balloon enteroscopy. Gastrointest Endosc 2005; 62:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/32\">",
"      May A, Nachbar L, Ell C. Extraction of entrapped capsules from the small bowel by means of push-and-pull enteroscopy with the double-balloon technique. Endoscopy 2005; 37:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/33\">",
"      Kita H, Yamamoto H. New indications of double balloon endoscopy. Gastrointest Endosc 2007; 66:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/34\">",
"      Emmett DS, Mallat DB. Double-balloon ERCP in patients who have undergone Roux-en-Y surgery: a case series. Gastrointest Endosc 2007; 66:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/35\">",
"      M&ouml;nkem&uuml;ller K, Fry LC, Bellutti M, et al. ERCP with the double balloon enteroscope in patients with Roux-en-Y anastomosis. Surg Endosc 2009; 23:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/36\">",
"      Saleem A, Baron TH, Gostout CJ, et al. Endoscopic retrograde cholangiopancreatography using a single-balloon enteroscope in patients with altered Roux-en-Y anatomy. Endoscopy 2010; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/37\">",
"      Matsushita M, Shimatani M, Ikeura T, et al. ERCP for altered Roux-en-Y anatomy: a single-balloon or short double-balloon enteroscope? Endoscopy 2011; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/38\">",
"      Yano T, Yamamoto H, Kita H, et al. Technical modification of the double-balloon endoscopy to access to the proximal side of the stenosis in the distal colon. Gastrointest Endosc 2005; 62:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/39\">",
"      Ross AS, Waxman I, Semrad C, Dye C. Balloon-assisted intubation of the ileocecal valve to facilitate retrograde double-balloon enteroscopy. Gastrointest Endosc 2005; 62:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/40\">",
"      Ohmiya N, Arakawa D, Nakamura M, et al. Small-bowel obstruction: diagnostic comparison between double-balloon endoscopy and fluoroscopic enteroclysis, and the outcome of enteroscopic treatment. Gastrointest Endosc 2009; 69:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/41\">",
"      Li X, Chen H, Dai J, et al. Predictive role of capsule endoscopy on the insertion route of double-balloon enteroscopy. Endoscopy 2009; 41:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/42\">",
"      Matsumoto T, Moriyama T, Esaki M, et al. Performance of antegrade double-balloon enteroscopy: comparison with push enteroscopy. Gastrointest Endosc 2005; 62:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/43\">",
"      May A, Nachbar L, Schneider M, Ell C. Prospective comparison of push enteroscopy and push-and-pull enteroscopy in patients with suspected small-bowel bleeding. Am J Gastroenterol 2006; 101:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/44\">",
"      May A, Nachbar L, Wardak A, et al. Double-balloon enteroscopy: preliminary experience in patients with obscure gastrointestinal bleeding or chronic abdominal pain. Endoscopy 2003; 35:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/45\">",
"      May A, Nachbar L, Ell C. Double-balloon enteroscopy (push-and-pull enteroscopy) of the small bowel: feasibility and diagnostic and therapeutic yield in patients with suspected small bowel disease. Gastrointest Endosc 2005; 62:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/46\">",
"      Ell C, May A, Nachbar L, et al. Push-and-pull enteroscopy in the small bowel using the double-balloon technique: results of a prospective European multicenter study. Endoscopy 2005; 37:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/47\">",
"      M&ouml;nkem&uuml;ller K, Weigt J, Treiber G, et al. Diagnostic and therapeutic impact of double-balloon enteroscopy. Endoscopy 2006; 38:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/48\">",
"      Heine GD, Hadithi M, Groenen MJ, et al. Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy 2006; 38:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/49\">",
"      Kaffes AJ, Koo JH, Meredith C. Double-balloon enteroscopy in the diagnosis and the management of small-bowel diseases: an initial experience in 40 patients. Gastrointest Endosc 2006; 63:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/50\">",
"      Sun B, Rajan E, Cheng S, et al. Diagnostic yield and therapeutic impact of double-balloon enteroscopy in a large cohort of patients with obscure gastrointestinal bleeding. Am J Gastroenterol 2006; 101:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/51\">",
"      Di Caro S, May A, Heine DG, et al. The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc 2005; 62:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/52\">",
"      Tanaka S, Mitsui K, Yamada Y, et al. Diagnostic yield of double-balloon endoscopy in patients with obscure GI bleeding. Gastrointest Endosc 2008; 68:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/53\">",
"      Gerson LB, Batenic MA, Newsom SL, et al. Long-term outcomes after double-balloon enteroscopy for obscure gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/54\">",
"      Gross SA, Stark ME. Initial experience with double-balloon enteroscopy at a U.S. center. Gastrointest Endosc 2008; 67:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/55\">",
"      Mehdizadeh S, Ross A, Gerson L, et al. What is the learning curve associated with double-balloon enteroscopy? Technical details and early experience in 6 U.S. tertiary care centers. Gastrointest Endosc 2006; 64:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/56\">",
"      Aktas H, de Ridder L, Haringsma J, et al. Complications of single-balloon enteroscopy: a prospective evaluation of 166 procedures. Endoscopy 2010; 42:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/57\">",
"      Sanaka MR, Navaneethan U, Kosuru B, et al. Antegrade is more effective than retrograde enteroscopy for evaluation and management of suspected small-bowel disease. Clin Gastroenterol Hepatol 2012; 10:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/58\">",
"      Nakase H, Matsuura M, Mikami S, Chiba T. Diagnosis and treatment of obscure GI bleeding with double balloon endoscopy. Gastrointest Endosc 2007; 66:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/59\">",
"      May A, Nachbar L, Schneider M, et al. Push-and-pull enteroscopy using the double-balloon technique: method of assessing depth of insertion and training of the enteroscopy technique using the Erlangen Endo-Trainer. Endoscopy 2005; 37:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/60\">",
"      M&ouml;schler O, May A, M&uuml;ller MK, et al. Complications in and performance of double-balloon enteroscopy (DBE): results from a large prospective DBE database in Germany. Endoscopy 2011; 43:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/61\">",
"      Messer I, May A, Manner H, Ell C. Prospective, randomized, single-center trial comparing double-balloon enteroscopy and spiral enteroscopy in patients with suspected small-bowel disorders. Gastrointest Endosc 2013; 77:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/62\">",
"      Pasha SF, Leighton JA, Das A, et al. Double-balloon enteroscopy and capsule endoscopy have comparable diagnostic yield in small-bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2008; 6:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/63\">",
"      May A, Friesing-Sosnik T, Manner H, et al. Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleeding. Endoscopy 2011; 43:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/64\">",
"      Samaha E, Rahmi G, Landi B, et al. Long-term outcome of patients treated with double balloon enteroscopy for small bowel vascular lesions. Am J Gastroenterol 2012; 107:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/65\">",
"      Mehdizadeh S, Han NJ, Cheng DW, et al. Success rate of retrograde double-balloon enteroscopy. Gastrointest Endosc 2007; 65:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/66\">",
"      Mensink PB, Haringsma J, Kucharzik T, et al. Complications of double balloon enteroscopy: a multicenter survey. Endoscopy 2007; 39:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/67\">",
"      M&ouml;schler O, May AD, M&uuml;ller MK, et al. [Complications in double-balloon-enteroscopy: results of the German DBE register]. Z Gastroenterol 2008; 46:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/68\">",
"      Tanaka S, Mitsui K, Tatsuguchi A, et al. Current status of double balloon endoscopy--indications, insertion route, sedation, complications, technical matters. Gastrointest Endosc 2007; 66:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/69\">",
"      Gerson LB, Tokar J, Chiorean M, et al. Complications associated with double balloon enteroscopy at nine US centers. Clin Gastroenterol Hepatol 2009; 7:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/70\">",
"      Honda K, Itaba S, Mizutani T, et al. An increase in the serum amylase level in patients after peroral double-balloon enteroscopy: an association with the development of pancreatitis. Endoscopy 2006; 38:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/71\">",
"      Kop&aacute;cov&aacute; M, Rejchrt S, Tachec&iacute; I, Bures J. Hyperamylasemia of uncertain significance associated with oral double-balloon enteroscopy. Gastrointest Endosc 2007; 66:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/72\">",
"      Yano T, Yamamoto H. Current state of double balloon endoscopy: the latest approach to small intestinal diseases. J Gastroenterol Hepatol 2009; 24:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/73\">",
"      Kuga R, Furuya CK Jr, Ide E, et al. Eosinophilic esophagitis and double-balloon enteroscopy: a dangerous combination. Endoscopy 2009; 41 Suppl 2:E85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/74\">",
"      Tsujikawa T, Saitoh Y, Andoh A, et al. Novel single-balloon enteroscopy for diagnosis and treatment of the small intestine: preliminary experiences. Endoscopy 2008; 40:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/75\">",
"      May A, F&auml;rber M, Aschmoneit I, et al. Prospective multicenter trial comparing push-and-pull enteroscopy with the single- and double-balloon techniques in patients with small-bowel disorders. Am J Gastroenterol 2010; 105:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/76\">",
"      Kawamura T, Yasuda K, Tanaka K, et al. Clinical evaluation of a newly developed single-balloon enteroscope. Gastrointest Endosc 2008; 68:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/77\">",
"      Upchurch BR, Sanaka MR, Lopez AR, Vargo JJ. The clinical utility of single-balloon enteroscopy: a single-center experience of 172 procedures. Gastrointest Endosc 2010; 71:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/78\">",
"      Frantz DJ, Dellon ES, Grimm IS, Morgan DR. Single-balloon enteroscopy: results from an initial experience at a U.S. tertiary-care center. Gastrointest Endosc 2010; 72:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/79\">",
"      Ramchandani M, Reddy DN, Gupta R, et al. Diagnostic yield and therapeutic impact of single-balloon enteroscopy: series of 106 cases. J Gastroenterol Hepatol 2009; 24:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/80\">",
"      Khashab MA, Lennon AM, Dunbar KB, et al. A comparative evaluation of single-balloon enteroscopy and spiral enteroscopy for patients with mid-gut disorders. Gastrointest Endosc 2010; 72:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/81\">",
"      Takano N, Yamada A, Watabe H, et al. Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. Gastrointest Endosc 2011; 73:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/82\">",
"      Domagk D, Mensink P, Aktas H, et al. Single- vs. double-balloon enteroscopy in small-bowel diagnostics: a randomized multicenter trial. Endoscopy 2011; 43:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/83\">",
"      Wang AY, Sauer BG, Behm BW, et al. Single-balloon enteroscopy effectively enables diagnostic and therapeutic retrograde cholangiography in patients with surgically altered anatomy. Gastrointest Endosc 2010; 71:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/84\">",
"      Yip WM, Lok KH, Lai L, et al. Acute pancreatitis: rare complication of retrograde single-balloon enteroscopy. Endoscopy 2009; 41 Suppl 2:E324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/85\">",
"      Akerman PA, Agrawal D, Chen W, et al. Spiral enteroscopy: a novel method of enteroscopy by using the Endo-Ease Discovery SB overtube and a pediatric colonoscope. Gastrointest Endosc 2009; 69:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/86\">",
"      Buscaglia JM, Dunbar KB, Okolo PI 3rd, et al. The spiral enteroscopy training initiative: results of a prospective study evaluating the Discovery SB overtube device during small bowel enteroscopy (with video). Endoscopy 2009; 41:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/87\">",
"      Judah JR, Draganov PV, Lam Y, et al. Spiral enteroscopy is safe and effective for an elderly United States population of patients with numerous comorbidities. Clin Gastroenterol Hepatol 2010; 8:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/88\">",
"      Akerman PA, Agrawal D, Cantero D, Pangtay J. Spiral enteroscopy with the new DSB overtube: a novel technique for deep peroral small-bowel intubation. Endoscopy 2008; 40:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/89\">",
"      Akerman P, Contero D. Severe complications of spiral endoscopy in the first 1750 patients. Gastrointest Endosc 2009; 69:AB127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/90\">",
"      Morgan D, Upchurch B, Draganov P, et al. Spiral enteroscopy: prospective U.S. multicenter study in patients with small-bowel disorders. Gastrointest Endosc 2010; 72:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24649/abstract/91\">",
"      Buscaglia JM, Richards R, Wilkinson MN, et al. Diagnostic yield of spiral enteroscopy when performed for the evaluation of abnormal capsule endoscopy findings. J Clin Gastroenterol 2011; 45:342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2652 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24649=[""].join("\n");
var outline_f24_4_24649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H388475325\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475148\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475156\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388475164\">",
"      Diagnostic applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388475172\">",
"      Therapeutic applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388475180\">",
"      Advanced techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475188\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475196\">",
"      BALLOON-ASSISTED ENTEROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388475204\">",
"      Double balloon enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H388475212\">",
"      - Patient preparation and sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H388475220\">",
"      - Technique for DBE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H388475228\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475244\">",
"      Diagnostic and therapeutic yields",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475252\">",
"      Learning curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475260\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475268\">",
"      - Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475276\">",
"      - Perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475284\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H388475292\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388475300\">",
"      Single balloon enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475317\">",
"      SPIRAL ENTEROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H388475325\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2652|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/33/16916\" title=\"diagnostic image 1\">",
"      Fluoroscopic view of double balloon enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2652|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/10/25761\" title=\"figure 1\">",
"      Components of Roux-en-Y gastric bypass procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/3/14392\" title=\"figure 2\">",
"      Double balloon technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/63/16374\" title=\"figure 3\">",
"      Single balloon enteroscopy technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2652|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/35/41524\" title=\"picture 1\">",
"      Double balloon endoscopy system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/38/25186\" title=\"picture 2\">",
"      Small bowel angiodysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2003\" title=\"picture 3\">",
"      Gastrointestinal stromal tumor in the small bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/11/30911\" title=\"picture 4\">",
"      Small bowel polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/18/15662\" title=\"picture 5\">",
"      Spiral enteroscopy overtube",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24650="Acquired inhibitors of coagulation";
var content_f24_4_24650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired inhibitors of coagulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Steven Coutre, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/4/24650/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/4/24650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired inhibitors of coagulation are antibodies that either inhibit the activity or increase the clearance of a clotting factor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some disorders may be associated with antibodies to a variety of clotting factors. In systemic lupus erythematosus, for example, antiphospholipid antibodies and antibodies directed against factors II, VIII, IX, XI, XII, and XIII have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H26#H26\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Antibodies to clotting factors and phospholipids'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Other antiphospholipid antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies represent a special problem; these antibodies prolong certain clotting assays, but result in thrombosis rather than bleeding. The pathogenesis, diagnosis, and treatment of conditions associated with antiphospholipid antibodies are discussed elsewhere in UpToDate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"       \"Pathogenesis of the antiphospholipid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common clinical manifestation in affected patients is a hemorrhagic diathesis. Acquired coagulation inhibitors that lead to bleeding will be reviewed here. The natural history and management of these inhibitors are quite different from inhibition due to alloantibodies that occur in patients with various inherited bleeding disorders (eg, congenital deficiencies of factors VIII, IX, or XI) treated with factor replacement. The latter problem is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link&amp;anchor=H13#H13\">",
"     \"Factor XI deficiency\", section on 'FXI inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTOR VIII INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common autoantibodies that affect clotting factor activity and lead to a bleeding disorder are directed against, and interfere with, the activity of factor VIII, a condition also called acquired hemophilia A [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Although there are no large series describing the immunoglobulin class of the factor VIII autoantibodies, most have been IgG antibodies that do not bind complement.",
"   </p>",
"   <p>",
"    The reasons for the production of factor VIII autoantibodies in a particular individual are not clear, but may involve the presence of certain gene polymorphisms (eg, HLA, CTLA4)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autoreactive CD4+ T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An individual patient, either nonhemophilic or hemophilic, can produce antibodies of different IgG subclasses directed against different epitopes on the factor VIII molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However, the production of multiple antibodies is much more common in patients with hemophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/10\">",
"     10",
"    </a>",
"    ]. Most of these antibodies bind to the C2 or, less often, the A2 domain on factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Loss of the C2 domain, which binds to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells and to von Willebrand factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/13\">",
"     13",
"    </a>",
"    ], leads to reduced procoagulant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22824?source=see_link\">",
"     \"Biology and normal function of factor VIII and factor IX\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar finding has been noted with factor V inhibitors that are associated with bleeding manifestations; the antibodies are usually directed against the C2 domain of the protein (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Factor V inhibitors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], which is also responsible for binding to phosphatidylserine on activated platelets and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population-based unselected cohorts of patients seen in South and West Wales and the United Kingdom have calculated an incidence of acquired factor VIII inhibitor of 1.3 to 1.5 cases per million population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In another survey of 118 physicians likely to see such patients, 215 were described over a 10-year period; the following characteristics were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most of the patients were over age 50, except for women who were pregnant or postpartum.",
"     </li>",
"     <li>",
"      The major identifiable causes were pregnancy or the postpartum period, rheumatoid arthritis, malignancy, systemic lupus erythematosus, and drug reactions (each responsible for 5 to 10 percent). However, in almost one-half of the patients no underlying disorder was present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of series and surveys of patients with acquired factor VIII inhibitors, including the author's own experience, and comprising 249 patients, has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/19\">",
"     19",
"    </a>",
"    ]. Median age was 64 (range: 8 to 93); 55 percent were female. Median inhibitor and factor VIII levels were 10 Bethesda units (range: 0.9 to 32,000) and 2 percent (range: 0 to 30), respectively. The most common associated diseases were malignancy, post-partum status, and autoimmune disorders. On multivariate analysis, factors predicting for improved overall survival were attainment of complete remission, age &lt;65, and post-partum status. Although treatment data appeared to suffer from publication bias, the highest rates of complete remission and lowest rates of disease-specific mortality were noted in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Postpartum",
"      </strong>",
"      &mdash; Several retrospective studies and reviews of acquired factor VIII inhibitors associated with pregnancy have come to similar conclusions regarding the course and prognosis of these inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/2,3,20,21\">",
"       2,3,20,21",
"      </a>",
"      ]. The inhibitors are typically diagnosed within two to three months postpartum. Most cases were associated with the first pregnancy (ie, in primigravidas) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/20\">",
"       20",
"      </a>",
"      ]. The survival of patients with pregnancy associated factor VIII inhibitors is nearly 100 percent, substantially better than that of patients with these inhibitors not associated with pregnancy. This excellent survival might reflect the younger age, overall better health, and reversibility of the condition that provoked the development of the inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Natural history'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Rheumatic disease",
"      </strong>",
"      &mdash; Among the rheumatic diseases, factor VIII inhibitors have primarily been described in patients with rheumatoid arthritis and systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/1,2,22-24\">",
"       1,2,22-24",
"      </a>",
"      ]. In occasional patients, these antibodies coexist with antiphospholipid antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"      &mdash; Anti-factor VIII antibodies are a rare complication of solid tumors. In a review of 27 analyzable cases, there was a close temporal relationship between detection of the inhibitors and diagnosis of the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/26\">",
"       26",
"      </a>",
"      ]. There was no association with a specific tumor; the possible causative role of treatment with immunomodulatory agents (eg, interferon,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      ) is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/27-31\">",
"       27-31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a second review of 41 patients identified through the available literature, there were 25 with solid organ tumors and 16 with hematologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/32\">",
"       32",
"      </a>",
"      ]. Adenocarcinomas comprised 64 percent of the solid tumors, with the most common sites being prostate and lung. Chronic lymphocytic leukemia was the most common of the hematologic malignancies. The median age was 70 and 68 percent of the subjects were men. Treatment of the inhibitor led to a complete response (CR) in 70 percent of patients. Patients achieving CR were more likely to have early stage tumors and a lower median inhibitor titer at the time of presentation, compared with nonresponders.",
"     </li>",
"     <li>",
"      <strong>",
"       Drug-induced",
"      </strong>",
"      &mdash; Anti-factor VIII antibodies have been associated some medications (eg, penicillin, sulfamides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ) and immunomodulatory agents such as interferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/4,33\">",
"       4,33",
"      </a>",
"      ]. These antibodies often resolve following cessation of the offending drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of acquired factor VIII antibodies is bleeding that, in some cases, is first noted after a surgical procedure. Symptomatic patients often present with large hematomas, extensive ecchymoses or severe mucosal bleeding, including epistaxis, gastrointestinal bleeding, and gross hematuria. Spontaneous hemarthroses, which are common in hereditary factor VIII deficiency, are unusual in those with acquired disease (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The range of bleeding manifestations can be illustrated by observations in women with postpartum factor VIII inhibitors. Soft tissue bleeding was most common (29 of 51 patients), followed by muscle, vaginal, joint bleeding, and hematuria (13 to 18 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/3\">",
"     3",
"    </a>",
"    ]. There were no episodes of intracerebral bleeding.",
"   </p>",
"   <p>",
"    Bleeding is often severe, constituting a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    . In the above survey of 215 patients, 87 percent experienced major bleeding and 22 percent died from complications attributed directly or indirectly to the inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United Kingdom cohort, bleeding was the cause of death in 9 percent and remained a risk until the inhibitor had been eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sudden presence of large hematomas or extensive ecchymoses in an elderly individual without significant trauma or known bleeding disorder should always raise the clinical suspicion of an acquired factor VIII inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the clinical features, factor VIII inhibitors are characterized by a prolonged activated partial thromboplastin time (aPTT) and a normal prothrombin time (PT). The differential diagnosis of this profile in a patient with a bleeding diathesis includes deficiencies of factors XI, IX or VIII, von Willebrand disease, inhibitors of these factors, and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 2",
"    </a>",
"    ). A prolonged aPTT is also seen in the antiphospholipid antibody syndrome, but these patients present with thrombosis rather than bleeding episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reasonable first step is to exclude the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as a cause of the patient's bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolongation of the aPTT. In addition to a review of the patient's medications, the presence of heparin in the blood sample can be suspected via one of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical use of coagulation tests\", section on 'Heparin in the sample'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The simplest approach is to redraw a blood sample using an uncontaminated peripheral vein. If the repeat aPTT is normal, the original sample was probably contaminated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"     </li>",
"     <li>",
"      If a prolonged aPTT or thrombin time is normalized after the addition of protamine or a commercially available ion exchange resin (Heparsorb),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or a heparin-like material is present.",
"     </li>",
"     <li>",
"      Perform a thrombin time and a reptilase time.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is present if the thrombin time is prolonged and the reptilase time is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inhibitor screen (mixing test)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary initial diagnostic test for a factor VIII inhibitor is the mixing test or inhibitor screen. In this assay, varying amounts of patient plasma and pooled normal plasma are mixed and the aPTT measured. After mixing, measurement of the aPTT should be performed not only immediately but also after incubation at 37&ordm;C for one to two hours. The second measurement is necessary to detect factor VIII inhibitors with slow reaction kinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correction of the prolonged aPTT suggests a factor deficiency or VWD, while persistent prolongation of the aPTT indicates the presence of an inhibitor. The mixing test will establish whether an inhibitor is present but will not identify the inhibitor's specificity.",
"   </p>",
"   <p>",
"    The next step is adding a source of phospholipid to the mixed plasma. Correction of the aPTT suggests the presence of antiphospholipid antibodies. If the aPTT does not correct, the Bethesda assay is performed. The Bethesda assay both establishes the diagnosis of a factor VIII inhibitor and quantifies the antibody titer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/35\">",
"     35",
"    </a>",
"    ]. By standardizing the strength of factor VIII inhibitors, this assay also permits comparison between different treatment regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bethesda assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Bethesda assay, serial dilutions of patient plasma are incubated with pooled normal plasma at 37&ordm;C for two hours; factor VIII activity is then measured using a clotting assay as one would in a patient with hereditary factor VIII deficiency. The reciprocal dilution of patient plasma that results in 50 percent factor VIII activity is defined as one Bethesda unit (BU). The stronger the inhibitor, the greater the dilution required to allow for factor VIII activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial, limited information has been presented on an immunoassay for anti-factor VIII antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF FACTOR VIII INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of acquired factor VIII inhibitors consists of two separate steps [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of bleeding",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Elimination of the inhibitor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with any other bleeding disorder, actions that might provoke bleeding (eg, intramuscular injections, invasive procedures, use of antiplatelet agents) should be avoided or minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Control of active bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment strategies to control active bleeding include the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/61/37844?source=see_link\">",
"     activated prothrombin complex concentrates",
"    </a>",
"    (anti-inhibitor coagulant complex, Feiba, Autoplex T), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/4,37,38,41-48\">",
"     4,37,38,41-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision regarding initial treatment should be made based upon the severity of bleeding and the titer of the inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with non life-threatening bleeding and low inhibitor titers, DDAVP at a dose of 0.3",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      SQ per day given for three to five days may be sufficient for control of bleeding or for hemostatic coverage of invasive procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/40,50,51\">",
"       40,50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most bleeding associated with low titer inhibitors (ie, &lt;5 Bethesda units) may be treated with human",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      at high doses (eg, 20 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      for each Bethesda unit of the inhibitor plus an additional 40 international",
"      <span class=\"nowrap\">",
"       units/kg,",
"      </span>",
"      with monitoring of factor VIII activity 10 minutes following bolus injection, and repeat IV bolus dosing if the incremental recovery is not adequate) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with higher titers, treatment with activated prothrombin complex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/44\">",
"     44",
"    </a>",
"    ] or human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/45\">",
"     45",
"    </a>",
"    ] can be employed. Recommended doses are similar to those employed in hemophilia patients with inhibitors. There are no comparative trials to determine which of these two agents is more effective in this setting. Results from an uncontrolled European registry in 501 patients with acquired factor VIII deficiency suggest that the two agents have similar efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link&amp;anchor=H11#H11\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inhibitor titer to porcine factor VIII is often 5 to 10 percent of the titer against human factor VIII, suggesting the use of porcine factor VIII in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/52\">",
"     52",
"    </a>",
"    ]. Although this product is no longer commercially available, a recombinant porcine factor VIII preparation is undergoing clinical trials and may prove to be effective in this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link&amp;anchor=H15#H15\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Porcine factor VIII concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Eliminating the inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elimination of the factor VIII inhibitor requires the use of immunosuppressive modalities which are described below. Of importance, some inhibitors will regress spontaneously (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Natural history'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There are no convincing data from randomized trials that one immunosuppressive regimen is better than another or that the choice of regimen should be based upon the inhibitor titer or factor VIII level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/39\">",
"     39",
"    </a>",
"    ]. The lack of definitive data from non-randomized studies was shown in a retrospective analysis of the outcomes of various immunosuppression regimens in 331 subjects enrolled in the European Acquired Hemophilia Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most commonly employed initial immunosuppressive regimens were glucocorticoids alone (n = 142), glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (n = 83), and glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (n = 28).",
"     </li>",
"     <li>",
"      Complete remissions (ie, undetectable inhibitor levels, factor VIII levels &gt;70 International",
"      <span class=\"nowrap\">",
"       units/mL,",
"      </span>",
"      and immunosuppression stopped) were noted in 48, 70, and 59 percent of those treated with glucocorticoids alone, glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , respectively.",
"     </li>",
"     <li>",
"      The median times to complete remission were approximately five weeks for the use of glucocorticoids with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -based regimens required approximately twice as long. Immunoglobulin administration did not improve outcome.",
"     </li>",
"     <li>",
"      Adverse events were common in all three treatment groups, and were reported in 25, 41, and 37 percent, respectively.",
"     </li>",
"     <li>",
"      Second-line therapy was successful in approximately 60 percent of cases that failed first-line therapy; outcome was not affected by the choice of first-line therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although patients were more likely to respond to glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    than with other regimens, outcome at final follow-up was not affected by the choice of first-line therapy. Data were insufficient to adjust the immunosuppression regimen based upon factor VIII levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inhibitor titer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prednisone and cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective randomized trial evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and the combination of both drugs in 31 nonhemophilic patients with factor VIII antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/54\">",
"     54",
"    </a>",
"    ]. All patients initially received prednisone (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO) for three weeks; if the antibody persisted, the patients were randomly assigned to continuation of prednisone for another six weeks, tapering of prednisone and initiation of cyclophosphamide (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO), or continuation of prednisone with the addition of cyclophosphamide. The antibody disappeared in 10 of the 31 subjects (32 percent) during the initial course of prednisone. Twenty of the 21 nonresponding patients were then randomly assigned to further treatment, with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antibody disappeared in three of the four subjects randomly assigned to receive continued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone, making the overall response to prednisone alone 42 percent.",
"     </li>",
"     <li>",
"      The antibody disappeared in three of six randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      alone.",
"     </li>",
"     <li>",
"      The antibody disappeared in 5 of 10 randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antibody titer was significantly lower in responders than nonresponders, but seven patients with titers &gt;5 Bethesda units had complete remissions. The authors concluded that all patients should receive initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy and that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was effective second-line therapy in many patients who were steroid-resistant.",
"   </p>",
"   <p>",
"    This conclusion was supported by results of a non-randomized retrospective analysis of 88 patients from a UK cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/18\">",
"     18",
"    </a>",
"    ]. No significant difference was found in the proportion of patients achieving complete remission or in the time to complete remission following treatment with steroids alone versus those treated with steroids plus cytotoxic therapy (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). Of interest, all four patients with rheumatoid arthritis responded to treatment with steroids alone, in contrast to reports that suggested such patients are resistant to treatment with steroids alone and do better when treated with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been noted in patients with postpartum disease. In the above retrospective series of 51 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    did not appear to be more effective than no therapy, but a shorter time to complete response was noted in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or 6-mercaptopurine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/3\">",
"     3",
"    </a>",
"    ]. The overall outcome was quite favorable, with 97 percent survival at two years and almost 100 percent probability of complete remission by 30 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option for the therapy of acquired factor VIII inhibitors is the administration of intravenous immune globulin (IVIG) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/24,40,55\">",
"     24,40,55",
"    </a>",
"    ]. In a prospective study, 19 patients were treated with IVIG (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    IV for two days or 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/55\">",
"     55",
"    </a>",
"    ]. Two patients had a decline in inhibitor titer within several days, and four patients responded over weeks to months. Because only some patients respond to IVIG and multiple courses are often required, and given the excellent results obtained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we suggest that IVIG not be used as initial therapy.",
"   </p>",
"   <p>",
"    Utility of the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , alone or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , has been demonstrated in a number of patients with acquired factor VIII inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/56-65\">",
"     56-65",
"    </a>",
"    ]. Highly anecdotal information suggests that subjects with high inhibitor titers (eg, &gt;100 BU) may require the use of all three agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/40,58,59,61,65\">",
"     40,58,59,61,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anecdotal information indicates that some patients resistant to all of the above therapies have responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/66-69\">",
"     66-69",
"    </a>",
"    ] or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/70\">",
"     70",
"    </a>",
"    ]. In the rare patient not responding to the above measures, the use of extracorporeal plasmapheresis with an immunoadsorption column to absorb the autoantibody can be tried [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/49,71-73\">",
"     49,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382370\">",
"    <span class=\"h3\">",
"     Monitoring response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of treatment for an acquired factor VIII inhibitor is cessation of bleeding, followed ultimately by a decrease in the titer of the inhibitor. The former is monitored via the usual clinical and laboratory observations (eg, observable blood loss, blood in urine or stool, repeated blood counts). Since inhibitor titers drop very slowly following successful treatment, it is neither necessary nor advisable to check the patient&rsquo;s aPTT or inhibitor titer more often than every two to four weeks once immunosuppressive therapy has been started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In terms of eliminating the inhibitor, most patients have been treated with immunosuppressive drugs. Although these drugs hasten the time to complete remission, there is an appreciable incidence of spontaneous recovery. In the survey of 215 nonhemophilic patients noted above, 31 received no therapy other than supportive transfusions or factor concentrates; the inhibitor disappeared spontaneously in 11 (36 percent) at an average duration of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar findings were noted in a report of 16 patients who received little or no therapy for an average of 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/74\">",
"     74",
"    </a>",
"    ]. There were no spontaneous hemarthroses, two died from retroperitoneal bleeding, and five (31 percent) had spontaneous disappearance of the inhibitor. Given the continued risk of bleeding, not treating with immunosuppressive therapy should be an informed decision made by the patient, since these therapies are usually successful.",
"   </p>",
"   <p>",
"    The relapse rate after a first complete remission has been estimated at about 20 percent; 70 percent of such relapsing patients achieve a second complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]. The relapse rate of pregnancy-associated factor VIII inhibitors appears to be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse of pregnancy-associated acquired factor VIII inhibitors may rarely occur in subsequent pregnancies; the antibody may affect fetal factor VIII levels, resulting in life-threatening hemorrhage in a subsequent fetus because of transplacental transfer of IgG antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/20,37,76,77\">",
"     20,37,76,77",
"    </a>",
"    ]. Patients with low antibody titers (ie, &lt;5 Bethesda units) tend to have remissions within months, whereas those with higher titers may have antibody persistence for years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In at least one case, treatment of the underlying condition (eg, malignancy) has resulted in disappearance of the inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER COAGULATION FACTOR INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies can be directed against a variety of clotting factors other than factor VIII, with variable clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/79\">",
"     79",
"    </a>",
"    ]. These will be described below, with the exception of antibodies to von Willebrand factor, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H13#H13\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Acquired von Willebrand disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prothrombin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prothrombin antibodies are most often detected in patients with antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The prothrombin antibodies, which can cause significant clinical bleeding, usually bind to a nonactive portion of the molecule, resulting in accelerated clearance of prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/80\">",
"     80",
"    </a>",
"    ]. Laboratory testing (ie, screening for an inhibitor) is most consistent with a factor deficiency rather than an inhibitor, since the functional activity of prothrombin is not impaired in a clotting assay when additional prothrombin is added. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible presence of prothrombin antibodies should be suspected if a patient with antiphospholipid antibodies develops bleeding rather than the expected thrombotic events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. An autoantibody directed against prothrombin has been well characterized in one patient who did not have a lupus anticoagulant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/83\">",
"     83",
"    </a>",
"    ]. It bound to a different epitope on the prothrombin molecule than described above, but still led to depletion of prothrombin without affecting prothrombin function.",
"   </p>",
"   <p>",
"    Specific immunochemical measurement of the prothrombin concentration is required to establish the diagnosis.",
"   </p>",
"   <p>",
"    Treatment of active bleeding consists of the use of fresh frozen plasma (FFP) to increase prothrombin levels. The recommended dose of FFP is 15 to 20",
"    <span class=\"nowrap\">",
"     ml/kg,",
"    </span>",
"    with a target prothrombin level &gt;30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H15#H15\">",
"     \"Rare (recessively inherited) coagulation disorders\", section on 'Prothrombin deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modalities used to treat factor VIII inhibitors also may apply to patients with prothrombin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment of factor VIII inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thrombin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors specific for human thrombin are quite rare as one might expect, given the multiple important functions of this enzyme. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) The majority of antibodies directed against thrombin are detected incidentally in the absence of clinical bleeding because of prolongation of the thrombin clotting time (thrombin time, TT) and other clot-based anticoagulation assays performed for some other reason.",
"   </p>",
"   <p>",
"    Thrombin antibodies typically arise after exposure to bovine thrombin found in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    or fibrin-glue preparations used in surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. These antibodies do not cause clinical bleeding unless they crossreact with human thrombin or, more often, when antibodies are also present against factor V, a common contaminant in bovine thrombin preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these patients the thrombin time is prolonged when using bovine reagent thrombin and is normal when the thrombin reagent is of human origin. The aPTT is prolonged and the prothrombin time is increased if factor V antibodies are also present [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/85,87\">",
"     85,87",
"    </a>",
"    ]. The availability of human, rather than bovine, thrombin for fibrin sealant and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    preparations should decrease the incidence of thrombin antibody formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical use of coagulation tests\", section on 'Thrombin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombin antibodies have also been described in several patients without exposure to exogenous thrombin. Most of these patients had a comorbid condition such as lupus erythematosus, rheumatoid arthritis, or monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]; however, one patient had no obvious underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/92\">",
"     92",
"    </a>",
"    ]. These inhibitors may cause severe bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/90,92\">",
"     90,92",
"    </a>",
"    ]. Anecdotal treatment approaches include immunosuppression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/92\">",
"     92",
"    </a>",
"    ]. Given the severity of bleeding that can occur in this setting, aggressive initial management including plasma exchange is probably warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Factor V inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with thrombin inhibitors, the majority of factor V inhibitors are autoantibodies that arise from exposure to topical fibrin glues or bovine thrombin preparations that are contaminated with bovine factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/85-87,93\">",
"     85-87,93",
"    </a>",
"    ]. One review evaluated 105 published cases of acquired factor V inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/88\">",
"     88",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-six (44 percent) were associated with bovine thrombin exposure. In the only prospective study that has evaluated this relationship, such exposure led to the generation of factor V inhibitors in 11 of 24 patients after cardiac surgery and 2 of 10 patients after neurosurgery, for a combined incidence of 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/87\">",
"       87",
"      </a>",
"      ]. Repeated exposure appeared to lead to more potent inhibitors.",
"     </li>",
"     <li>",
"      Twenty-four patients (23 percent) developed inhibitors following surgery without known exposure to bovine proteins. These antibodies showed specificity for human factor V, but can crossreact with bovine factor V. They do not prolong the thrombin time, in contrast to patients exposed to bovine thrombin.",
"     </li>",
"     <li>",
"      Other associated conditions included malignancy, autoimmune disease, the postpartum state, and congenital factor V deficiency. Nineteen had apparently idiopathic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of 12 patients (with and without bovine thrombin exposure), only the antibodies from patients with hemorrhagic manifestations inhibited factor V activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/14\">",
"     14",
"    </a>",
"    ]. These antibodies usually recognize the C2 domain of the protein. Loss of this domain, which binds to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/16\">",
"     16",
"    </a>",
"    ], results in loss of procoagulant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/15\">",
"     15",
"    </a>",
"    ]. As noted above, some factor VIII antibodies are directed against the C2 domain on that protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemorrhagic manifestations associated with factor V inhibitors are variable, ranging from asymptomatic to life-threatening bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/14,85,86,88\">",
"     14,85,86,88",
"    </a>",
"    ]. In the large review cited above, bleeding occurred in one-third of patients with inhibitors following exposure to bovine proteins, compared with two-thirds of other cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two factors contribute to this variability. First, bleeding is primarily associated with antibodies directed against the C2 domain of the protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/14\">",
"     14",
"    </a>",
"    ]. Second, functionally important factor V is concentrated on platelets. One patient who did not have a severe bleeding disorder had an inhibitor that neutralized plasma factor V but not the less accessible platelet factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/94\">",
"     94",
"    </a>",
"    ]. Platelet factor V may be more important for assembly of the prothrombinase complex than circulating factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a factor V inhibitor should be suspected in a patient with prolongation of the aPTT and PT but a normal thrombin time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/86\">",
"     86",
"    </a>",
"    ]. However, the thrombin time may be prolonged in patients with bovine thrombin exposure and the production of antibodies to thrombin as well as to factor V. As described for factor VIII inhibitors, mixing studies should confirm the diagnosis and the inhibitor titer can be determined using the Bethesda assay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute severe bleeding due to a factor V inhibitor may be life-threatening. For those patients who survive the acute bleeding episode, the prognosis is generally excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/88\">",
"     88",
"    </a>",
"    ]. Most inhibitors disappear within a period of months; it is not clear if immunosuppressive therapy accelerates this response.",
"   </p>",
"   <p>",
"    Treatment modalities for acutely bleeding patients include platelet transfusions, plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], and intravenous immune globulin (IVIG) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. For serious bleeding, we suggest the use of platelet transfusions and plasma exchange; such patients should also receive immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , as described above in patients with factor VIII inhibitors;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has also been used successfully in a few patients with acquired factor V inhibitors refractory to other therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/98\">",
"     98",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment of factor VIII inhibitors'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Factor VII inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies directed against factor VII are rare and only a small number of cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. As expected, the PT is prolonged but the aPTT is normal, since factor VII is not involved in either the intrinsic coagulation pathway or the final common pathway (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 2",
"    </a>",
"    ). Mixing studies will confirm the presence of an inhibitor; a low level or absence of residual factor VII activity, especially after prolonged incubation (one hour) is necessary to confirm the diagnosis.",
"   </p>",
"   <p>",
"    The clinical manifestations in the few reported cases have ranged from minor bleeding to life-threatening events such as intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. One such patient did not improve after IVIG but was successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , corticosteroids, and plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/101\">",
"     101",
"    </a>",
"    ]. This response is similar to that described for severe bleeding with other acquired inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Factor IX inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired antibodies directed against factor IX in the absence of hemophilia B are also very rare; two cases have been reported in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. The natural history is similar to factor V inhibitors. The role of immunosuppressive therapy is uncertain, but one child seemed to respond to IGIV and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Factor X inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only three patients have been described with documented inhibitors against factor X [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. Other patients have presented with the sudden onset of bleeding, prolonged PT and aPTT measurements, and transient, severe deficiency of factor X. There was often an antecedent acute respiratory infection, and inhibitors were not conclusively demonstrated.",
"   </p>",
"   <p>",
"    Amyloidosis can lead to deficiency of factor X due to binding of the protein to amyloid fibrils [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In this disorder, other hemostatic defects probably also contribute to the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link&amp;anchor=H143177#H143177\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One well-characterized case of an acquired inhibitor involved the spontaneous appearance of an autoantibody in an elderly man who presented with hemoptysis, hematuria, and bleeding into the thigh after an intramuscular injection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/109\">",
"     109",
"    </a>",
"    ]. The patient was successfully treated with steroids with disappearance of the inhibitor within two weeks. It is unclear if the inhibitor would have resolved spontaneously had such therapy not been given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Factor XI inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor XI autoantibodies not occurring in patients with congenital factor XI deficiency are often associated with lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Affected patients usually have little or no bleeding despite a prolonged aPTT that does not fully correct in a mixing study. The relative lack of bleeding, which is also noted in congenital factor XI deficiency, probably reflects the tertiary role for factor XI in factor X activation, although bleeding can occur under certain circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link&amp;anchor=H13#H13\">",
"     \"Factor XI deficiency\", section on 'FXI inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Factor XIII inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated factor XIII stabilizes and crosslinks overlapping fibrin strands. Factor XIII inhibitors, which are exceedingly rare, can act by one of several mechanisms: inhibition of activation of factor XIII; interference with enzymatic function; or prevention of binding to fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H603267860#H603267860\">",
"     \"Overview of hemostasis\", section on 'Continuation of the coagulation cascade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical hallmark of a factor XIII inhibitor is delayed bleeding after surgery or an invasive procedure, since the initial clot which does form is mechanically weak and unstable. Large spontaneous hematomas or intracranial hemorrhage can occur. Most patients are over age 50, and death from bleeding is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/115,117\">",
"     115,117",
"    </a>",
"    ]. As an example, in a review of 33 cases, nine died of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor XIII inhibitors can be associated with immune dysregulation. In one review, development of an anti-factor XIII antibody was associated with systemic lupus erythematosus in a third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/118\">",
"     118",
"    </a>",
"    ]. Other associated conditions include other autoimmune disorders, lymphoid malignancies, and some drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor XIII inhibitors produce a unique pattern on coagulation testing. The PT and aPTT, which measure fibrin generation, are normal, but the clot stability assay is abnormal, since the absence of fibrin crosslinking causes the clot to lyse much more rapidly in 5 molar urea, 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , or 1 percent monochloroacetic acid. In one review, clot solubility testing was used to make the diagnosis in half of the patients, with the remainder diagnosed by a variety of other tests (eg, Berichrom FXIII, which is a photometric assay for quantitative measurement of FXIII level) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Urea clot solubility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management typically involves immunosuppression; most patients have received immunosuppressive therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , plasma exchange, IVIG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/772?source=see_link\">",
"     factor XIII concentrates",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/119-123\">",
"     119-123",
"    </a>",
"    ]. Reviews of patients with acquired factor XIII antibodies have reported eventual disappearance of the antibodies in up to half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/4/24650/abstract/115,117\">",
"     115,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired hemophilia results from the development of autoantibodies to the coagulation factors. Antibodies to factor VIII are the most common, and their treatment has been more extensively studied than that of other acquired inhibitors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Factor VIII inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired antibodies to the clotting factors are often diagnosed by mixing studies, in which addition of patient plasma to normal plasma causes the relevant clotting test to become abnormal due to the antibody. The clotting tests affected by each type of inhibitor are discussed above.",
"     </li>",
"     <li>",
"      The most common conditions associated with the development of acquired",
"      <strong>",
"       factor VIII",
"      </strong>",
"      inhibitors are rheumatic diseases, the postpartum period, malignancy, and some drugs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       factor VIII",
"      </strong>",
"      inhibitors, we suggest initial control of active bleeding be done using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      for those with low inhibitor titers (ie, &lt;5 Bethesda units) and either activated prothrombin complex or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      for those with higher titers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Control of active bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To eliminate",
"      <strong>",
"       factor VIII",
"      </strong>",
"      inhibitors we recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at an initial oral dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in all patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Based upon weak evidence from the literature and our own experience, we suggest that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) be added to the initial prednisone treatment regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Eliminating the inhibitor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhibitors of",
"      <strong>",
"       prothrombin",
"      </strong>",
"      are frequently associated with antiphospholipid antibodies. Treatment of active bleeding is done with fresh frozen plasma (FFP). Modalities associated with factor VIII antibodies may also be useful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H15#H15\">",
"       \"Rare (recessively inherited) coagulation disorders\", section on 'Prothrombin deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhibitors of",
"      <strong>",
"       thrombin",
"      </strong>",
"      can develop in patients exposed to bovine thrombin, or in patients with autoimmune diseases. Antibodies provoked by exposure to exogenous thrombin do not always cause bleeding, while those associated with autoimmune disease can cause severe bleeding. Although only anecdotal information is available for treatment, we suggest immunosuppression and aggressive initial management including plasma exchange (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Thrombin inhibitors'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Inhibitors of",
"      <strong>",
"       factor V",
"      </strong>",
"      tend to arise after exposure to exogenous clotting products such as thrombin glue. The clinical phenotype can be quite variable. For serious bleeding, we suggest the use of platelet transfusions and plasma exchange; such patients should also receive immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Factor V inhibitors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Inhibitors of",
"      <strong>",
"       factors VII, IX, X, XI, and XIII",
"      </strong>",
"      are exceedingly rare. Suggested treatment for these conditions includes cyclophosphamide, corticosteroids, and plasma exchange (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Infusion of coagulation factor concentrates, where available (eg, factor XI and factor XIII) may also be helpful (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Other coagulation factor inhibitors'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Laurence J, Wong JE, Nachman R. The cellular hematology of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, 2nd ed, Lahita RG (Ed), Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/2\">",
"      Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/3\">",
"      Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/4\">",
"      Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/5\">",
"      Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/6\">",
"      Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol 2012; 156:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/7\">",
"      Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/8\">",
"      Fulcher CA, Lechner K, de Graaf Mahoney S. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/9\">",
"      Moreau A, Lacroix-Desmazes S, Stieltjes N, et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000; 95:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/10\">",
"      Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/11\">",
"      Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/12\">",
"      Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/13\">",
"      Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/14\">",
"      Ortel TL, Moore KD, Quinn-Allen MA, et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood 1998; 91:4188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/15\">",
"      Ortel TL, Quinn-Allen MA, Charles LA, et al. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest 1992; 90:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/16\">",
"      Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/17\">",
"      Collins P, Macartney N, Davies R, et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/18\">",
"      Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/19\">",
"      Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/20\">",
"      Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/21\">",
"      Tengborn L, Baudo F, Huth-K&uuml;hne A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/22\">",
"      Green D, Schuette PT, Wallace WH. Factor VIII antibodies in rheumatoid arthritis. Effect of cyclophosphamide. Arch Intern Med 1980; 140:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/23\">",
"      Soriano RM, Matthews JM, Guerado-Parra E. Acquired haemophilia and rheumatoid arthritis. Br J Rheumatol 1987; 26:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/24\">",
"      Lafferty TE, Smith JB, Schuster SJ, DeHoratius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/25\">",
"      Ballard HS, Nyamuswa G. Life-threatening haemorrhage in a patient with rheumatoid arthritis and a lupus anticoagulant coexisting with acquired autoantibodies against factor VIII. Br J Rheumatol 1993; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/26\">",
"      Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 1999; 82:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/27\">",
"      Tiplady CW, Hamilton PJ, Galloway MJ. Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haematol 2000; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/28\">",
"      English KE, Brien WF, Howson-Jan K, Kovacs MJ. Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother 2000; 34:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/29\">",
"      Komminoth A, Dufour P, Bergerat JP, et al. Hairy cell leukemia and factor VIII inhibitor: a case report. Nouv Rev Fr Hematol 1992; 34:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/30\">",
"      Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001; 86:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/31\">",
"      Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/32\">",
"      Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/33\">",
"      Sborov DW, Rodgers GM. Acquired hemophilia a: a current review of autoantibody disease. Clin Adv Hematol Oncol 2012; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/34\">",
"      Lossing TS, Kasper CK, Feinstein DI. Detection of factor VIII inhibitors with the partial thromboplastin time. Blood 1977; 49:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/35\">",
"      Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/36\">",
"      Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/37\">",
"      Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/38\">",
"      Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/39\">",
"      Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/40\">",
"      Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/41\">",
"      Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26 Suppl 1:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/42\">",
"      Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/43\">",
"      Liebman HA, Chediak J, Fink KI, et al. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/44\">",
"      Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/45\">",
"      Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/46\">",
"      Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/47\">",
"      Holme PA, Brosstad F, Tj&oslash;nnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/48\">",
"      Baudo F, Collins P, Huth-K&uuml;hne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/49\">",
"      Kessler CM. New perspectives in hemophilia treatment. Hematology Am Soc Hematol Educ Program 2005; :429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/50\">",
"      Gandini G, Franchini M, Manzato F, et al. A combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired hemophilia A with high-titer inhibitor. Haematologica 1999; 84:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/51\">",
"      Franchini M, Girelli D, Olivieri O, et al. Clinical heterogeneity of acquired hemophilia A: a description of 4 cases. Haematologica 2005; 90:ECR16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/52\">",
"      Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/53\">",
"      Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/54\">",
"      Green D, Rademaker AW, Bri&euml;t E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/55\">",
"      Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/56\">",
"      Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100:3426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/57\">",
"      Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/58\">",
"      Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103:4424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/59\">",
"      Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/60\">",
"      Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/61\">",
"      Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia 2007; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/62\">",
"      Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/63\">",
"      Onitilo AA, Skorupa A, Lal A, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/64\">",
"      Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/65\">",
"      Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011; 9:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/66\">",
"      Schulman S, Langevitz P, Livneh A, et al. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/67\">",
"      Brox AG, Laryea H, Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 1998; 57:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/68\">",
"      Maclean PS, Tait RC, Lowe GD, et al. Successful elimination of factor VIII inhibitor using cyclosporin A. Br J Haematol 2003; 122:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/69\">",
"      Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica 2000; 85:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/70\">",
"      Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003; 101:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/71\">",
"      Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/72\">",
"      Freedman J, Rand ML, Russell O, et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/73\">",
"      Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/74\">",
"      Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/75\">",
"      Coller BS, Hultin MB, Hoyer LW, et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood 1981; 58:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/76\">",
"      Scully MF, Shublaq W, Oliver GD. Acquired hemophilia a presenting as a bleeding diathesis in a postpartum patient: diagnosis and management. J Obstet Gynaecol Can 2002; 24:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/77\">",
"      Mytopher K, Dudebout J, Card R, Gilliland B. Acquired hemophilia A presenting post partum. CMAJ 2007; 177:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/78\">",
"      Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol 1995; 50:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/79\">",
"      Lollar P. Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost 2005; 3:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/80\">",
"      Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/81\">",
"      Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/82\">",
"      Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 1999; 8:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/83\">",
"      Bajaj SP, Rapaport SI, Barclay S, Herbst KD. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanism and management. Blood 1985; 65:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/84\">",
"      Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/85\">",
"      Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/86\">",
"      Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/87\">",
"      B&auml;nninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/88\">",
"      Kn&ouml;bl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/89\">",
"      LOELIGER A, HERS JF. Chronic antithrombinaemia (Antithrombin V) with Haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia). Thromb Diath Haemorrh 1957; 1:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/90\">",
"      Scully MF, Ellis V, Kakkar VV, et al. An acquired coagulation inhibitor to factor II. Br J Haematol 1982; 50:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/91\">",
"      Gabriel DA, Carr ME, Cook L, Roberts HR. Spontaneous antithrombin in a patient with benign paraprotein. Am J Hematol 1987; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/92\">",
"      La Spada AR, Sk&aring;lhegg BS, Henderson R, et al. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 1995; 333:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/93\">",
"      Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/94\">",
"      Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/95\">",
"      Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/96\">",
"      Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997; 19:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/97\">",
"      de Raucourt E, Barbier C, Sinda P, et al. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 2003; 74:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/98\">",
"      Navarrete MA, van der Meer FJ, Damiani G, et al. The use of rituximab therapy in patients with acquired factor V inhibitors. Am J Hematol 2012; 87:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/99\">",
"      Campbell E, Sanal S, Mattson J, et al. Factor VII inhibitor. Am J Med 1980; 68:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/100\">",
"      Weisdorf D, Hasegawa D, Fair DS. Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation. Br J Haematol 1989; 71:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/101\">",
"      Delmer A, Horellou MH, Andreu G, et al. Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood 1989; 74:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/102\">",
"      Okajima K, Ishii M. Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency. Int J Hematol 1999; 69:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/103\">",
"      Miller K, Neely JE, Krivit W, Edson JR. Spontaneously acquired factor IX inhibitor in a nonhemophiliac child. J Pediatr 1978; 93:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/104\">",
"      Mazzucconi MG, Peraino M, Bizzoni L, et al. Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Haemophilia 1999; 5:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/105\">",
"      Largo R, Sigg P, von Felten A, Straub PW. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 1974; 26:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/106\">",
"      Berman BW, McIntosh S, Clyne LP, et al. Spontaneously acquired Factor IX inhibitors in childhood. Am J Pediatr Hematol Oncol 1981; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/107\">",
"      Mulhare PE, Tracy PB, Golden EA, et al. A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X. Am J Clin Pathol 1991; 96:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/108\">",
"      Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992; 93:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/109\">",
"      Rao LV, Zivelin A, Iturbe I, Rapaport SI. Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost 1994; 72:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/110\">",
"      Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977; 297:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/111\">",
"      Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/112\">",
"      Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/113\">",
"      Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature. Arch Intern Med 1984; 144:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/114\">",
"      Vercellotti GM, Mosher DF. Acquired factor XI deficiency in systemic lupus erythematosus. Thromb Haemost 1982; 48:250.",
"     </a>",
"    </li>",
"    <li>",
"     Lorand L. Acquired inhibitors of fibrin stabilization: A class of hemorrhagic disorders of diverse origins. In: Anticoagulants: Physiologic, Pathologic and Pharmacologic, Green D (Ed), CRC Press, Cleveland 1994. p.169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/116\">",
"      Tosetto A, Castaman G, Rodeghiero F. Acquired plasma factor XIII deficiencies. Haematologica 1993; 78:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/117\">",
"      Boehlen F, Casini A, Chizzolini C, et al. Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013; 109:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/118\">",
"      Kohler HP, Ichinose A, Seitz R, et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/119\">",
"      Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/120\">",
"      Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/121\">",
"      Tosetto A, Rodeghiero F, Gatto E, et al. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/122\">",
"      Ajzner E, Schlammadinger A, Ker&eacute;nyi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/4/24650/abstract/123\">",
"      Ichinose A, Souri M, Japanese collaborative research group on \"Acquired haemorrha-philia due to factor XIII deficiency\". As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105:925.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1305 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24650=[""].join("\n");
var outline_f24_4_24650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTOR VIII INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inhibitor screen (mixing test)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bethesda assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF FACTOR VIII INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Control of active bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Eliminating the inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prednisone and cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1382370\">",
"      - Monitoring response to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER COAGULATION FACTOR INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prothrombin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thrombin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Factor V inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Factor VII inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Factor IX inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Factor X inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Factor XI inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Factor XIII inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 2\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22824?source=related_link\">",
"      Biology and normal function of factor VIII and factor IX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_4_24651="Luxation injuries";
var content_f24_4_24651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of luxation injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Luxation injury",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Concussion",
"      </td>",
"      <td>",
"       The tooth is neither loose nor displaced; it may be tender with the pressure of biting because of inflammation of the periodontal ligament",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subluxation",
"      </td>",
"      <td>",
"       The tooth is loose but not displaced from its socket; the periodontal ligament fibers are damaged and inflamed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intrusion",
"      </td>",
"      <td>",
"       The tooth is driven into the socket, compressing the periodontal ligament and fracturing the alveolar socket",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extrusion",
"      </td>",
"      <td>",
"       The tooth is centrally dislocated from its socket; the periodontal ligament is lacerated and inflamed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lateral luxation",
"      </td>",
"      <td>",
"       The tooth is displaced labially, lingually, or laterally; the periodontal ligament is lacerated, and the supporting bone is fractured",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avulsion",
"      </td>",
"      <td>",
"       The tooth is completely displaced from the alveolar ridge; the periodontal ligament is severed, and fracture of the alveolus may occur",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Andreasen, J, Andreasen, F. Textbook and Color Atlas of Traumatic Injuries to the Teeth, 3rd ed, Munksgaard, Copenhagen 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24651=[""].join("\n");
var outline_f24_4_24651=null;
var title_f24_4_24652="Periop endocrine agents";
var content_f24_4_24652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative management of endocrine agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name or class of drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical considerations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with brief NPO state",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended strategy for surgery with prolonged NPO state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"       <td>",
"        Continuation may increase risk of venous thromboembolism. Stopping can result in unwanted pregnancies.",
"       </td>",
"       <td>",
"        Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism. Stop 4 to 6 weeks before surgery for procedures with high risk for thromboembolism. Instruct on alternate forms of contraception and obtain serum pregnancy test immediately before surgery.",
"       </td>",
"       <td>",
"        Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism. Stop 4 to 6 weeks before surgery for procedures with high risk for thromboembolism. Instruct on alternate forms of contraception and obtain serum pregnancy test immediately before surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormone replacement therapy",
"       </td>",
"       <td>",
"        Continuation may increase risk of venous thromboembolism.",
"       </td>",
"       <td>",
"        Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism. Stop 4 to 6 weeks before surgery for procedures with high risk for thromboembolism.",
"       </td>",
"       <td>",
"        Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism. Stop 4 to 6 weeks before surgery for procedures with high risk for thromboembolism. Resume when tolerating oral medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective estrogen receptor modulators",
"       </td>",
"       <td>",
"        Continuation may increase risk of venous thromboembolism.",
"       </td>",
"       <td>",
"        Continue for surgeries with low risk of venous thromboembolism, and discontinue for surgeries with moderate to high risk for venous thromboembolism. When stopped should be stopped at least 4 to 6 weeks prior to surgery. When SERMs are used for breast cancer treatment consult oncologist.",
"       </td>",
"       <td>",
"        Continue up to and including the day of surgery for procedures with low risk of venous thromboembolism. Stop 4 to 6 weeks before surgery for procedures with moderate to high risk for thromboembolism. Resume when tolerating oral medications When SERMs areused for breast cancer treatment consult oncologist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral hypoglycemics and insulin",
"       </td>",
"       <td colspan=\"3\">",
"        See \"Perioperative management of diabetes mellitus\" topic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td colspan=\"3\">",
"        See \"The surgical patient taking glucocorticoids\" topic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24652=[""].join("\n");
var outline_f24_4_24652=null;
var title_f24_4_24653="Ovarian tumor markers";
var content_f24_4_24653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Markers secreted by germ cell and sex cord-stromal tumors of the ovary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        AFP",
"       </td>",
"       <td class=\"subtitle1\">",
"        hCG",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDH",
"       </td>",
"       <td class=\"subtitle1\">",
"        E2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inhibin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Testost",
"       </td>",
"       <td class=\"subtitle1\">",
"        Andro",
"       </td>",
"       <td class=\"subtitle1\">",
"        DHEA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysgerminoma",
"       </td>",
"       <td>",
"        -*",
"       </td>",
"       <td>",
"        &plusmn;&bull;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Embryonal",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immature teratoma",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endodermal sinus",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gonadoblastoma&Delta;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyembryona",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed germ cell",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Sex cord-stromal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thecoma-fibroma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulosa cell",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sertoli-Leydig",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein; hCG: human chorionic gonadotrophin; LDH: lactate dehydrogenase; E2: estradiol; testost: testosterone; andro: androstenedione; DHEA: dihydroepiandrostenedione.",
"     <br>",
"      * Borderline elevations in case reports (&lt;16 ng/ml).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Low level seen in dysgerminomas with either nondysgerminomatous elements of syncytiotrophobalstic cells.",
"       <br>",
"        &Delta; Type of germ cell-sex cord stromal tumor consisting of neoplastic germ cells and sex cord-stromal derivatives.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24653=[""].join("\n");
var outline_f24_4_24653=null;
var title_f24_4_24654="Mean serum melatonin";
var content_f24_4_24654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Mean serum melatonin profiles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean serum melatonin profiles of 20 subjects sampled at intervals after ingesting 0.1, 0.3, 1.0, and 10 mg of melatonin or placebo at 11:45 am.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, bodytemperature, and performance. Proc Natl Acad Sci 1994; 91:1824. Copyright &copy; 1994 National Academy of Sciences, USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24654=[""].join("\n");
var outline_f24_4_24654=null;
var title_f24_4_24655="Chronic ulcerative colitis BE";
var content_f24_4_24655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema in a patient with chronic ulcerative colitis shows a featureless colon with complete loss of folds in the sigmoid colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_4_24655=[""].join("\n");
var outline_f24_4_24655=null;
